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General introduction 
Epilepsy is a neurological disorder consisting of recurrent seizures, resulting from 
excessive, uncontrolled electrical activity in the brain. Despite the pharmacological 
development of new treatments, still one third of the epilepsy patients does not respond 
sufficiently to anti-epileptic drugs (AEDs). Those patients are called refractory patients. 
Hence, there is a constant impetus to search for other treatment strategies like epilepsy 
surgery, gamma knife surgery, vagus nerve stimulation and deep brain stimulation. Besides 
the ongoing research on the efficacy of anti-epileptic treatments in suppressing seizures (anti-
seizure effect), we want to seek therapies that can lead to plastic changes in the epileptic 
network and in this way have a modulating effect. The impact of such therapies cannot be 
overlooked, because they may slow down processes underlying epilepsy, might prevent or 
even cure epilepsy.   
This thesis deals with the potential of neuromodulatory treatments for patients with 
refractory epilepsy. The treatments that are considered include the pharmacological therapy 
with levetiracetam and vagus nerve stimulation. The effect of these therapies was 
investigated in chronic models of epilepsy, which imitate human epilepsy.  
 
1.1 A short introduction to epilepsy 
The word ‘epilepsy’ derives from the Greek verb έπιλαμβαυειυ (epilambanein), 
meaning ‘to be seized, to be overwhelmed by surprise’. Epilepsy is the most common serious 
brain disorder affecting 0.5-1% of the general population (Hauser, 1998), but still there is a lot 
of prejudice and misunderstanding about the disease. Epileptic seizures are characterized by a 
paroxysmal manifestation of highly synchronized abnormal neuronal activity of a part of the 
brain (partial) or the whole brain (generalized) resulting in various clinical symptoms which 
can manifest as motor, sensory, emotional or mixed phenomena possibly with alteration or 
loss of consciousness. Although 9% of the population experiences a seizure once in a lifetime, 
epilepsy is only diagnosed when seizures are recurring. The conversion from a normal 
neuronal network into a hyperexcitable epileptic network is called epileptogenesis, which 
consists of complex and dynamic processes.  
Several epilepsy syndromes exist, but they are all characterized by repetitive seizures. 
There are multiple causes for epilepsy and seizures can be classified according to their 
etiology into three categories: idiopathic (primary, without a known or suggested genetic 
origin), symptomatic (secondary, resulting from known origins e.g. tumors, lesions, 
infections, vascular causes) or cryptogenic (presumably symptomatic but currently of 
unknown specific etiology) (Engel and Pedley, 1999). Furthermore, the International League 
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Against Epilepsy has classified epilepsies according to their seizures onset zone: focal 
(partial) or generalized.  
 
1.2 Treatment of epilepsy  
Epilepsy treatment is indicated following two or more unprovoked epileptic seizures 
and is successful in the majority of the cases. Despite the pharmacological development of 
new treatments still, one third of the epilepsy patients do not respond sufficiently to AEDs 
and are called ‘refractory patients’ (Kwan and Brodie, 2000). This leads to a constant search 
for other treatment strategies such as epilepsy surgery, gamma knife surgery, ketogenic diet, 
deep brain stimulation, vagus nerve stimulation and transcranial magnetic stimulation but also 
the development of new AEDs with novel mechanisms of action.  
Pharmacological treatment is still the most important way to treat epilepsy and newly 
developed AEDs (e.g. levetiracetam) can provide seizure freedom in up to 7% of refractory 
patients (Fisher, 1993). AEDs are mainly administered as a long-term treatment to prevent the 
occurrence of seizures. During the last two or three decades, considerable advances have been 
made in our understanding of the mechanism of action (MOA) of AEDs (Table 1). This 
allowed a more rational approach to drug treatment. There are different ways by which AEDs 
can suppress epileptic seizures: i) decrease in neuronal excitation (glutamatergic system), ii) 
increase in neuronal inhibition (GABAergic system) or iii) by modulation of ion channels 
(modification of cellular excitability) (Bradford, 1995). The difficulty of treating epilepsy is 
that it can involve multifactorial causes and that the use of one approach is often insufficient. 
 
The original goal of pharmacological therapy for patients with epilepsy is to suppress 
seizures without side effects. In seizure free patients, seizures will mostly remain suppressed 
as long as the treatment continues, but may reoccur once therapy stops. Anti-epileptogenic 
Table 1: Different AEDs with their mechanisms of action (Brodie and French, 2003). 
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treatment is therefore an attractive idea. However, for the rational development of anti-
epileptogenic therapies there is need for a better understanding of epileptogenesis.  
Levetiracetam (LEV) is believed to belong to a novel class of AEDs having anti-
epileptogenic properties and it was discovered by unconventional drug screening. LEV has a 
favorable pharmacokinetic profile with rapid absorption following oral administration, 
excellent bioavailability, quick achievement of steady-state concentrations, linear kinetics and 
a minimal plasma binding (Patsalos, 2000). The MOA of LEV differs from other AEDs and is 
as yet not fully elucidated.  
Epilepsy surgery is an invasive but often curative treatment option that aims at 
removing the ictal onset zone believed to be responsible for seizure occurrence (Figure 1). 
Depending on the underlying epilepsy syndrome, 
approximately 70% of the patients are rendered 
seizure free after resective epilepsy surgery (Engel, 
1996). The risk-benefit-analysis for surgery must be 
individualized using a presurgical evaluation protocol 
and eventually a substantial number of patients have 
to be rejected (Boon et al., 1999).  
 
A promising alternative is gamma knife surgery (GKS), which is based on the 
convergence of 201 gamma ray beams. Cortical structures can be targeted with GKS with a 
stereotaxic precision, without opening the skull and with a limited risk. A recent multicenter 
study demonstrates that GKS has positive outcomes in patients with epilepsy (Regis et al., 
2004). 
The ketogenic diet is a high-fat, adequate protein, low carbohydrate diet that mimics 
the biochemical changes associated with starvation, which create ketosis. It appears to be a 
very effective treatment for epilepsy, particularly during childhood, but has many side effects. 
It must be prescribed thoughtfully, implemented carefully and monitored closely (Nordli, 
2002).   
Different sites in the nervous system have been stimulated electrically in an attempt to 
treat seizures resulting in several types of neurostimulation (Figure 2). Deep brain stimulation 
(DBS) consists of continuous stimulation of specific deep brain regions at the seizure onset 
zone e.g. amygdala, hippocampus, thalamus (Vonck et al., 2002). On the other hand, electrical 
stimulation of relay nuclei may have the capacity to influence electrical activity in widespread 
regions of the brain, useful for multifocal seizure types. DBS is still far from being an 
established therapeutic technique. Basic research to date has been insufficient to answer 
questions needed prior to large-scale use of this technique.   
 
Figure 1: resection of epileptic tissue. 
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Vagus nerve stimulation (VNS) is a less invasive extracranial form of stimulation. The 
left vagus nerve is stimulated intermittently by means of a pulse generator to reduce frequency 
and severity of epileptic seizures. Controlled randomized studies showed a 50% decrease in 
overall seizure frequency in approximately one third of the patients, between 30-50% decrease 
in seizure frequency in another third op patients and, finally, one third of the patients has less 
than 30% decrease in seizure frequency and are consider to be non-responders (Salinsky, 
2003). Through diffuse projections of the vagus nerve in the cerebral hemispheres, VNS can 
have a broad effect on neuronal excitability (Rutecki, 1990). However, the precise MOA of 
VNS remains unknown. Several studies in humans describe a cumulative effect of VNS 
resulting in an increased efficacy over a longer period of time (Vonck et al., 1999; Boon et al., 
2001). 
Transcranial magnetic stimulation (TMS) with either a hand-held magnet or a frame 
is used widely in clinical neurophysiology to measure motor-cortex excitability. Recently, 
low frequency repetitive TMS (RTMS) has been used to reduce motor-cortex excitability 
(Ziemann et al., 1998). However, clinical experience is limited and only a few epilepsy 
patients have been treated with RTMS. 
Figure 2: Overview of the different targets for brain stimulation adapted from Vonck (2003). 
Deep brain stimulation (DBS) is a form of intracranial stimulation, whereas vagus nerve 
stimulation (VNS) and transcranial magnetic stimulation (TMS) are both forms of extracranial 
stimulation. Abbreviations: STN, subthalamic nucleus; MCS, motor cortex stimulation. 
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1.3 Animal models of epilepsy  
The development and characterization of existing and future animal models will lead 
to greater insight into the pathophysiology underlying epilepsy and will contribute to the 
evaluation and the development of new anti-epileptic and anti-epileptogenic therapies.  
A number of characteristics can be suggested for an ideal animal model imitating 
human epilepsy such as similar pathology and spontaneous seizures after a period of 
epileptogenesis. Therefore, chronic models (animals made epileptic or with inborn epilepsy) 
are preferable to acute models (seizure induction in naïve, healthy (non-epileptic) animals). At 
present, there are two distinct groups of chronic models: models for idiopathic (genetic) 
epilepsy and models for symptomatic (acquired) epilepsy.  
A discussion of all possible animal models of epilepsy is beyond the scope of the 
present thesis. Subsequently, we will be focusing on two chronic models of absence epilepsy 
(WAG/Rij and genetic absence epilepsy rats from Strasbourg- GAERS) and two chronic 
models of temporal lobe epilepsy (status epilepticus model and kindling model).   
1.3.1 Models of absence epilepsy (idiopathic epilepsy) 
It has become increasingly obvious during recent decades that genetic factors play a 
main role in the idiopathic generalized epilepsies, including absence epilepsy. Absence 
seizures are characterized by paroxysmal unresponsiveness to environmental stimuli and 
cessation of ongoing activity. In humans, absence seizures are associated with the appearance 
of bilaterally synchronous 3 Hz spike and wave discharges (SWDs) on the EEG. They occur 
mainly during quiet wakefulness, inattention and in the transition between sleep and waking 
(Guey et al., 1969). Absence epilepsy has a genetic predisposition without evidence of any 
structural lesion as its substrate (Niedermeyer, 1996). A thalamocortical dysfunction is 
assumed to play a major role in the underlying pathophysiology (Danober et al., 1998). 
Research on absence epilepsy is greatly facilitated by the use of animal models. 
Both models discussed are validated models for spontaneous absence seizures in 
humans. The hallmark is the appearance of bilateral generalized SWDs on the electro-
encephalogram (EEG) (Figure 3), which are of higher frequency than in man (7-12 Hz versus 
3 Hz, respectively). In addition, absence seizures in rats appear later during life than in 
humans (during adulthood in rats versus childhood with tendency to disappear with adulthood 
in humans). However, in both animals and humans, absence seizures are believed to have the 
same pathophysiological background. The involvement of a thalamocortical circuit, 
particularly the contribution of the ventrobasal thalamus (VB) and the nucleus reticularis of 
the thalamus (NRT), in the propagation of absence seizures has been established for several 
years (Marescaux et al., 1992; Danober et al., 1998). Aberrant corticothalamic rhythms are 
believed to be the substrate of SWDs. Recently, it has been demonstrated that SWDs have a 
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focus in the peri-oral region of the somatosensory cortex from where they spread over the rest 
of the cortex (Meeren et al., 2002). This does not inevitably mean that the focus is also the 
source of the defect underlying SWDs (Crunelli and Leresche, 2002). 
The WAG/Rij strain has been developed in Rijswijk (the Netherlands). The main 
difference between GAERS and the WAG/Rij strain is that the latter has two types of SWDs 
on the EEG. The type 2 SWD is not accompanied by behavioral signs and seems to be a more 
localized phenomenon (Midzianovskaia et al., 2001). The discharges in WAG/Rij rats are also 
less frequent, shorter in duration than in GAERS and can be accompanied with mild clinical 
manifestations (facial myoclonic jerks) (Coenen and Van Luijtelaar, 2003). The WAG/Rij rat 
will not be discussed any further as we chose to work with GAERS. 
We preferred to utilize the GAERS model because they do not display the type 2 
SWDs and GAERS have longer and more frequent SWDs, which makes them favorable to 
work with. The absences are characterized by behavioral arrest and are sometimes 
accompanied by rhythmic twitching of the vibrissae. Seizures develop gradually and the first 
SWDs appear around postnatal day 30. They are rare (1 or 2/hour), short lasting (0.5 to 3 s), 
with a low frequency (4 to 7 Hz) and variable morphology (Marescaux et al., 1992; 
Dedeurwaerdere et al., 2005). At the age of four months, 100% of the GAERS have 
developed SWDs on the EEG. Adult animals typically have 60 SWDs per hour, 0.5-75 s in 
duration and with a frequency of 7-12 Hz (Marescaux et al., 1992). 
 
Figure 3: Bilateral generalized SWDs on the EEG in GAERS. Abbreviations: F1, frontal left; P2, 
parietal right; Ref, reference. 
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Drugs effective against absence seizures in humans (ethosuximide, valproate, 
trimethadione, benzodiazepines and topiramate) suppress SWDs dose-dependently, whereas 
drugs for convulsive or focal seizures (carbamazepine, phenytoin) are ineffective or aggravate 
absence seizures (Marescaux et al., 1992).  
The frequent spontaneous seizures, the similarity with human absence epilepsy and 
the gradual development of epilepsy make this an attractive model to study epileptogenesis 
and treatments that can interfere with epilepsy. Another strong point is that SWDs appearing 
on the cortical EEG strictly correlate with the occurrence of the numerous clinical absences. 
Therefore, EEG recordings can be used to quantify the appearance of SWDs and absences. 
1.3.2 Models of temporal lobe epilepsy (symptomatic epilepsy)  
Of the various epilepsies and epilepsy syndromes the acquired epilepsies account for 
approximately 30-49% of the new cases (Herman, 2002). Acquired epilepsy is a consequence 
of brain-damaging insults such as: head trauma, stroke, brain infection, brain surgery or status 
epilepticus. Epileptic processes consist of three phases: the initial insult followed by the latent 
period (epileptogenesis) resulting in recurrent seizures (symptomatic epilepsy).  
The models we are focusing on are most closely approximating human temporal lobe epilepsy 
(TLE). Temporal lobe epilepsy with complex partial seizures is in 70% of cases associated 
with hippocampal sclerosis as a pathologic substrate (Engel et al., 1999). 
Ten percent of all acquired epilepsies in humans evolve after status epilepticus (SE) 
and the risk of developing epilepsy as a consequence of SE ranges between 30 and 80% 
(Shorvon, 2002; Herman, 2002).  SE can be induced in animals by a number of different 
stimuli. In rodents, it is typically induced by kainic acid, pilocarpine or by sustained electrical 
stimulation of the amygdala, perforant path or hippocampus. Unlike kindling and other 
models of acquired epilepsy, a high proportion of the animals that survive the initial status 
develop spontaneous seizures after a latent period. Disadvantage is the high mortality during 
the SE and the aggressiveness of the survivors caused by destruction of parts of the limbic 
system. For the purpose of drug or other treatment efficacy studies, the status epilepticus 
model is laborious and time consuming, because the rats have to be continuously recorded for 
spontaneous seizures during several weeks or even months after the status (Loscher, 2002). 
In the current study we used the electrical amygdala kindling model. Kindling is 
currently the most widely used animal model for epilepsy and can be performed in many 
species like rats, mice, cats, dogs, primates and even amphibians. Different brain structures 
(e.g. amygdala, hippocampus, piriform cortex) can be targeted electrically or chemically (e.g. 
glutamate, kainate). During the kindling process seizure severity and duration gradually 
progress. Its relatively slow onset due to daily or more frequent brief stimulation, allows 
detailed study of the events associated with the epileptogenic process. In addition, it offers the 
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advantage that seizures can be elicited at will. On the other hand these animals will not 
develop spontaneous seizures with traditional kindling protocols.  
Because of the growing need for an animal model of complex partial seizures based 
on a genetic predisposition, two new lines of rats have been developed that are kindling-prone 
(Fast rats) or kindling-resistant (Slow rats) (Racine et al., 1999). These Fast-kindling and 
Slow-kindling rats are a parent mixture of two outbred strains that showed strong genetic 
control in the rate of amygdala kindling, with faster kindling rates in the Fast rats (Racine et 
al., 1999). Obvious differences between the two strains in cholinergic, monoaminergic and 
glutamatergic systems are not found (McIntyre et al., 2002). However, there are large strain 
differences in their response to GABA modulators. The Fast rats are very sensitive to negative 
modulators like bicuculline and picrotoxin and experience convulsive seizures to those drugs 
at much lower concentrations than the Slow rats (Racine et al., 2003). By contrast, the Slow 
rats are more sensitive to positive GABA modulators like pentobarbital and diazepam and 
experience sedation at doses that do not significantly affect the Fast rats (McIntyre et al., 
1999). In agreement with this differential sensitivity to GABAergic agents, the pattern of 
GABAA subunit expression in the two strains is importantly different. Besides differences in 
excitability and epileptogenesis, the Fast strain also shows other natural differences with the 
Slow strain such as behavioral comorbidities including impulsivity, learning impairment, an 
attention deficit disorder and increased body weight during development (Anisman and 
McIntyre, 2002). Therefore, these Fast rats are of great interest to determine the therapeutic 
effects of VNS on memory and body weight next to kindling development and seizures. 
 
1.4 Rationale and outline of the thesis 
As outlined before, there is a continuous impetus to search for new and innovative 
treatment strategies. Neuromodulation is the science of how electrical, chemical and 
mechanical interventions can modulate or change central and peripheral nervous system 
functioning by initiating and influencing neurophysiological signals. Modulatory synapses in 
the central nervous system transmit information that will have long-lasting effects on the 
postsynaptic neuron’s metabolic activity and on its response to subsequent input. These 
effects are fundamental to the development and adaptation of the nervous system and are 
believed to underlie higher functions such as learning and memory. Lately, neuromodulation 
has been defined by the Journal of the International Neuromodulation Society as “the 
therapeutic alteration of activity in the central, peripheral or autonomic nervous systems, 
electrically or pharmacologically, by means of implanted devices. Since, many 
neuromodulation therapies have been developed in several research fields, e.g. heart rate 
disorders, breathing disorders, movement disorders, pain, incontinence, spasticity, paralysis, 
depression and epilepsy. However, the definition of neuromodulation as “a form of therapy in 
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which neurophysiological signals are initiated or influenced with the intention of changing the 
function and performance of the nervous system to achieve therapeutic effects” covers this 
dissertation probably best. 
The potential of such modulating and maybe even anti-epileptogenic therapies could 
be of great significance. They could slow down, alter processes underlying epilepsy or might 
prevent and even cure epilepsy. The current research project investigated the modulation 
capability of treatments (LEV and VNS) for patients with refractory epilepsy. Studies in man 
are hampered by the heterogeneity of patient populations (age, course of the epilepsy, type of 
epilepsy, AED regime and genetic background) and the difficulty to study therapy-related 
effects in a systematic way. Therefore, investigation was performed utilizing two models 
mimicking epilepsy in humans. They are both chronic models with seizures evolving from 
true and genetically-driven epileptogenesis. GAERS have inborn epilepsy and Fast rats have a 
genetically determined sensitivity for electrical amygdala kindling. 
Levetiracetam (LEV) is a novel well tolerated AED approved as an adjunctive therapy 
for epilepsy patients with refractory partial seizures with or without secondary generalization. 
Anti-epileptogenic effects of LEV in addition to anti-epileptic effects have been reported in 
the rat amygdala kindling model for temporal lobe epilepsy (Loscher et al., 1998; Stratton et 
al., 2003) and the spontaneously epileptic rat (SER), a model of primary generalized epilepsy 
characterized by spontaneous tonic convulsions and absence seizures (Sasa et al., 2003). LEV 
suppresses kindling development at doses devoid of adverse effects with persistent reduction 
in afterdischarge duration after termination of treatment (Loscher et al., 1998). In the SER 
model study, only reported as an abstract, LEV was administered before the appearance of 
spontaneous seizures and was terminated at the expected age for seizure expression, which 
resulted in a lower seizure number in pre-treated animals (Sasa et al., 2003). These exciting 
findings have motivated us to evaluate the effect of chronic LEV administration early in life 
on the development of spontaneous SWDs in GAERS. 
Vagus nerve stimulation (VNS) has been used since 1988 and at present 
approximately 30 000 patients are being treated with VNS worldwide. Experience and 
knowledge about VNS is rapidly increasing, however several questions remain unclear. VNS 
is used in generalized and partial epilepsy (Ben-Menachem, 2002), although responder groups 
have not been clearly identified. Currently 30% of patients treated with VNS will not benefit 
from VNS. Understanding VNS could improve seizure outcome by identifying specific 
epilepsy syndromes or types of epilepsy that respond well to VNS or by optimizing 
stimulation parameters. The precise MOA by which VNS exerts its anti-epileptic effect has 
not been elucidated yet. Through stimulation of the vagal afferent fibers in the neck, a large 
number of intracerebral structures are potentially affected. Initial animal studies with VNS 
showed promising results in reducing both ictal and interictal EEG abnormalities (Lockard et 
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al., 1990; Woodbury and Woodbury, 1990; Woodbury and Woodbury, 1991; Zabara, 1992; 
McLachlan, 1993; Takaya et al., 1996). These findings laid the foundation for further 
development of VNS as a treatment for human epilepsy. However, VNS efficacy in animals 
has primarily been assessed in acute models (3-mercaptopropionate, pentylenetetrazole, 
maximal electroshock, penicillin or strychnine application) utilizing application protocols 
immediately before and/or after seizure provocation. Only a few studies have assessed the 
effect of VNS in chronic animal models of epilepsy (Lockard et al., 1990; Munana et al., 
2002), which is probably related to practical issues of chronic VNS in animals. It is clear that 
additional research is needed using chronic animal models and using both acute and chronic 
VNS protocols. Moreover, such fundamental data for idiopathic epilepsy are presently 
completely lacking. Information about the potential efficacy of VNS in GAERS, a validated 
animal model of absence epilepsy, could help to clarify the general principles that underlie 
VNS, although extensive therapeutic use of VNS in absence epilepsy is unlikely. In addition, 
we have investigated the effect of VNS on epileptogenesis and seizures in a model of partial 
epilepsy. We examined whether VNS could interfere with the development of amygdala 
kindling and whether seizures could be aborted in Fast rats. 
Recently, VNS has been explored as a treatment for cognitive disorders and obesity 
(Sjogren et al., 2002; Kneedy-Cajem et al., 2002). Therefore, we also have performed more 
detailed research concerning effects on memory and body weight in the Fast rat strain, which 
has natural abnormalities like impaired learning and increased body weight. 
Several functional imaging studies have been conducted to investigate the activation 
or inhibition of brain structures by VNS. These studies found changes on both sides of the 
brain by unilateral left VNS and pointed out a key role for the thalamus and medial temporal 
lobe structures in the MOA of VNS (Vonck et al., 2000; Van Laere et al., 2002; Chae et al., 
2003). However, there is no consensus on other activated structures neither on the type of 
changes (inhibition or excitation). This discrepancy can be attributed to a number of 
confounding factors such as the differences between the imaging techniques used (PET, 
SPECT, fMRI), the contrast agents, scanning protocols, stimulation parameters, medication 
regimes, course of the illness and treatment response. Heterogeneity of the patient samples is 
difficult to avoid. In addition, data gathering from healthy subjects is impossible for ethical 
reasons as VNS is a relatively invasive procedure. Therefore, we have explored the possibility 
to investigate the effects of VNS on brain metabolism in rats using small animal PET. 
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The aim of this thesis was to investigate the effect of chemical (chronic treatment 
with LEV) and electrical (acute and chronic VNS) neuromodulation in chronic animal models 
of epilepsy. The following questions were raised: 
 
1. Effects of chronic LEV treatment on seizure development 
a) Do young GAERS have comparable SWDs (morphology, number, duration) as adult 
GAERS? 
b) What is the effect of chronic LEV administration on SWDs in young GAERS?  
c) Are SWDs in young GAERS altered after discontinuing chronic LEV treatment? 
d) If SWDs are altered after discontinuing chronic LEV treatment, is this still the case when 
these animals reach adulthood? 
 
2. Efficacy and spectrum of vagus nerve stimulation 
a) Is it practically feasible to stimulate the vagus nerve of rats acutely and chronically? 
b) Can home-made cuff-electrodes activate different vagal nerve fibers?  
c) Does chronic VNS induce nerve damage? 
d) Does VNS interrupt ongoing SWDs when applied immediately after their onset in a 
model of absence epilepsy? 
e) Does acute VNS decrease SWDs in number and duration? 
f) Does chronic VNS decrease SWDs in number and duration? 
g) Does acute VNS interrupt generalized convulsions in rats? 
h) Does chronic VNS have a prophylactic effect on generalized convulsions in rats? 
i) Can chronic VNS interfere with epileptogenesis in rats? 
j) Does VNS cause permanent changes in the epileptic network? 
k) Does chronic VNS improve spatial memory in rats? 
l) Does chronic VNS reduce body weight in rodent models of epilepsy? 
m) What are the side-effects of chronic VNS in rats? 
 
3. Mechanism of action of vagus nerve stimulation 
a) Can small animal PET be used to detect changes in brain glucose metabolism induced by 
VNS? 
b) Does acute VNS induce changes in glucose metabolism in rats? 
c) Does chronic VNS induce changes in glucose metabolism in rats? 
d) Do acute and chronic VNS induce different changes in glucose metabolism in rats? 
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Chapter 1 provides a general introduction on epilepsy, treatments for epilepsy and animal 
models for epilepsy. Also the rationale and the aim of this thesis have been outlined. Specific 
questions regarding neuromodulation and epilepsy are formulated. 
Chapter 2 gives a general description of the methods and materials used in this animal study 
with emphasis on the cuff-electrode constructed for VNS in rats, including an 
electrophysiological and morphological evaluation. 
Chapter 3 deals with the effect of chronic LEV treatment in GAERS. We have investigated 
the effect of LEV on the age-related SWDs in GAERS by chronic administration of LEV 
starting before the age of occurrence of SWDs. The effect of early chronic LEV 
administration on development of SWDs was evaluated in young GAERS during treatment, 
immediately after treatment termination and two months after the last LEV injection (age four 
months), when brain maturation was achieved and SWDs recorded on cortical EEG were 
numerous. 
Chapter 4 describes the efficacy of acute and chronic vagus nerve stimulation in two animal 
models of epilepsy reported in three manuscripts. First, we investigated whether VNS applied 
at seizure onset can interrupt SWDs in GAERS. Subsequently, we determined whether SWD 
are suppressed or shortened in duration when VNS is applied several hours per day. Chronic 
VNS for one week was also evaluated in this validated model of absence epilepsy. Finally, we 
studied the effects of vagus nerve stimulation (VNS) on spatial memory, development of 
amygdala kindling, generalized convulsions and body weight using a Fast-kindling rat strain 
known to be prone to seizures and exhibiting several associated comorbid behaviors. 
Chapter 5 focuses on the mechanism of action of VNS. The first manuscript is a review of 
the historical basis of VNS underlying the development of VNS for human use. In addition, 
animal and human research data on the mechanism of action of VNS are presented. The 
second manuscript was a pilot study to explore the potential of 2-[18F]-fluoro-2-deoxy-D-
glucose (FDG) PET to investigate the effect of acute and chronic VNS on glucose metabolism 
in the brain of normal rats. 
Chapter 6 discusses the results obtained from this thesis. The different observations from the 
experiments are related to each other and are discussed with regard to the current literature 
and the main questions and objectives. Future perspectives for further research within the 
field of neuromodulation for epilepsy are provided.  
Finally a summary of the thesis is presented in English, Dutch and French. 
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General methodology 
 This chapter consists of the general description of the methods used in the different 
experiments. For the purpose of the VNS experiments in rats we developed specific novel 
hardware such as simple cuff-electrodes and spiral silicone embedded cuff-electrodes. In the 
second part of this chapter, we describe an electrophysiological and morphological evaluation 
of the use of these electrodes. 
 
2.1 Overview of the materials and methods 
2.1.1 Animals 
Wistar rats were purchased from a recognized breeder (Harlan, Netherlands). Genetic 
absence epilepsy rats from Strasbourg (GAERS) were bred and raised at the animal facility of 
Ghent University Hospital. All animals were treated according to guidelines approved by the 
European Ethics Committee (decree 86/609/CEE). The study protocols were approved by the 
Animal Experimental Ethical Committee of Ghent University Hospital. The Fast rats were 
bred and raised in the Life Science Animal Facility of Carleton University (Ottawa, CA). The 
experiments at Carleton University with the Fast rats were performed in accordance with the 
guidelines of the Canadian Council on Animal Care and a protocol approved by the Carleton 
University Animal Care Committee. 
2.1.2 Housing 
The animals were kept under environmentally controlled conditions (12 h light/dark 
cycles, lights on at 7 a.m., 20-23 °C, ± 50 % relative humidity) with standard food pellets 
(Pavan service PVBA, Carfil quality) and tap water ad libitum. Cages were provided with 
bedding and with additional nesting material for pregnant females or nursing mothers. The 
animals were housed in pairs in type III standard opaque plastic cages (22 cm x 32 cm x 19 
cm, type III, Macrolon® Technilab-BMI). Operated adults were single housed in taller cages 
(Type III).  
When acute experiments (short-term experiments) 
were performed, the animals were moved to square 
glass cages (30 cm x 30 cm x 30 cm, Figure 1).  The 
animals stayed at maximum 8 h in this acute setup. 
The electrodes on their heads were connected with a 
flexible lead to the EEG or the stimulation device 
(for vagus nerve stimulation or kindling).  EEG was Figure 1: Experimental setup with glass 
square cages and flexible leads for acute 
experiments in rats. 
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acquired using a H2O™ portable digital 32-channel EEG-recorder (Telefactor Corporation, 
USA). Data were saved digitally on a dedicated PC. 
 In our laboratory, we also have a long-term video-monitoring unit for 16 rats (Figure 
2). The cages were equipped with spring covered flexible leads (to avoid gnawing at the leads 
by the rat; Plastics One INC, USA), a spring (allows up and down movements of the rat) and 
a communicator or swivel (allows the rat to walk around in the cage without cables getting 
mixed up, Plastics One INC, USA). Leads (flat cables) were connecting the swivel with the 
EEG recorder. If required, video images could be simultaneously recorded with the EEG.  
 
 
 
 
2.1.3 Surgical techniques 
Before surgery, the surgical area was cleaned and disinfected with H.A.C. (Hospital 
antiseptic concentrate, chlorhexidine: 150 mg/l and cetrimidine: 1500 mg/l). Surgical 
instruments were sterilized by dry heat (30 min at 180 °C).  
After a presurgical evaluation (vivid reaction to stimuli, healthy fur, bright eyes, not 
too skinny) to insure that the animal was not ill, the rat was anesthetized and shaved (Figure 
3). The rats were anesthetized with ketamine/xylazine (80 mg/kg and 7.5 mg/kg respectively, 
i.p.). The ketamine/xylazine mix was diluted with saline (0.9 % NaCl) till an injection volume 
of 2 ml/kg was reached. Ketamine is a dissociative anesthetic with a probable action on 
NMDA receptors which results in analgesia. Xylazine is an α-2-adrenergic agonist, which 
stimulates α-2 adrenoceptors and causes sedation and analgesia by a decreased release in 
norepinephrine in the central nervous system (negative feedback system). During the 
operation, additional ketamine (5 mg/kg) was given when sensorial pain stimuli, by squeezing 
Figure 2: Video-EEG monitoring unit. A. Cage with flexible lead (a), a spring (b) and a swivel (c). 
B. Rats in video-EEG monitoring unit; a, flat cables to EEG recorder.  
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the foot pad, were felt. An electric heat pad was provided to preserve the rat’s body 
temperature during surgery. Then the surgical site (neck and head) was disinfected with 
Hibitane, ethanol and Iso-betadine (10% polyvidon iodine) from the centre of the site to the 
periphery. 
 
 
Implantation of the vagus nerve stimulation-cuff-electrode 
• Simple cuff-electrode 
The assembly consisted of two isolated stainless steel wires 
(bare/coated diameter= 0.2 mm/ 0.4 mm) and silk thread was 
used to hold the assembly together (Figure 4). The isolated 
wires were stripped on one side over a length of 3 mm and 
were fold in the shape of a cuff to hold the nerve. The 
stimulation poles were spaced out 1.5 mm from each other. 
• Self-sizing spiral silicone cuff-electrode 
The manufacture of the spiral silicone embedded cuff-electrode was adapted for small 
diameter cuffs (inner diameter= 0.8 mm), as previously described (Naples and Mortimer, 
1988) and was also made in house (Figure 5). Two 1 x 3 mm dot contacts were cut in a 25-μm 
platinum foil (Alfa Aesar, USA) and the inclusion of contacts and leads was carried out 
according to Veraart et al. (1993). Electrode contacts were 
glued with a spiral silicone elastomer (MED-4210, Nusil 
Technology, CA) on a silicone rubber sheet (MED-4750 
from Statice Santé, France with NuSil components). A 
second stretched sheet of silicone was then pressed on top of 
the first one. After curing of the silicone elastomer, 
rectangular windows (0.7 mm x 2 mm) were opened in the 
inner layer using the sharp section of a hypodermic needle. 
The electrodes were finally trimmed at 5 mm cuff-width.  
Figure 3: Presurgical preparations: weighing, anesthetizing, shaving and surgical equipment. 
Figure 4: Simple cuff-electrode 
with lead wires. 
Figure 5: Fabrication of the spiral cuff-electrodes. Upper panel: 
three electrodes are manufactured on one silicone sheet and are cut 
above and below the electrode contacts at 5 mm cuff-width. 
Middle panel: magnification of the electrode contacts with 
indication of the measurements; the centers of the electrode 
contacts (rectangular window of 0.7 mm x 2 mm) are spaced out 3
mm. Lower panel: finished spiral cuff-electrode with flexible 
wires.
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• Cuff-electrode implantation 
An overview of the procedure to implant a cuff-
electrode around the vagus nerve is presented in 
figure 8.  
The rat was fixated with hooks or tape on the 
sterile operating field. An incision (1.5 cm) was 
made over the left ventral region of the neck to 
allow free dissection of the left vagus nerve. The 
subcutaneous tissues were incised and blunt 
dissection was extended through the muscle 
layers. The left vagus nerve was isolated from 
connective tissue and the arteria carotis. 
Subsequently, the cuff-electrode was placed 
around the vagus nerve (Figure 6). The cuff-
electrode was sutured in place to prevent 
displacement by animal movement and to secure 
the connection between the nerve and electrode. 
The wires were bended in a strain relief loop and 
sutured to the surrounding tissue (muscles). In this way, potential tension on the cuff-
electrode due to animal movements (e.g. neck stretching) is avoided. The ends of the cuff-
electrode were tunneled subcutaneously using a shunt-passing tool from the ventral cervical 
incision via the dorsal cervical region to the head, where they were fixated with acrylic 
cement together with the EEG electrodes.  
 
Implantation of the EEG electrodes 
The animal was fixated in the stereotaxic frame by means of ear bars (Figure 9 and 
11). A midline incision was made on the head of the rat. After exposure of the skull, 
dependent on the number of epidural EEG electrodes small holes were bored for the 
positioning of the screws (Figure 11).  
Epidural electrodes (Figure 7), consisting of a stainless steel screw attached 
to an isolated silver wire, were positioned on the skull opposite to the 
frontal cortex (2 mm anterior to bregma and 1.2 mm lateral to the midline) 
and were placed on the parietal cortex (2 mm posterior to bregma and 1.2 
mm lateral to the midline). An epidural reference electrode was screwed at 
lambda. 
Figure 6: Positioning of the VNS cuff-
electrode. The cuff-electrode is implanted in
the cervical region around the left vagus
nerve, which is located next to the arteria
carotis. The cathode and anode are indicated
on the picture as ‘−’ and ‘+’, respectively.
The electrode wires are later on
subcutaneously tunneled towards the head of
the rat. 
Figure 7: Epidural electrode made of a stainless steel screw, a silver wire and a 
connection piece. Magnification 2x. 
5 mm 
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Figure 8: Overview of the implant procedure of two types of cuff-electrodes around the left vagus 
nerve. Upper panel: fixation of the rat on the operation field, midline incision, blunt dissection of
the muscles; middle panel: isolation of the left vagus nerve from the arteria carotis and connective
tissue, implantation of the simple cuff-electrode, implantation of the silicone cuff-electrode; lower 
panel: tunnelling of the lead wires subcutaneously towards the head, fixation of the electrode
underneath the muscles and suturing of the incision wound. 
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 In case depth electrodes were required for amygdala kindling, bipolar 
stimulating/recording electrodes were implanted in both amygdalae (Figure 10 and 11). These 
home-made electrodes consisted of two twisted strands of 0.127 mm diameter Diamel-
insulated Nichrome wire and were cut at approximately 1 cm. Coordinates for the 
implantation were 2 mm 
posterior to bregma, 4.5 mm 
lateral to the midline and 8.4 
mm below the skull surface 
(Paxinos and Watson, 1998).  
In addition, five stainless steel 
screws, embedded in the skull 
were used to anchor the 
electrodes in place. The 
electrodes and screws were 
secured in place by dental 
acrylic (Figure 11).  
 
 Following surgery, the rats were given acetaminophen rectal gel, a topical analgesic 
(xylocaine gel, 0.2%) at the wound edges and a subcutaneous injection of saline (NaCl 0.9%, 
2 ml/kg) and were then placed in plastic cages under warming lamps to maintain normal body 
temperature until they became behaviorally active again. The recovering animals were closely 
observed until they were breathing normally and were able to move around easily. The rats 
were then returned to the colony room and allowed up to two weeks of recovery before the 
beginning of the recordings. 
Figure 10: Amygdala placement of the bipolar electrodes. Red
lines encircle the amygdalair nuclei. 
Figure 9: Operation field with the rat fixated in the stereotaxic frame.  
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2.1.4 Kindling procedures 
The kindling model is currently the most widely used animal model for temporal lobe 
epilepsy. During the kindling process seizure severity and duration gradually progress. It 
offers the advantage that seizures can be elicited at will and that it allows detailed study of the 
events associated with the epileptogenic process. 
Afterdischarge threshold determination 
Two weeks after surgery, initial (prekindling) afterdischarge thresholds (ADTs) were 
determined for both amygdalae. The ADT was defined as the minimum stimulus intensity 
necessary to provoke a clearly discriminable, high-voltage, electrographic seizure event (an 
AD, Figure 12) that outlasted the stimulus by two or more seconds (Kelly et al., 1999). To 
assess the threshold a 1 s, 500 µs pulse duration, 60 Hz square wave stimulus of progressively 
increasing intensity (15, 25, 35, 50, 75, 100, 150, 200, 300, 400, 500, 600 µA) was delivered 
using a constant current generator until an AD was triggered. The interval between 
stimulations was 1 min. Post-kindling ADTs were determined the day after kindling was 
completed.   
Figure 11: Implantation of EEG electrodes. Upper panel: fixation of the rat with ear bars in the 
stereotaxic frame and preparation of the skull, placement of the epidural EEG electrodes; lower panel: 
position of epidural screw electrodes, implantation of the depth stimulating/recording electrodes and 
fixation of the electrodes with acrylic cement.  
 
General methodology                                                                                                                   Chapter 2 
 32
Kindling 
Twenty-four hours after the ADT determination, kindling 
began. All rats were stimulated in the amygdala once daily at 
their individual ADT intensity until five stage-5 generalized 
convulsive seizures, characterized by forelimb clonus with 
rearing and falling, had occurred (Racine, 1972). During the 
course of kindling, if the rat failed to respond with an AD, the 
rat was stimulated at a higher intensity until an AD was evoked 
(using the increment technique described at ADT 
determination).  
The typical behavior associated with the initial amygdala ADs 
is behavioral arrest. With repeated stimulations, duration and 
severity of seizures gradually progress. Seizures are usually 
classified according to Racine (1972): stage 1, immobility, eye 
closure, twitching of vibrissae, sniffing, facial clonus; stage 
2, head nodding associated with more severe facial clonus; 
stage 3, clonus of one forelimb; stage 4, rearing, often 
accompanied by bilateral forelimb clonus; stage 5, rearing with 
loss of balance and falling accompanied by generalized clonic 
seizures. Stage-5 seizures represent the final seizure stage 
(Figure 12). Typically between 10 and 15 stimulation trials are 
required before a stage-5 seizure is successfully triggered from an amygdala focus. The exact 
rate of amygdala kindling is dependent not only on the strain of rat, but also on the particular 
amygdala nucleus in which the stimulation electrode is situated.  
2.1.5 Vagus nerve stimulation 
Vagus nerve stimulation (VNS) was performed by connecting the cuff-electrode to an 
external NeuroCybernetic Prosthesis device (NCP, model 100; Cyberonics Inc., USA). As in 
patients, output current was ramped up to a just tolerable level of stimulation (Handforth et 
al., 1998). When a stimulus of higher intensity was given, animals behaviorally reacted by 
flattening the ears (Dedeurwaerdere et al., 2004) and a fixed posture. The following 
stimulation parameters were used: pulse duration 500 µs and frequency 30 Hz. Output current 
was dependent on the type of cuff-electrode and the tolerable level was 1.5 mA for the simple 
cuff-electrode and 0.5 mA for the spiral silicone cuff-electrode.   
 A short test stimulus was delivered daily in treated animals to confirm that true 
stimulation had been delivered by evoking a behavioral response and to check the impedance 
and integrity of the electrode-to-vagus nerve interface (using the Lead Test of the NCP 
Figure 12: AD on the EEG 
and behavioral stage-5 seizure 
(characterized by generalized
convulsions with rearing and
falling) evoked by kindling. 
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500 µV 
1 s
A 
B 
Figure 13: Different types of SWDs. A. Typical
adult SWD (amplitude: >3 times baseline
amplitude; peak frequency: 7-12 Hz; duration >
0.5 s); B. SWD-like events i.e. SISWDs in young
GAERS (PN57-PN64) consist of irregular short
discharges, with clear spike and wave aspects
characterized by lower amplitude (< 3 times
baseline amplitude) or lower peak frequency (5-7 
Hz). 
programming software). The impedance values were always within the attainable range to 
deliver the desired output current by the pulse generator. However, the simple cuff-electrode 
had lower impedances than the spiral cuff-electrode. Factors that can influence the impedance 
are measuring aspects such as frequency, pulse duration or difference in voltage applied. As 
these parameters were the same during the impedance measurements of both electrodes 
numerous other factors which can influence impedance should be considered. The simple 
cuff-electrode has stainless steel contacts whereas the spiral cuff has platinum contacts. 
Stainless steel can initially result in lower impedance. Indeed, these electrodes first have 
lower impedance values, however, after prolonged stimulation of a few days up to 2 weeks 
impedance increased dramatically. In addition, a closer contact of the simple cuff with 
surrounding fluid could also contribute to the initial lower impedance. 
2.1.6 EEG analysis 
 For the analysis of the spike and wave discharges (SWDs) (Figure 13, A) on the EEG 
of adult GAERS, a previously described and validated detection software package was used 
(Van Hese et al., 2003). Once a list of marked time instances was obtained by the detection 
method, a number of post-processing steps were performed by the software package: 
detections lasting less than 0.5 s were discarded and two detections less than 1 s apart were 
taken together. SWDs detected by the software package were visually confirmed. In these 
animals, both the number per hour and mean 
duration of the SWDs during the recording 
hours were calculated as well as the 
cumulative duration of the SWDs per hour 
(summation of the duration of all SWDs per 
hour) as a quantitative measure for seizure 
evaluation. 
GAERS (under the age of 4 months) may not 
all have developed typical SWDs yet or have 
infrequent SWDs (Marescaux et al., 1992). 
For quantification purposes, epileptiform 
events were classified into two closely related 
types, because the morphology of SWDs in 
young GAERS was found to be less 
pronounced and more variable when 
compared with SWD patterns in adult 
GAERS (Figure 13): i) typical SWDs also 
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present in adult GAERS (amplitude: >3 times baseline; peak frequency: 7-12 Hz; duration > 
0.5 s) and ii) SWD-like activity, which we have termed ‘short irregular spike and wave 
discharges’ (SISWDs), with clear spike and wave aspects characterized by lower amplitude (< 
3 times baseline amplitude) or lower peak frequency (5-7 Hz) and shorter in duration (< 2 s).  
 The software package specifically developed for the detection of SWDs was not 
appropriate for the scoring of the more irregular variant of the SWDs (SISWDs). Hence, 
epileptiform events in young GAERS (PN57-PN64) were quantified by means of visual 
inspection of the EEG using TWIN™ off-line EEG analysis (Telefactor Corporation, USA) 
by an experienced electroencephalographer (SD).  
2.1.7 Histology 
In the electrical kindling experiments, brains were collected for electrode placement 
verification. The rats were perfused 24 h after the experiments. Each rat was deeply 
anesthetized with 65 mg/kg sodium pentobarbital and was then perfused intracardially with 
saline followed by 10% formalin. One day later, the electrodes were removed from the 
cranium and the brains were excised and stored in 30% sucrose for at least three days before 
sectioning. Frozen sections of 40 µm were taken through the electrode tract tips and stained 
with cresyl violet to identify the kindled sites (Figure 14). 
Figure 14: A. Serial coronal slices (40 µm) of the rat brain stained with
cresyl violet. The electrode tract tips can be followed on the different
slices. B. Magnification of coronal slice with electrode placement in left
amygdala. Electrode placements are indicated with an arrow. 
A
B 
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2.2 Electrophysiological and morphological evaluation of the use of two 
cuff-electrodes for vagus nerve stimulation in rats. 
 This study has been presented as a poster at the 26th International Epilepsy 
Conference (Paris, France, 2005) and was published in abstract form in Epilepsia. It was 
beyond the scope of this Ph.D. thesis to develop a new cuff-electrode stimulation interface or 
to perform a detailed physiological and morphometrical study on cuff-electrodes. Hence, the 
aim was to evaluate two types of ready-designed cuff-electrodes fabricated in house on an 
electrophysiological and morphological basis for their use in stimulating the vagus nerve of 
rats on an acute and chronic basis.  
2.2.1 Abstract 
Purpose: A better understanding of the mechanism of action of vagus nerve stimulation 
(VNS) could lead to stimulation parameter optimization and identification of responder 
groups. Animal research is therefore crucial. The aim of this study was to evaluate two types 
of stimulation cuff-electrodes for rat nerves on electrophysiological and morphological basis.  
Methods: Two cuff-electrodes were evaluated: i) a simple cuff-type electrode and ii) a self-
sizing spiral silicone cuff-electrode. 
Electrophysiological measurements of compound nerve potentials induced by the two cuff-
electrodes were performed under deep xylazine/ketamine anesthesia. Subsequently, several 
combinations of stimulation parameters (amplitude: 50-1500 µA, pulse duration: 50-500 µs) 
were tested.   
For the evaluation of morphological modifications, vagus nerves were dissected from non-
implanted control animals (n= 6). The simple cuff and spiral silicone cuff-electrodes were 
implanted around the left vagus nerve of respectively 27 and 10 rats and vagus nerves were 
dissected after 34 to 377 days of implantation. Nerve tissue was fixated with formalin, 
embedded in paraffin and subsequently stained. 
Results: Both cuff-electrodes were able to elicit A, B and C fiber compound action potentials. 
The spiral silicone cuff-electrode required lower stimulus currents to trigger the different 
fibers. 
Long-term simple cuff-electrode implantation caused substantial nerve damage, which was 
mainly mechanical in nature in contrast to the spiral silicone cuff-electrode, which induced 
significantly less morphological changes (p< 0.05). 
Conclusion: Both cuff-electrodes were able to induce vagus nerve compound action 
potentials, but the spiral silicone cuff-electrode required lower output current. For long-term 
implantation, the spiral silicone cuff-electrode induced less morphological changes than the 
simple cuff-type electrode and was therefore recommended. 
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2.2.2 Electrophysiological evaluation of two cuff-electrodes 
During our animal studies on VNS, we have used two types of cuff-electrodes, which 
were fabricated in house. The first electrode was a simple cuff-type electrode for acute 
experiments, which was easy to manufacture and inexpensive (Figure 4). The second 
electrode was a more sophisticated self-sizing spiral silicone cuff-electrode developed for 
long-term use, which took more time and specific equipment to manufacture and was more 
expensive (Figure 5).  
We have tested the capability of both electrodes to induce compound action potentials (CAPs) 
in the vagus nerve. Electrophysiological measurements of compound nerve potentials induced 
by the two cuff-electrodes were performed under ketamine/xylazine anesthesia (80 mg/kg and 
7.5 mg/kg respectively, i.p.). Firstly, the measurements of nerve potentials evoked by the 
simple cuff-electrode were performed at the Center of Neuroscience, University of 
Amsterdam (Amsterdam, the Netherlands). We have recently started to use the more 
sophisticated spiral silicone embedded cuff-electrode. Testing of this electrode took place at 
the Neural Rehabilitation Engineering Laboratory, Université Catholique de Louvain, 
(Brussels, Belgium) were this electrode was developed. During this electrophysiological 
evaluation, two spiral silicone cuff-electrodes were placed around the vagus nerve, the caudal 
one was used to stimulate and the more rostrally positioned electrode to record the evoked 
CAPs. The experimental setup is shown in figure 15. It was possible to measure the three 
fiber components (A, B and C) of the vagus nerve (Figure 15). Both cuff-electrodes were able 
to induce CAPs in the vagus nerve.  
 
Figure 15: Overview of the setup for vagus nerve stimulation and recording with the self-sizing spiral 
silicone cuff-electrode. CAPs of A, B and C fibers of the vagus nerve evoked at output current 1000 µA 
and pulse duration 50 µs using the silicone cuff-electrode. The response of the A fibers appeared first 
and was partially enclosed by the stimulation artifact. Subsequently, the CAPs of the slower B and C 
fibers could be measured. Distance between cathode and registration electrode was 3.6 mm. 
 
 
5 mm
25 µV 
1 ms 
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 The amplitude of the CAPs increased when stimulation intensity was augmented 
(Figure 16). Threshold current values to excite large myelinated fibers (A and B fibers) are 
often low (15-70 µA; 100-200 µs) (Fenik et al., 2001). We found relative low stimulation 
thresholds for myelinated A and B fibers with both electrode types. To activate the C fibers 
higher current was needed. However, it has been argued that the activation of these C fibers is 
not required for the anti-epileptic effect of VNS (Krahl et al., 2001). The spiral silicone cuff-
electrode required lower stimulus currents to trigger the different fibers than the simple cuff-
electrode. Indeed, thresholds to elicit side effects were lower in the spiral silicone electrode 
than in the simple cuff (0.5 mA versus 1.5 mA). Most likely, the nerve is better isolated in the 
spiral silicone cuff, which prevents current to leak to the surrounding tissue.  
Figure 16: CAPs recorded after stimulation of the vagus nerve with the simple cuff. A. Input/output
curve of CAPs recorded from the vagus nerve evoked by increasing current (0-950 µA) at pulse 
duration 200 µs using the simple cuff-electrode. B. The amplitude of the CAPs increased as a function 
of the stimulation intensity. A fibers (1) have a lower threshold than B fibers (2) and the two responses
are clearly discriminable. C fibres activation was not present at these stimulation parameters. Distance 
between cathode and registration electrode (Teflon coated wire with isolation removed from the tip, 80 
µm diameter, California Fine Wire, Canada) was 10 mm. a.u., arbitrary unit. 
A 
B 
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2.2.3 Morphological evaluation of two cuff-electrodes 
The left vagus nerve was sampled in 35 implanted animals and six control non-
implanted animals for histological evaluation. At the conclusion of the implant period, the 
animals are brought under a deep level of anesthesia (overdose pentobarbital; 180 mg/kg, 
i.p.); this is a pain-free and stress-free death. Nerve tissue were resected and subsequently 
fixated with formalin and embedded in paraffin. Longitudinal sections were taken for 
examination of the nerve tissue and external epineurium. Thick sections (10 µm) were cut, 
mounted on slides, stained with hematoxylin and eosin (cells and nuclei), s100 (calcium 
binding proteins present in nerves) or myelin basic protein (mbp, staining of myelin) and 
coverslipped (Figure 17).  
Long-term implantation of simple cuff-electrode caused substantial nerve damage, 
which was mainly mechanical in nature in contrast to the spiral silicone cuff-electrode, which 
induced less morphological changes (Dedeurwaerdere et al., 2005). 
The thickness of the external epineurium was 
significantly increased in the stimulated simple 
cuff group when compared to the right intact 
(non-implanted) nerve of the animals (p< 0.01, 
Wilcoxon signed rank test) (Figure 18). Such a 
trend was also noticeable in the non-stimulated 
simple cuff group, but not in the spiral silicone 
cuff group. This is not surprising because the 
simple cuff-electrode consists of rigid leads, 
which may have caused friction with the nerve. 
Relative movement between cuff or cuff-leads 
and underlying nerve may have induced a 
continued proliferation of connective tissue, 
which could have led to the increase in 
thickness of the epineurium.  
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Figure 18: Effect of electrical stimulation and
cuff implantation on epineurium and nerve
thickness of the vagus nerve in rats.
Abbreviations: non-stim, non-stimulated; stim,
stimulated; data are expressed as mean ± SEM,
significance is set at P< 0.05, * significantly
higher than control nerve. 
Figure 17: Staining of nerve tissue with hematoxylin/eosin, s100 and mbp (left to right respectively) 
of a normal nerve. Abbreviations: e, external epineurium; n, nerve. 
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The thickness of the vagus nerve was significantly higher in the stimulated spiral 
silicone-cuff group when compared to the control group (p< 0.05, Mann-Whitney U test) and 
to the non-stimulated spiral silicone cuff group (p< 0.05, Mann-Whitney U test) (Figure 18). 
This was not the case for nerves stimulated through the simple cuff-electrode. Increase in 
thickness of the internal epineurium might be a possible cause. However, it is difficult to 
explain why this is only present in the stimulated spiral silicone group and not in the simple 
electrode group. 
The epineurial sheath included blood vessels, sometimes foreign object reaction and 
fibrosis. Blood vessels were significantly increased in the non-stimulated (p< 0.05, Wilcoxon 
signed rank test) and stimulated (p< 0.01, Wilcoxon signed rank test) simple cuff group when 
compared to their corresponding intact right nerves. Fibrosis was increased significantly in 
the stimulated simple cuff group only. Electrical stimulation is considered in itself to be a 
conspicuous element of potential nerve injury. Prolonged (> 8h), high-frequency (> 50 Hz) 
electrical stimulation of a peripheral nerve induces neural injury (Agnew et al., 1999). Neural 
damage due to electrical stimulation is decreased or abolished by reduction of the frequency 
of stimulation, by stimulating at 20 Hz (versus 50 Hz) or by the use of an intermittent duty 
cycle (Agnew and McCreery, 1990; McCreery et al., 1995). In addition, it has been suggested 
that continuous electrical stimulation of peripheral nerves at a low frequency induces little or 
no neural damage, even if the stimulus amplitude is very high (McCreery et al., 1995). Based 
on these findings, it has been established that VNS should not exceed 30 Hz and continuous 
stimulation protocols should be avoided (Agnew and McCreery, 1990). In our studies, we 
bore these guidelines in mind and VNS was applied at 30 Hz. In the spiral silicone cuff-
electrode there was no stimulation induced fibrosis. Hence, the increased fibrosis in the 
stimulation simple cuff-group is likely due to a combination of the rigid simple cuff and 
stimulation rather than to stimulation alone. Also inflammation was significantly increased 
(p< 0.025, Wilcoxon signed rank test) in the epineurium of the simple cuff groups. Improving 
the quality of the fabrication environment should reduce the chronic inflammation element of 
this immunological response.  
In the spiral silicone cuff groups, components of the epineurial sheath were not 
altered. This is in line with a previous morphometrical study stating that the effects produced 
by the chronic implant of this spiral silicone cuff-electrode were negligible (Romero et al., 
2001). The spiral silicone cuff-electrode has been manufactured under a laminar flow bench 
in a clean room. This is possibly the reason why significant inflammation of the vagus nerve 
was not present in the animals implanted with the spiral silicone cuff-electrode.  
Transverse sections of samples from the spiral silicone cuff-electrode were made for 
electron microscopy (Figure 19). Appearance of the myelinated axons was not different 
between non-stimulated and stimulated groups. However, in both groups, nerves were found 
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with decreased myelination of axons. Previous studies were unable to establish a link between 
morphological abnormalities caused by chronic cuff implantation and functional deficit (Grill 
and Mortimer, 2000). Epineurial electrodes have been found to induce axonal degeneration, 
however, the pathology had no apparent effect on the functional response to electrical 
stimulation (Koller et al., 1992). 
The simple cuff-electrode was a handy electrode for short term experiments. It was 
easy to fabricate, to implant and was assembled with inexpensive materials. For long-term 
implantation, the spiral silicone cuff-electrode was recommended, because of its more flexible 
cabling and contacts it induced less morphological changes than the simple cuff-type. In 
addition, less current is required to activate the different fibers, which is preferred for the 
battery life. 
 
 
 
Figure 19: Electron microscopy of the myelination of the vagus nerve. Upper panel: non-implanted 
nerves, lower panel: non-stimulated implanted nerve with decreased myelination (left) and stimulated 
nerve with almost normal myelination (left). Abbreviations: A, A fiber; B, B fiber and C, C fiber. 
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Purpose: In genetic absence epilepsy rats from Strasbourg (GAERS) age-related absence 
seizures start to appear from postnatal day (PN) 30 concomitant with ‘spike and wave 
discharges’ (SWDs) appearing on cortical EEG recordings. The aim of this study was to 
investigate the effect of early chronic levetiracetam (LEV) treatment on the development of 
SWDs in young and adult GAERS.  
Methods: From PN23 until PN60, LEV (54 mg/kg, i.p.) was administered once daily to 
GAERS (n= 8), while control GAERS (n= 7) received saline (0.9% NaCl, i.p.). All animals 
were implanted with four epidural EEG electrodes at PN51. EEG was recorded for 3 h daily, 
during the last four days of the treatment (PN57-PN60) and during four additional days after 
treatment had been terminated (PN61-PN64). The animals were monitored again at the age of 
four months (PN120-PN124), about two months after the last administration of LEV. 
Results: During treatment, epileptiform events in the LEV group were significantly reduced 
(62%, p< 0.05) in comparison with the control group. During the following four days, 
epileptiform events were reduced in the LEV group, with an average difference of 53% (p= 
0.064). Once the animals had reached adult age, there was no difference in epileptiform 
events between the LEV group and controls. 
Conclusion: In this study, chronic LEV administration induced a reduction in epileptiform 
events in young GAERS. This effect persisted in some extent after treatment cessation (PN61-
PN64), which might indicate a slowing down of epileptogenic processes. However, at the age 
of four months all animals revealed a similar expression of epileptiform discharges.  
 
Key words: levetiracetam, anti-epileptogenic, absence epilepsy, GAERS, spike and wave 
discharges (SWDs) 
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1. Introduction 
 Every year the incidence of new epilepsy cases is between 26 and 70 per 100 000 
(Hauser, 1998). Despite the development of new pharmacological treatments, approximately 
one third of epilepsy patients does not respond to anti-epileptic drugs (AEDs), and are 
referred to as refractory patients (Kwan and Brodie, 2000). Treatments with anti-
epileptogenic potential could modulate the processes underlying the development of epilepsy. 
Anti-epileptogenic properties have been attributed to some AEDs like valproate (Silver et al., 
1991), lamotrigine (Stratton et al., 2003), and pregabalin (Andre et al., 2003) as well as to 
vagus nerve stimulation (Fernandez-Guardiola et al., 1999). Anti-epileptogenic effects of 
levetiracetam (LEV) in addition to anti-epileptic effects have been reported to appear in the 
rat amygdala kindling model for temporal lobe epilepsy (Loscher et al., 1998; Stratton et al., 
2003) and the spontaneously epileptic rat (SER), a model of primary generalized epilepsy 
(Sasa et al., 2003). 
LEV is a novel well tolerated AED approved as an adjunctive therapy for epilepsy 
patients with refractory partial seizures with or without secondary generalization (Cereghino 
et al., 2000). LEV has an anti-epileptic effect in a broad range of animal models mimicking 
both partial (Loscher and Honack, 1993; Loscher et al., 2000; Glien et al., 2002) and 
generalized epilepsy in man (Loscher and Honack, 1993) including genetic absence epilepsy 
rats from Strasbourg (GAERS) (Gower et al., 1995). In contrast, LEV revealed no effect in 
the two conventional screening tests, namely the maximal electroshock and pentylenetetrazole 
models (Loscher and Honack, 1993). The mechanism of action of LEV differs from other 
AEDs and is as yet not fully elucidated.  
Studies conducted on AEDs administered during the process of epileptogenesis have 
so far focused on animal models of acquired symptomatic epilepsy (Pitkanen, 2002; Andre et 
al., 2003). In contrast, animal models of genetic idiopathic epilepsy have only been used 
scarcely. This study was stimulated by the ability of LEV to suppress seizure activity in 
animal models mimicking absence epilepsy in man (Gower et al., 1995; Boon et al., 2002; 
Bouwman and van Rijn, 2004). Moreover, in a previous pilot study of chronic LEV 
administration to young GAERS, a preliminary indication of an anti-epileptogenic effect was 
found (Boon et al., 2002). Indeed, it was felt that investigating the effect of chronic LEV 
treatment in young GAERS could provide new insights and strategies for the treatment of 
epilepsy. 
GAERS is an isomorphic and predictive model of absence epilepsy. The hallmark is 
the appearance of bilateral generalized ‘spike and wave discharges’ (SWDs) in the cortical 
EEG recordings during spontaneous absence seizures characterized by behavioral arrest. The 
first SWDs appear around postnatal day (PN) 30-PN40 and at the age of four months 100% of 
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the GAERS have SWDs, which persist throughout the lifespan of the animal (Danober et al., 
1998).  
In the present study, we have investigated the effect of LEV on the age-related 
development of SWDs in GAERS by chronic administration of LEV (PN23-PN60) starting 
before the age of occurrence of SWDs. The effect of early chronic LEV administration on the 
development of SWDs was evaluated in young GAERS during treatment (PN57-PN60), 
immediately after treatment termination (PN61-PN64) and two months after the last LEV 
injection (age four months), when brain maturation was achieved and SWDs recorded on 
cortical EEG were numerous. 
 
2. Methods 
2.1 Animals 
 Fifteen GAERS were used in this study. The animals were born and raised under 
environmentally controlled conditions (12 h light/dark cycles, lights on at 7 a.m., 20-22°C) 
with food and water ad libitum at the animal facility of the Ghent University Hospital. All 
animals were treated according to the guidelines approved by the European Ethics Committee 
(decree 86/609/CEE). The study protocol was approved by the Animal Experimental Ethical 
Committee of Ghent University Hospital. 
2.2 Surgery  
The pups (n= 15) were randomly assigned to the two treatment groups: LEV and 
control group. LEV (54 mg/kg, provided by UCB Pharma, Belgium) was dissolved in saline 
(0.9% NaCl) and injected intraperitoneally (i.p.) in a dose-volume of 2 ml/kg body weight, 
whereas control rats received an equivalent dose-volume of saline. From PN23 until PN60, 
LEV was administered once daily to eight GAERS, while the control GAERS (n= 7) received 
saline. All animals were weighed daily. 
At age PN51, four epidural EEG stainless steel screw electrodes were bilaterally 
implanted over the fronto-parietal cortex of all 15 animals. The rats were anesthetized with 
ketamine/xylazine (80 mg/kg and 7.5 mg/kg respectively, i.p.) and additional ketamine (5 
mg/kg, i.p.) was given when sensorial pain stimuli, by squeezing the foot pad, elicited motor 
reflexes. One epidural electrode was positioned on the left side of the skull at height of the 
frontal cortex (AP= +2 mm, ML= +1.2 mm, referred to bregma) and one was placed on the 
right sided parietal cortex (AP= -2 mm, ML= -1.2 mm, referred to bregma). The reference 
electrode was placed at lambda with the ground electrode on the left side of lambda (ML= 
+1.2 mm, referred to lambda). The EEG electrodes were fixed on the skull of the rat with 
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acrylic cement. Lidocaine gel (2%) was applied at the incision wound and the rats were 
placed under a heating lamp until they had recovered from anesthesia. 
2.3 EEG recording 
EEG was recorded by means of a H2O™ portable digital 32-channel EEG-recorder 
(Telefactor Corporation, U.S.A.). To avoid any interference with the circadian cycle, all 
recordings were performed during daytime (light period) starting at 10 a.m. in awake and 
freely moving animals (Rigoulot et al., 2003). Every 10 min a standardized sound stimulus 
was provided, to prevent the rats from falling asleep (Gower et al., 1995; Manning et al., 
2004). During the recording sessions, the rats were continuously observed. 
 
2.4 Effect of early chronic LEV administration on epileptiform events in young 
GAERS (PN57-PN64) 
One week after surgery, the animals were placed in the EEG recording chambers and 
stayed there from PN56 (one day before the start of the EEG recordings) until PN64 with food 
and water ad libitum. During the last four days of the treatment (PN57-PN60), EEG was 
recorded for 3 h daily. In this period, LEV or saline was injected 1 h after the start of the EEG 
recording. From PN61 on, treatment was halted, animals (controls and LEV group) received 
no longer injections and EEG was recorded during four additional days (PN61-PN64), 3 h 
daily (Figure 1). The EEG was recorded on several days to have a more robust dataset on the 
effect of LEV in these young animals. 
 
Epileptiform events in young GAERS (PN57-PN64) were quantified by means of 
visual inspection of the EEG using TWIN™ off-line EEG analysis (Telefactor Corporation, 
U.S.A.) by an experienced electroencephalographer (SD). Young GAERS (under the age of 4 
Figure 4: Study design. LEV (45 mg/kg, i.p.) was administered once daily at 11 a.m. from PN23 till 
PN60. During the last four days of the treatment (PN57-PN60) EEG was recorded for 3 h starting at 10 
a.m.; the following four days (PN61-PN64), treatment was terminated and EEG was again recorded for 
3 h a day. 
LEV treatment EEG recording
PN0 PN20 PN40PN30 PN50
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months) may not all have developed typical SWDs yet or have infrequent SWDs (Danober et 
al., 1998). For quantification purposes, epileptiform events were classified into two closely 
related types, because the morphology of SWDs in young GAERS was found to be less 
pronounced and more variable when compared with SWD patterns in adult GAERS (Figure 
2): i) typical SWDs also present in adult GAERS (amplitude: > 3 times baseline; peak 
frequency: 7-12 Hz; duration > 0.5 s) and ii) 
SWD-like activity, which we have termed 
‘short irregular spike and wave discharges’ 
(SISWDs), with clear spike and wave 
aspects characterized by lower amplitude (< 
3 times baseline amplitude) or lower peak 
frequency (5-7 Hz) and shorter in duration 
(< 2 s). Only the numbers of different SWD 
types (SWDs and SISWDs) per hour were 
used as dependent values. The durations of 
SWDs and SISWDs were still very short in 
these young animals; therefore relevant 
differences in discharge duration between 
treated and control animals could not be 
detected.   
 
 
2.5 Evaluation of SWDs in adult GAERS (age four months) after chronic LEV 
treatment during early life 
About the age of four months (range PN120-PN124), EEG was recorded for one day 
(duration of recording between 6 and 8 h) in 15 animals. For the analysis of the SWDs on the 
EEG of the adult GAERS a previously described and validated detection software package 
was used (Van Hese et al., 2003). Once a list of marked time instances was obtained by the 
detection method, a number of post-processing steps were performed by the software 
package: detections lasting less than 0.5 s were discarded and two detections less than 1 s 
apart were taken together. SWDs detected by the software package were visually confirmed. 
In these animals, both the number per hour and mean duration of the SWDs during the 
recording hours were calculated as well as the cumulative duration of the SWDs per hour 
(summation of the duration of all SWDs per hour). 
The software package specifically developed for the detection of SWDs was not 
appropriate for the scoring of the more irregular variant of the SWDs (SISWDs). Hence, the 
Figure 5: Different types of SWDs. A. Typical
adult SWD (amplitude: > 3 times baseline
amplitude; peak frequency: 7-12 Hz; duration > 0.5
s); B. SWD-like events i.e. SISWDs in young
GAERS (PN57-PN64) consist of irregular short
discharges, with clear spike and wave aspects
characterized by lower amplitude (< 3 times
baseline amplitude) or lower peak frequency (5-7 
Hz). 
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EEG was visually inspected for SISWDs, fulfilling the conditions described above, and the 
number per hour was calculated. 
2.6 Statistical analysis 
In young GAERS, statistical analysis was performed on both pooled and unpooled 
data. Data could be pooled after exclusion of interactions (hour x treatment and day x 
treatment) by ANOVA with repeated measurements. The number of SWDs and SISWDs per 
3 h was taken together; this was termed the number of epileptiform events. Statistical analysis 
was also performed on unpooled data, which consisted of the number of typical SWDs and 
SISWDs per hour at the different time points during a total recording time of 24 hours (3 h a 
day, during 8 consecutive days).  
For the inter-group comparison between the LEV and control group the Mann-
Whitney U-test was used. For the intra-group comparisons within the LEV and control group, 
a Friedman test was utilized. For the intra-group comparison between the mean number of 
epileptiform events on the two time points: during the last four days of treatment (PN57-
PN60) and during the following four days after treatment had been terminated (PN61-PN64), 
a Wilcoxon signed rank test was used. 
Through the further course of this paper (results and discussion), the results obtained 
in young GAERS will be presented and discussed according to the recording periods: a) the 
last four days of the treatment (PN57-PN60) and b) the following four days after treatment 
cessation (PN61-PN64). 
In adult rats, the Mann-Whitney U-test was used to compare the number per hour, the 
mean duration and the cumulative duration/hour of the SWDs between the LEV and control 
group. For SISWDs, the number per hour was compared between the LEV and control group 
using the Mann-Whitney U-test. 
All statistical tests were performed utilizing the statistical software package SPSS 12. 
Data are presented as the mean ± the standard error of the mean (SEM), and the significance 
level has been set at α= 0.05. 
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3. Results 
Chronic administration of LEV during 38 days in young GAERS (PN23-PN60) did 
not induce growth changes. Normal body weight in LEV treated GAERS (157 ± 8 g for males 
and 144 ± 10 g for females at PN60) was achieved in comparison with the control group (140 
± 15 g for males and 121 ± 6 g for females at PN60) treated with saline (NS, Student’s t-test).  
3.1 Effect of chronic LEV administration on epileptiform events in young GAERS 
(PN57-PN64) 
LEV treated rats (n= 8) showed less SWDs and SISWDs than control rats (n= 7) 
during treatment and also during the four days after the discontinuation of the treatment. 
During this 8-day recording period, typical SWDs were observed in three control rats. Only 
one of these rats had frequent (12 ± 2 per hour) SWDs on the EEG, which were short in 
duration (1.6 ± 0.2 s). None of the LEV treated rats had typical SWDs; hence, there were too 
few SWDs to detect significant differences in SWDs between LEV and control group. 
SISWDs were observed in all rats. These SWD-like events were short lasting (< 1.5 s) in the 
LEV and in the control group.  
a) Effect of chronic LEV administration on epileptiform events during the last four days of 
the treatment period (PN57-PN60) 
 During LEV treatment (PN57-PN60), the mean number of epileptiform events 
(pooled data) was 62% lower (p< 0.05, Mann-Whitney U-test) in the LEV group. The control 
group had a mean number of 86 ± 18 epileptiform events per 3 h, whereas this figure in the 
LEV group was 33 ± 11. Significant differences could also be found in the number of 
SISWDs (up to 81%) between LEV and control group on different time points during 
treatment (Figure 3). Also during the pre-injection hours (PN57-PN60), SISWDs were 
significantly lower in the LEV group (8 ± 2; 6 ± 2; 4 ± 2 and 7 ± 3) than in the control group 
(28 ± 8; 32 ± 6; 17 ± 6 and 20 ± 4) (Figure 3).  
 Pre- and post-injection hours differed significantly in treated animals on PN59 and 
PN60 (Friedman test). Surprisingly, the number of SISWDs in the post-injections hours was 
higher than in the pre-injection hour in the LEV treated group (Figure 3). However, a trend of 
a higher number of SISWDs in the post-injection hours was also present in the control group 
on PN59 (p= 0.066; Friedman test).  
No differences were found between the four individual days during treatment (PN57-PN60) 
within LEV and control group (data not shown, Friedman test).  
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b) Effect of chronic LEV administration on epileptiform events after treatment cessation 
(PN61-PN64) 
When treatment was discontinued (PN61-PN64), there was a borderline missed 
reduction of 53% in the mean number of epileptiform events (p= 0.064, pooled data, Mann-
Whitney U-test) in the LEV group compared with the control group. The control group had a 
mean number of 73 ± 14 epileptiform events per 3 h, whereas this figure in the LEV group 
was 34 ± 8. However, significant differences could be found in SISWDs (up to 66%) between 
LEV and control group at different separate time points (unpooled data, Figure 3).  
After treatment had been stopped, there were no differences between the recording 
hours within the LEV and the control group (Friedman test).   
Within LEV and control group, there was a significant difference between the four 
days after treatment cessation (pooled data, Friedman test); this was manifested by an increase 
in the number of epileptiform events on the last two days of the recording period. In the LEV 
group these number of epileptiform events on PN61, 62, 63 and 64 were respectively 25 ± 8; 
23 ± 7; 40 ± 10 and 48 ± 9. In the control group these figures were 52 ± 14; 57 ± 10; 94 ± 19 
and 88 ± 19.  
The Wilcoxon signed rank test did not reveal differences between the mean number 
of epileptiform events during treatment period and after treatment cessation in both groups 
(86 ± 13 versus 73 ± 14 for the control group and 33 ± 11 versus 34 ± 6 for the LEV group). 
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Figure 6: Effect of chronic LEV administration (PN23-PN60) on SISWDs in young GAERS (PN57-
PN64).  Number of SISWDs in the LEV group treated with LEV (solid bars, n= 8) and in the control
group treated with saline (open bars, n= 7) during treatment (PN57-PN60) and after treatment 
discontinuation (PN61-PN64). Data are expressed as mean ± SEM; SISWDs= short irregular spike and
wave discharges; PN= post natal day; 1 h= pre-injection hour or first recording hour; 2 h= first post-
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Differences between control and LEV group are assessed using the Mann-Whitney U-test and 
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indicates p< 0.05, ** indicates p< 0.01. 
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3.2 Evaluation of SWDs in adult GAERS (age four months) after chronic LEV 
treatment during early life 
 At the age of four month all animals had typical SWDs. EEG recordings showed no 
significant difference between the LEV and control group in number, mean duration and 
cumulative duration of the SWDs (Mann-
Whitney U-test). These numbers were only 
slightly lower in the LEV group (Figure 4).  
Also in SISWDs no differences could be found 
between both groups (Figure 4). However, 
SISWDs were decreased substantially in favor of 
typical SWDs in comparison with young 
GAERS (PN57-PN64), which had more SISWDs 
than SWDs.  
 
 
4. Discussion 
A new approach to drug screening, including the process of epileptogenesis, may 
identify new classes of drugs (Kupferberg, 2001; Klitgaard and Pitkanen, 2003). LEV is a 
novel AED with potential anti-epileptogenic properties, which was discovered using non-
conventional drug screening. It suppresses kindling development at doses devoid of adverse 
effects with persistent reduction in afterdischarge duration after termination of the treatment 
(Loscher et al., 1998). In the SER-model, LEV was administered before the appearance of 
spontaneous seizures and was terminated at the expected age for seizure expression, which 
resulted in a lower seizure number in pre-treated animals (Sasa et al., 2003). In the present 
study, we found that chronic LEV administration induced a decrease in epileptiform events 
(SWDs and SISWDs) in young GAERS (PN57-PN60), which persisted immediately 
following cessation of treatment (PN61-PN64), but not until adulthood. 
In GAERS, SWDs strictly correlate with the occurrence of clinical absences (Danober 
et al., 1998), which was also observed in this study. However, behavioral absence seizures 
can be subtle as they mostly appear during quiet wakefulness (Danober et al., 1998). 
Therefore, EEG recordings were used to quantify the appearance of SWDs. In our study, we 
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Figure 7: Evaluation of epileptiform events in adult 
GAERS (age 4 months) after chronic LEV treatment 
during early life. A. Number of SWDs and SISWDs 
per hour, B. mean duration of SWDs (s) and C.
cumulative duration of SWDs per hour (s/h) in the 
LEV group (solid bars, n= 8) and in the control group 
(open bars, n= 7). Data are expressed as mean ± 
SEM. 
Efficacy of levetiracetam                                                                                                            Chapter 3                                      
    
 54
found that typical SWDs are rare in young GAERS. Only three out of seven young control 
GAERS showed typical SWDs on the EEG and none of the LEV treated animals (n= 8). 
SISWDs, however, were the most prevalent type of discharge on the EEG during quiet 
wakefulness. Hence, these more irregular discharges were taken into account to quantify the 
effect of LEV on epileptiform events. While it is difficult to correlate SISWDs with 
behavioral arrest because of their short duration (< 1.5 s), it can be assumed that these 
discharges are closely related to SWDs and reflect premature SWDs given their 
morphological resemblance with typical SWDs and their strong decrease in favor of typical 
SWDs as the rats grow older. 
In this study, epileptiform events (SWDs + SISWDs) were significantly suppressed 
(difference of 62%) during chronic LEV treatment in young GAERS (PN57-PN60) in 
comparison with control animals. This is in line with a previous acute study of Bouwman and 
van Rijn (2004), which found a similar difference in SWDs between control and LEV treated 
adult rats in the WAG/RIJ model of absence epilepsy. 
The LEV treated animals displayed less SISWDs (up to 81%) than the control group 
even in the pre-injection hours during PN57-PN60. This could suggest that there was a 
slowing down of the epileptogenic processes by early chronic treatment (PN23-PN60) with 
LEV. Yet, the lower number of SISWDs in the pre-injection hours might also be caused by 
retention of LEV in the brain from previous injections, although LEV was already eliminated 
from the blood plasma.  
Interestingly, there was no acute decrease in SISWDs after injection of LEV (PN57-
PN60) and even the opposite could be observed. This is in contrast with previous acute 
experiments in adult GAERS, in which a clear decrease in SWDs could be observed after a 
single LEV injection (Gower et al., 1995; Boon et al., 2002; Bouwman and van Rijn, 2004). 
These studies, which were performed in adult GAERS, report the effect of a first and single 
LEV injection, while the effect of chronic LEV administration was not investigated. 
Moreover, several studies dealing with the chronic administration of LEV in animal models of 
temporal lobe epilepsy report increased functional tolerance towards LEV and some loss of 
efficacy after prolonged administration (Loscher et al., 1998; Loscher and Honack, 2000; 
Glien et al., 2002). This could be a possible reason for the lack of an acute decrease in 
SISWDs in rats that were already pretreated.  
The acute increase in SISWDs on PN59 and PN60 after LEV administration could 
represent a flaring up which stabilized again towards the next day. A trend for this 
phenomenon was also observed in the control group on PN59 (p= 0.066). There was no 
difference between recording hours during the last four days, when the rats were no longer 
injected with saline or LEV (PN61-PN60). Hence, stress after injection could be a responsible 
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factor for this increase in SISWDs, although the animals were accustomed to the handling 
procedures.  
When treatment was stopped, there was no sudden increase in epileptiform events 
(SWDs and SISWDs). This is in line with previously performed rat and mice experiments, 
where chronic treatment with LEV did not lead to withdrawal hyperexcitability (Klitgaard et 
al., 1998; Loscher and Honack, 2000). During different time points, epileptiform events were 
still significantly lower (up to 66%) in young LEV treated GAERS. This difference in number 
of absence seizures between controls and LEV treated rats is comparable to the study in the 
SER model (Sasa et al., 2003). In the SER-study, absence seizures were still decreased two 
weeks after treatment cessation during the 30 min recording period. However, the next week 
there was no longer a significant difference between the control and LEV pretreated group. In 
the study of Glien et al. (2002), spontaneous partial seizures in the pilocarpine model of 
temporal lobe epilepsy were also still decreased one week after termination of chronic LEV 
administration (two weeks) in certain rats, this was described as a carryover effect.  
In both LEV and control group, epileptiform events started to increase on the last 
days of recording, which can be due to the progressive nature of absence epilepsy in young 
GAERS. Still, significant lower SISWDs (up to 66%) in the LEV group could be detected on 
these last days of EEG recording (PN63 and PN64) in comparison with the control group. 
Early chronic treatment with LEV in young GAERS might have caused an initial 
slowing down of the epileptogenic processes, which had persisting effects after treatment 
termination. The major metabolite of LEV is pharmacologically inactive, and other 
metabolites are produced at levels below those that are relevant for pharmacological activities 
(Loscher et al., 1998). LEV does not interfere with enzyme systems (Patsalos, 2000; 
Benedetti, 2000) and is washed out rapidly (half-live ~2-3 h) after stopping the treatment 
(Loscher et al., 1998). As we used a relatively high dose to inject and LEV is already effective 
in low doses in GAERS (Gower et al., 1995), we expect that relevant therapeutic 
concentrations are present in the blood plasma for 8 h. Hence, the prolonged decrease in 
epileptiform events on PN61-PN64 is probably not due to a prolonged acute effect caused by 
accumulated LEV or other metabolites.  
Early chronic administration of LEV had no effect on the later expression of SWDs at 
the age of four months. SISWDs have diminished considerably in both groups; this supports 
its role as premature SWDs. Most likely, after discontinuation of the treatment, 
epileptogenesis could further progress. To our knowledge, there is only one other study where 
an AED i.e. remacemide was chronically administered in young GAERS (PN7-PN25) to 
establish its effect on SWD development (Nehlig and Boehrer, 2003). This study failed to 
demonstrate an effect of early remacemide treatment on the expression of SWDs in adult 
GAERS (Nehlig and Boehrer, 2003). In the present study, adult GAERS displayed fewer 
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seizures and shorter mean SWD durations compared to previously published experiments in 
GAERS, which were monitored only for a short period of time (Danober et al., 1998). 
However, these values were similar to a previous chronic experiment performed by our group 
(Dedeurwaerdere et al., 2004). This phenomenon of a decrease in seizures during longer 
recording periods is correlated with the decrease of vigilance resulting in more sleep episodes 
and less and shorter seizures (Dufour et al., 2001; Rigoulot et al., 2003). 
Until now, it is not described in what manner LEV exerts its effect on absence 
seizures in GAERS. LEV has no effect on the T-type voltage-activated Ca2+ current (Zona et 
al., 2001), a common target for absence epilepsy drugs. A possible effect of LEV that might 
contribute to its action against SWDs in GAERS could be by progressively decreased firing of 
the substantia nigra pars reticulata (SNR) neurons (Loscher et al., 1996). The SNR is not part 
of the epileptic circuit underlying absence seizures, but it may belong to a system 
participating in a remote control over seizures (Danober et al., 1998). Indeed, high frequency 
stimulation of the SNR has been shown to interrupt SWDs in GAERS (Feddersen et al., 2004) 
and intracerebral microinjections of GABA mimetics in the SNR suppress absence seizures 
(Danober et al., 1998). A part of LEV’s ability to suppress seizures may origin in its effect on 
neuronal firing in the SNR, but the anatomical network and molecular mechanisms by which 
this is mediated remains to be demonstrated (Klitgaard et al., 1998). By this way LEV could 
suppress SWDs in GAERS, but it is not known if this might interfere with epileptogenesis. In 
GAERS pups, metabolic increases in SNR compared to non-epileptic control rats were 
observed, which was suggested to reflect a mechanism of prevention of epileptogenesis in 
GAERS (Nehlig et al., 1998).  
 
4. Conclusion 
In this study, chronic LEV administration induced a decrease in epileptiform events 
in young GAERS (PN57-PN60), although this was not obtained by a decrease immediately 
after injection. This effect persisted partly after cessation of treatment (PN61-PN64), which 
might reflect a slowing of epileptogenic process due to previous chronic treatment with LEV. 
However, when LEV and saline treated animals grew up, they all developed a similar 
expression of spontaneous absence seizures.  
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We evaluated the efficacy of vagus nerve stimulation (VNS) in genetic absence epilepsy rats 
from Strasbourg (GAERS), a validated model for absence epilepsy. In the first experiment, 
we investigated whether VNS applied at seizure onset can interrupt spike and wave 
discharges (SWDs). In the second experiment, we investigated whether SWDs are suppressed 
or shortened in duration when VNS is applied several hours per day. Both control and VNS 
groups underwent EEG and VNS electrode implantation. For the first experiment, a 
randomized crossover design was used. Stimuli (amplitude: 3 V; frequency: 30 Hz; pulse 
duration: 500 µs) were given when an SWD occurred on the EEG. The experiment was 
repeated the next day. In the second experiment, treated animals were stimulated (amplitude: 
1.5 mA; frequency: 30 Hz; pulse duration: 500 µs; on/off time cycle: 30 s/ 5 min) for three 
hours per day, during five consecutive days.  In the first experiment, the duration of the 
SWDs was increased on day 1, (p< 0.05). There was no difference in SWD duration on day 2. 
In the second experiment, no significant differences could be found in number, duration and 
EEG frequency of SWDs. VNS applied at the onset of an SWD can prolong the duration of 
SWDs in GAERS. As a five-day stimulation protocol had no effect, long-term VNS might be 
necessary to affect SWDs. 
 
Key words: vagus nerve stimulation, absence epilepsy, GAERS, EEG 
 
 
1. Introduction 
Vagus nerve stimulation (VNS) is an efficacious broad-spectrum add-on treatment for 
patients with medically or surgically refractory epilepsy (Ben-Menachem, 2002). The left 
vagus nerve is stimulated intermittently by means of an implanted pulse generator and reduces 
the frequency and severity of epileptic seizures. Controlled randomized trials showed a 50% 
decrease in overall seizure frequency in approximately 30% of the patients (Salinsky, 2003). 
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The precise mechanism of action of VNS is not known. Mechanistic VNS research 
generally presumes that VNS exerts its effect by inducing action potentials in the afferent 
fibres of the left vagus nerve (Zagon et al., 1999; Henry, 2002). Through diffuse projections 
of the vagus nerve in the cerebral hemispheres, VNS can have a broad effect on neuronal 
excitability (Rutecki, 1990). 
VNS is being used to treat generalized and partial epilepsy, but responder groups are 
not clearly identified. The efficacy profile of VNS in non-convulsive generalized epilepsy, 
such as absence epilepsy is limited. Fundamental research of VNS in convulsive generalized 
and partial animal models preceded and supports the use of VNS in epilepsy patients 
(Lockard et al., 1990; Woodbury and Woodbury, 1990; Woodbury and Woodbury, 1991; 
Zabara, 1992; McLachlan, 1993; Takaya et al., 1996; Fernandez-Guardiola et al., 1999). Such 
fundamental research of VNS in absence epilepsy is presently lacking. 
Absence seizures are characterized by paroxysmal unresponsiveness to environmental 
stimuli and cessation of ongoing activity. Absence seizures are associated with the appearance 
of bilaterally synchronous 3 Hz spike and wave discharges (SWDs) on the EEG. They occur 
mainly during quiet wakefulness, inattention and in the transitions between sleep and waking 
(Guey et al., 1969). Human absence epilepsy has a genetic predisposition, without evidence of 
any structural lesion as its substrate (Niedermeyer, 1996). A thalamocortical dysfunction is 
assumed to play a major role in the underlying pathophysiology (Danober et al., 1998).  
Research on absence epilepsy is greatly facilitated by the use of animal models. 
Genetic absence epilepsy rats from Strasbourg (GAERS) constitute an experimental animal 
model and fulfill the requirements for an isomorphic and predictive model of absence 
epilepsy (Marescaux, 1992). The absence seizures in GAERS are accompanied by typical 
SWDs (7-12 Hz) on the EEG. The absences are characterized by behavioral arrest and are 
sometimes accompanied by rhythmic twitching of the vibrissae. Unexpected environmental 
stimuli can interrupt the seizures. Absence seizures in GAERS differ from human absences in 
SWD frequency (7-9 Hz versus 3 Hz) and the occurrence during lifetime (adulthood versus 
childhood with tendency to disappear with adulthood). But both GAERS and human absence 
seizures are believed to arise from the same pathophysiological background. 
In this short-term study, it was our intention to investigate the efficacy of VNS in 
GAERS. In the first experiment, we investigated whether SWDs can be interrupted by acutely 
applying VNS at a SWD onset. In the second experiment we investigated whether SWDs are 
suppressed or shortened in duration when VNS is applied during several hours/day during 
five consecutive days. 
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2. Methods 
2.1 Animals 
Twenty-one GAERS (male and female), weighing 200-300 g and aged four to six 
months, were used in this study. The animals were born and raised under environmentally 
controlled conditions (12 h light/dark cycles, 20-22°C) in the animal facility of the Ghent 
University Hospital with food and water ad libitum. All animals were treated according to 
guidelines approved by the European Ethics Committee (decree 86/609/EEC). The study 
protocol was approved by the Animal Experimental Ethical Committee of Ghent University 
Hospital (ECP 01/26). 
2.2 Surgical and technical procedures 
The animals were implanted with a cuff-electrode around the left vagal nerve and five 
epidural EEG electrodes. The GAERS were anasthetized with pentobarbital (40 mg/kg, i.p.). 
For implantation of the stimulation cuff-electrode an incision was made over the left anterior 
cervical region to allow free dissection of the left vagus nerve over 1 cm. The ends of the 
cuff-electrode were tunnelled under the skin over the back of the neck to the head, where they 
were fixated with acrylic cement.  
Stimulation was performed by connecting the cuff-electrode to an external Tektronix 
stimulator (Tektronix, Inc., USA) (experiment 1) or to an external NeuroCybernetic 
Prosthesis device (NCP, model 100; Cyberonics Inc., USA) (experiment 2). The impedance of 
the electrode-to-vagus nerve interface was measured at the beginning and end of each 
experiment; impedance values were the same before and after the experiments for all animals 
and were always between 1 and 3 kΩ. In the first experiment, output voltage was set at 3 V 
(~1.5 ± 0.75 mA). Behaviourally, animals did not react to the stimulus given. In the second 
experiment, a current source (an external NeuroCybernetic Prosthesis device) was used, to 
assure that a constant current (1.5 mA) was provided. When a stimulus of higher intensity was 
given, animals behaviourally reacted by turning away of the head and sometimes by 
scratching toward the neck. A short test stimulus (duration: 1s; amplitude: 5 V or 2.5 mA, 
frequency: 30 Hz and pulse duration: 500 µs) was delivered after each experiment to confirm 
that true stimulation had been delivered. 
Epidural EEG stainless steel screw electrodes were bilaterally implanted over the 
fronto-parietal cortex. Two epidural electrodes were positioned left and right on the skull 
opposite to frontal cortex (AP= +2 mm, ML= ±1.2 mm, DV= 0 mm, referred to bregma) and 
two were placed left and right on the parietal cortex (AP= -2 mm, ML= ±1.2 mm, DV= 0 mm, 
referred to bregma). The reference electrode was placed at lambda. The EEG electrodes were 
fixed together with the cuff-electrode leads on the skull of the rat with acrylic cement. For the 
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EEG recording a H2O™ portable digital 32-channel EEG recorder (Telefactor Corporation, 
USA) was used. The data were quantified by visual inspection of the EEG using TWIN™ off-
line EEG-analysis (Telefactor Corporation, USA). In GAERS, during the awake state EEG 
amplitude is lower then 300 µV. During sleep, there is a high voltage synchronized activity, 
often accompanied with sleep spindles, but the appearance of SWDs on the EEG of sleeping 
GAERS is extremely rare (Pinault et al., 2001). Therefore, the following criteria were used for 
the detection of SWDs: duration: ≥ 1 s; amplitude: > 300 µV; EEG frequency: 7-12 Hz. 
The animals were allowed to recover for three to seven days before the experiments 
were performed. They were placed in the recording chambers one day before the experiments 
began and stayed there during the whole experimental period. The experiments were carried 
out during morning and early afternoon hours (light period). During the experiments, the 
animals were not receiving anesthetics and were freely moving. 
2.3 Experimental design  
2.3.1 Experiment 1: acute VNS at the onset of a SWD  
Stimulation parameters were set at 3 V, 30 Hz frequency and 500 µs pulses. The EEG 
was visually inspected and VNS was manually initiated every time a SWD occurred on the 
EEG and was stopped when the SWD ended. An automated detection system for SWDs in 
GAERS triggering VNS online when a SWD appeared on the EEG, was not available. Stimuli 
were given with an external Tektronix stimulator (Tektronix, Inc., USA). 
A randomized crossover design was used. Thirteen animals were implanted as 
described above. During two consecutive days, 2 h of EEG were recorded. During one hour, 
VNS was applied (VNS condition) and during the other hour, the animals were not stimulated 
(baseline condition). In the VNS group, baseline and VNS conditions were randomly 
assigned. The stimulation protocol of the stimulated animals (n= 8) is described in figure 1. 
To provide baseline values and to allow inter-group comparison a control group (n= 5) was 
included. 
Following the experiments, the duration of the SWDs (start and end of the SWD), 
was manually marked on the EEG recordings. The average latency to initiate VNS when a 
SWD appeared on the screen was 2.5 ± 1.0 s. Consequently, all SWDs with duration shorter 
than 2.5 s were left out of the analysis during baseline and VNS conditions, in both the 
control and stimulated group. 
For the statistical analysis of the intra-group comparison, we used the non parametric 
Wilcoxon signed rank test for paired samples. In the VNS group, paired comparisons were 
made for baseline conditions and VNS conditions in the same rat, on day 1 and day 2. Inter-
group comparison between the baseline values of the control group and the VNS condition 
values of the VNS group was performed by using a Mann-Whitney U test for day 1 and day 2. 
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2.3.2 Experiment 2: continuous application of VNS during ongoing SWD recording  
 For the purpose of this protocol, VNS was delivered by means of a 
programmable stimulating device (NeuroCybernetic Prosthesis, model 100; Cyberonics Inc., 
USA) using the following parameters: amplitude: 1.5 mA; frequency: 30 Hz; pulse duration: 
500 µs; on/off cycle: 30 s/ 5 min.  
On day 1, baseline EEG was recorded during four hours. For a period of five 
consecutive days, six rats were stimulated for 3 h/day. On day 2, 3 and 6, EEG was recorded 
during 4 h starting 1 h before stimulation (baseline). Two control GAERS underwent 
implantation of the recording and stimulation electrodes but were not stimulated, EEG was 
recorded during 4 h on day 1, 2, 3 and 6.  
On day 1, 2, 3 and 6, the number, the mean duration and EEG frequency of SWDs 
were compared between the first hour (hour 1, baseline) and the last hour of stimulation (hour 
4) in the control and the VNS group. For this purpose, a Wilcoxon signed rank test was used 
for paired samples. The Fisher’s exact test was used to compare the last hour of stimulation 
(hour 4) of day 1 with the last hour of stimulation (hour 4) of day 2, day 3 and day 6 in the 
control and the VNS group. 
 
3. Results 
3.1 Experiment 1: acute application of VNS at the onset of a SWD (Figure 1) 
On the first day of the experiment, the mean duration of the SWDs increased 
significantly (p< 0.05) in the stimulated hour versus the non-stimulated hour of the VNS 
group. The mean duration of SWDs without VNS was 13.3 s (SD= 4.1) and 19.4 s (SD= 4.7) 
with VNS in the stimulated group.  
When the experiment was repeated, there was no change in SWD duration on the 
second day of the study (day 2). When VNS conditions of the VNS group were compared 
with the baseline values of the control group, there were no significant differences on day 1 
and day 2. 
 
3.2 Experiment 2: continuous application of VNS during ongoing SWD recording 
(Figure 2) 
When baseline conditions (hour 1 of day 2, 3 and 6 and hour 4 of day 1) were 
compared to VNS conditions (hour 4 of day 2, 3 and 6) in the stimulated GAERS (n= 6) and 
in the control group (n= 2), no statistically significant differences could be found in number, 
duration and EEG frequency (Figure 2) of the SWDs. 
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On day 2, in both controls and VNS group, the average number of SWDs in all 
recording hours was lower than on the other days. 
 
 
 
 
 
 
 
4. Discussion 
The precise mechanism of action by which VNS exerts its anti-epileptic effect has not 
been elucidated. A better insight in the mechanism of action may help to identify specific 
epilepsy syndromes or types of epilepsy that respond well to VNS, a major issue that has not 
been resolved. Absence seizures in humans are usually a benign form of epilepsy (Wolf and 
Inoue, 1984). Despite the good pharmacological response in this type of epilepsy, 
investigating the efficacy of VNS in GAERS aims at identifying clues on the mechanism of 
action of VNS.   
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Figure 8: Acute effect of VNS on SWD duration in GAERS, experiment 1. Upper panel: 
study design (cross over); lower panel: X-axis: treatment group and Y-axis: mean 
duration of SWD per hour (s). Data are expressed as mean ± SD, * indicates 
significance, which is set at p< 0.05. 
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Initial animal studies with stimulation of vagal afferents showed promising results in 
reducing both ictal and interictal EEG abnormalities (Lockard et al., 1990; Woodbury and 
Woodbury, 1990; Woodbury and Woodbury, 1991; Zabara, 1992; McLachan, 1993; Takaya 
et al., 1996; Fernandez-Guardiola et al., 1999). These findings laid the foundation for the 
further development of VNS as a treatment for human epilepsy. So far, VNS has not been 
investigated in GAERS. As in this model the SWDs correlate strictly with the occurrence of 
clinical absences, we can state that this study investigated the effect of VNS both on ictal 
Figure 9: Effect of VNS on the number, duration and EEG frequency of SWD/hour in GAERS,
experiment 2. X-axis: day of the experimentation period; Y1-axis: mean number of SWD per hour;
Y2-axis: mean duration of SWD (s) and Y3-axis: mean frequency of SWD (Hz). Data are presented as
mean ± SD. 
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EEG and seizures. In the present study we were not able to suppress or shorten the typical 
EEG pattern associated with absence seizures in these animals when VNS was applied acutely 
or in a prolonged pattern over several days. On day 2 of experiment 2, there was a reduction 
in number of SWDs both in the VNS group and in the control group. It is unlikely that this 
reduction is due to the treatment. It could be related to external factors, as the occurrence of 
absence seizures in GAERS is sensible for changes to environmental conditions. 
VNS decreases interictal epileptiform spikes and spike and wave activity on the EEG 
over time, but may induce an initial synchronization of this epileptiform activity (Koo, 2001). 
This previous finding in man could correlate with our finding of an initial prolongation of the 
SWDs in GAERS during acute VNS in the first experiment. This prolongation was only seen 
on the first day of experiment 1. Precautions were taken to assure true stimulation during the 
whole experiment. This included the measurement of the impedance and a test stimulus at the 
end of the day. In a previous study, utilizing the same stimulation protocol, a decrease in body 
weight was observed after two weeks of VNS (Dedeurwaerdere et al., 2003). There remains 
however a need for a more direct and accurate measuring of the efficacy of the stimulation, 
both in animals and humans. Adapting the electrode to include measuring capability of action 
potentials of the different nerve fibres induced by VNS, could provide an answer to this 
question. 
 VNS efficacy in animals has mainly been assessed using acute models. In contrast, 
GAERS are a genetic model in which it takes four months before full epileptogenesis is 
established and can be considered as a chronic model with spontaneous seizures. Anti-
epileptic and even anti-epileptogenic effects of VNS were found in a chronic kindling model 
(Fernandez-Guardiola, 1999). But when VNS was tested for its efficacy in dogs with 
refractory epilepsy, seizure reduction was found only after nine weeks of stimulation 
(Munana et al., 2002). These animals studies, investigated VNS efficacy in convulsive 
seizures. Absence seizures, which are non-convulsive, use neuronal mechanisms that are 
different from convulsive events (Eskazan et al., 2002). The effect of VNS on convulsive 
seizures may be different from the effect on non-convulsive seizures. This differential effect 
has also been shown for certain anti-epileptic drugs (Marescaux et al., 1992). 
There are some reports of the use of VNS in human absence epilepsy (Labar et al., 
1998; Frost et al., 2001; Helmers et al., 2001; Labar et al., 2001; Farrag et al., 2002). Ben-
Menachem et al. (1999) described a positive effect of VNS in a small number of patients such 
as primary generalized epilepsy with absence seizures and generalized tonic clonic seizures. 
As these patients were treated with VNS, the absence seizures were most likely medically 
refractory. Typical absences and more refractory absence seizures may be distinct clinical 
entities. It is unknown to what extent GAERS are also a valuable model for refractory absence 
seizures. Apart from these reports in the literature, suggesting that generalized epilepsy 
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responds equally well to VNS as partial epilepsy, it appears that in several patients with 
absence epilepsy a significant decrease in seizure frequency was found only after six to 
twelve months of treatment with VNS (Parain et al., 2003). 
Some imaging studies show a differential effect of acute and chronic VNS on cerebral 
blood flow (Henry, 2000; Vonck et al., 2003). It could be that acute and chronic VNS have a 
different mechanism of action. Whereas acute VNS likely reflects a purely anti-convulsive 
effect, the major therapeutic effect of VNS has been assigned to chronic VNS, which is 
probably related to an anti-epileptic effect (Boon et al., 2002).  
Finally, the role of different stimulation parameters needs to be further investigated. It 
may be that different stimulation parameters are more efficacious in different types of 
epilepsy. Our experimental setup used stimulation parameters comparable to the ones used in 
humans.  
 
5. Conclusion 
 Acute application of VNS at the onset of SWDs and continuous application of VNS 
during ongoing SWD recording in GAERS failed to show seizure suppressing effects. VNS 
applied at the onset of SWDs can prolong the duration of SWDs in GAERS. It could be of 
great value to stimulate GAERS over an extended period to observe chronic effects. 
Epileptogenesis in GAERS is a process that takes months so it is not unlikely that a longer 
stimulation period is required to make a difference and to affect an established pathology. 
This reasoning is supported by several studies in humans that describe a cumulative effect of 
VNS resulting in increased efficacy over a longer period of time. Further research using 
different stimulation parameters and/or a longer stimulation period is necessary to elucidate 
the real nature of the effect of VNS on SWDs in GAERS. 
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PURPOSE: The aim of this study is to evaluate the efficacy of acute and chronic vagus nerve 
stimulation (VNS) in genetic absence epilepsy rats from Strasbourg (GAERS). This is a 
validated model for absence epilepsy, characterized by frequent spontaneous absences 
concomitant with spike and wave discharges (SWDs) on the EEG. Although absences are a 
benign form of seizures, it is conceptually important to investigate the efficacy of VNS in a 
controlled study by using this chronic epilepsy model.  
METHODS: Both control and stimulated GAERS were implanted with five epidural EEG 
electrodes and a stimulation electrode around the left vagus nerve.  
In the first experiment, VNS was given when SWDs occurred on the EEG; this was repeated 
the next day. A randomized cross-over design (n= 8) was used. 
In the chronic experiment, GAERS underwent EEG monitoring during a first baseline week. 
During the second week, the treated group (n= 18) received VNS, controls (n= 13) on the 
other hand only underwent EEG recordings.  
RESULTS: On day 1 of the acute VNS experiment, the mean duration of the SWDs when 
VNS was applied was higher than in baseline conditions (p< 0.05). However, on day 2, there 
was no difference in mean duration of the SWDs.  
In the chronic VNS experiment no statistically significant differences were found between 
control and stimulated GAERS.  
CONCLUSION: Acute VNS applied shortly after the onset of SWDs prolonged the mean 
duration of SWDs in GAERS at least during the first day of VNS. Chronic stimulation hardly 
affected SWDs in GAERS.  
 
Key words: vagus nerve stimulation (VNS), GAERS, absence epilepsy 
 
 
1. Introduction 
Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy. It is 
used in generalized and partial epilepsy (Ben-Menachem, 2002), although responder groups 
have not been clearly identified. Knowledge about the efficacy profile of VNS in non-
convulsive generalized epilepsy, i.e. absence epilepsy, is limited because patients with this 
type of epilepsy generally have a good pharmacological response. Extensive therapeutic use 
of VNS in absence epilepsy is therefore unlikely, but information about the potential efficacy 
of VNS in this type of epilepsy could help to clarify the general principles that underlie VNS.  
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GAERS are a validated genetic model for absence epilepsy characterized by typical 
spike and wave discharges (SWDs) on the EEG during absence seizures (Danober et al., 
1998).  
 This work evaluates the efficacy of acute and chronic VNS in this model of primary 
generalized epilepsy. We investigated if acute VNS can abort SWDs and if chronic 
stimulation suppresses absence seizures. 
 
2. Methods 
Thirty-nine GAERS (male and female), weighing 200-300 g and between four to six 
months of age, were used in this study. All animals were treated according to guidelines 
approved by the European Ethics Committee (decree 86/609/EEC), confirmed by an approval 
of the local ethical committee for animal studies. 
 The animals were implanted with a cuff-electrode around the left vagal nerve and 
with five epidural EEG electrodes as described previously (Dedeurwaerdere et al., 2004). This 
cuff-electrode has been successfully used in suppressing pentylenetetrazole (PTZ) evoked 
seizures during experiments of Takaya et al. (1996).  
After one week of recovery, the animals were placed in a recording cage one day 
before EEG recordings began and stayed there for the whole experimental period. Stimulation 
parameters used in this study were based upon previous experiments (Woodbury and 
Woodbury, 1990; Woodbury and Woodbury, 1991; McLachlan et al., 1993; Takaya et al., 
1996). The impedance of the electrode-to-vagus nerve interface was measured at the 
beginning and end of each stimulation session. A short test stimulus of higher intensity (2.5 
mA, 500 µs pulses at 30 Hz for 1 s), which provoked a behavioral reaction of the rat (turning 
away of the head or flattening of the ears and sometimes scratching toward the neck), was 
used to check proper functioning of the stimulation configuration. Strong and unexpected 
sensory stimulations immediately interrupt SWDs in GAERS (Danober et al., 1998). This was 
also the case for the high intensity test stimulus and we therefore selected a subthreshold 
stimulation of 1.5 mA in this study. 
2.1 Experiment 1: acute VNS  
Because the response time of the stimulator normally used in VNS (see below) was 
too long (> 1 s) for the acute interference experiments, stimuli (500 µs pulses at 30 Hz) had to 
be applied by a standard voltage source (Tektronix, Inc., USA). Cuff-impedance was 
measured before and after each experiment (between 1 and 3 kΩ) and stimulation voltage was 
adjusted to deliver a current of 1.5 mA. EEG was visually inspected by an experienced 
electroencephalographer (SD) and VNS was manually switched on every time a SWD 
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occurred; it was stopped once the SWD had ended. A randomized crossover design (n= 8) 
was used: two hours of EEG were recorded on two consecutive days. During one hour, VNS 
was applied (VNS condition) and during the other hour, the animals were not stimulated 
(baseline condition).  
Following the experiments, the start and end of the SWDs and VNS were marked on 
the EEG recordings. The average latency between the start of the SWD and the activation of 
VNS was 2.5 ± 0.4 s. Consequently, all SWDs with duration shorter than 2.5 s were left out of 
the analysis during baseline and VNS conditions.  
Averaged data are presented as mean ± standard error of the mean (SEM). For the 
statistical analysis, we used the non-parametric Wilcoxon signed rank test for paired samples 
to compare mean duration in baseline conditions and VNS conditions in the same rat, on day 
1 and on day 2. P< 0.05 is assumed to indicate a significant difference. 
2.2 Experiment 2: chronic VNS   
In the chronic VNS experiment, stimuli were delivered by a constant current 
stimulator, normally used in VNS (NeuroCybernetic Prosthesis system, model 100, 
Cyberonics Inc., USA). Following settings were used: amplitude: 1.5 mA; frequency: 30 Hz; 
pulse duration: 500 µs; on/off cycle: 60 s/ 12 s. During a first week (baseline period), animals 
(n= 31) were not stimulated. During a second week, 18 GAERS were stimulated 24/24 h and 
control GAERS (n= 13) were only recorded. EEG was recorded for 3 h on day 7 and again on 
day 14. The detection of the SWDs on the EEG was performed using a custom designed 
software package in Labview (Van Hese et al., 2003). 
The number of SWDs per hour, their mean duration, cumulative duration per hour 
and peak frequency is compared. Data are presented as the mean and the SEM. Groups are 
compared using the Mann-Whitney U-test (controls and VNS group) or the Wilcoxon signed 
rank test (paired observations: day 7 and day 14). P< 0.05 was assumed to indicate a 
significant difference. 
 
3. Results 
3.1 Experiment 1: acute VNS  
 On the first day of the acute VNS experiment animals (n= 8) received 23 ± 5 
stimulations, on the second day 29 ± 7 stimulations were given (NS). When the experiment 
was performed for the first time, the mean duration of the SWDs was higher when VNS was 
switched on (19.4 ± 1.7 s) compared to the baseline condition (13.3 ± 1.4 s) (p< 0.05, Figure 
1). The second day of the experiment, the small difference in mean duration of the SWDs: 
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15.7 ± 2.8 s under baseline conditions versus 16.8 ± 1.8 s with VNS switched on, did not 
reach significance.  
3.2 Experiment 2: chronic VNS  
SWD characteristics (number per hour, mean duration, cumulative duration per hour 
and peak frequency) of controls (n= 13) were compared with those of stimulated GAERS (n= 
18). No differences in any of these parameters between control and treated animals could be 
detected (Table 1, Figure 2).  
A decrease in cumulative duration of SWDs between baseline condition (day 7) 
versus stimulation condition (day 14) was observed in both the control group (n= 13) and the 
VNS group (n= 18) (Figure 2). This cumulative duration of SWDs/hour in the VNS group 
was significantly higher before (day 7): 472 ± 94 s, than after (day 14) one week of VNS: 300 
± 61 s (Figure 2). The other SWD characteristics were not significantly different between 
both conditions (Table 1). 
 
4. Discussion 
Basic research of VNS in convulsive generalized and partial epilepsy models 
(Lockard et al., 1990; Woodbury and Woodbury, 1990; Woodbury and Woodbury, 1991; 
Zabara, 1992; McLachlan et al., 1993; Takaya et al., 1996; Fernandez-Guardiola et al., 1999) 
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Figure 1: Experiment 1: Acute vagus nerve
stimulation (VNS). Mean duration of SWD in
GAERS (n= 8), without (open bars) and with
(filled bars) the initiation of acute VNS once
the SWD was detected. Identical experiments
were performed on day 1 and day 2. Vertical
lines on the bars indicate SEM. * indicates p<
0.05. 
Figure 2: Experiment 2: Chronic vagus nerve 
stimulation (VNS). Cumulative duration of 
SWD in seconds over one hour of recording 
for GAERS without ( n= 13) and with (n= 18) 
the application of the chronic VNS protocol 
(0.5 ms, 1.5 mA, pulses at 30 Hz, 60 s on, 12 
s off). Vertical lines on the bars indicate 
SEM. * indicates p< 0.05. 
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predicted positive results of VNS in epilepsy patients, but has so far failed to clearly identify 
good responders. Such fundamental data are presently completely lacking for absence 
epilepsy, a benign form of epilepsy. Human data are limited because VNS is only applicable 
in refractory absence epilepsy or when unacceptable side effects of anti-epileptic drugs 
(AEDs) occur. Investigating the efficacy of VNS in GAERS, a chronic epilepsy model with 
spontaneous seizures, could help to identify clues that predict the outcome of VNS. In this 
study we investigated the efficacy of VNS in a chronic animal model of epilepsy (seizures 
evolving from true and genetically-driven epileptogenesis) different from the common acute 
seizure models used so far, such as the PTZ model and the maximal electroshock model. 
In experiment 1, a prolongation of the SWDs was found when VNS was started about 
2.5 seconds after the initiation of the SWDs. An initial synchronization of epileptiform spikes 
and spike-wave activity on the EEG during VNS has been reported in man (Koo, 2001), 
which might resemble the initial increase in mean SWD duration observed here. We do not 
have a simple explanation for the aggravating effect of VNS on SWDs. At least it indicates 
that VNS stimulation can quickly exert an effect on local neuronal circuitry. On the other 
hand it also shows that SWDs are not easily aborted by VNS once they are ongoing. Absence 
seizures are non-convulsive and they most likely use different neuronal mechanisms than do 
convulsive events (Eskazan et al., 2002). Besides anecdotal reports of seizure aggravation by 
acute VNS, this is the first situation where VNS systematically prolongs an epileptic event, a 
phenomenon not uncommon for anti-epileptic drugs such as carbamazepine, phenytoin and 
GABAA mimetics (Danober et al., 1998).  
The prolongation seems related to an acute effect of VNS; it disappears in a subacute 
experimental setting with several hours of VNS per day (Dedeurwaerdere et al., 2004) and 
also in the chronic setting of the second experiment. A difference between the effect of acute 
and continuous subthalamic nucleus (STN) stimulation on SWDs in GAERS has also been 
reported (Verceuil et al., 1998). SWDs could be aborted by acute STN stimulation, while 
there was no effect during a 10-min stimulation period.  
 VNS in man is typically delivered on the left vagus nerve. Krahl et al. (2003) have 
stated that right VNS is as effective as left VNS and should not induce significant cardiac 
effects when using clinically relevant stimulation parameters and a careful surgical technique. 
Stimulating both vagus nerves may affect a larger part of the brain and have a stronger effect 
on neuroexcitability, but this hypothesis has not yet been investigated. In the case of 
trigeminal nerve stimulation (TNS), bilateral TNS was more effective at reducing PTZ 
induced seizures than unilateral stimulation (Fanselow et al., 2000). 
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Table 2: Experiment 2: Chronic vagus nerve stimulation (VNS).  
Number over one hour of recording, mean duration and peak frequency of SWDs in control (n= 13) and 
chronic VNS group (n= 18) on day 7 and day 14. 
 
In the chronic VNS experiment, cumulative SWD duration was significantly reduced 
in the VNS group, but the effect was very similar in the control group where it just did not 
reach significance. A previously reported spontaneous reduction of seizures in GAERS may 
be an interfering factor (Dufour et al., 2001; Rigoulot et al., 2003). This phenomenon is 
correlated with the decrease of vigilance resulting in more sleep episodes and less and shorter 
seizures (Dufour et al., 2001; Rigoulot et al., 2003). It could also explain the fewer seizures 
and shorter mean SWD durations that we found in our chronic experiment (Table 1) 
compared to previously published experiments in GAERS, which were monitored only for a 
short period of time (Danober et al., 1998). 
Epileptogenesis in GAERS is a process that takes months, so it cannot be excluded 
that a longer VNS period is required to affect an already established absence epilepsy 
syndrome. This assumption is supported by several studies in humans describing a cumulative 
effect of VNS resulting in increased efficacy over a longer period of time (Vonck et al., 
1999). 
 From this study we can conclude that acute and chronic (during one week) VNS have 
no suppressing effect on SWDs in GAERS. Moreover, acute VNS applied shortly after the 
onset of SWDs prolongs the mean duration of SWDs in GAERS at least during the first day 
of VNS. 
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Number of SWDs/h Mean duration of SWDs (s) 
Peak frequency of 
SWDs (Hz) 
Day 7 37.0 ± 8.4 11.6 ± 1.7 8.1 ± 0.2 Control group 
(n= 13) Day 14 27.5 ± 6.4   9.6 ± 1.6 7.7 ± 0.2 
Day 7 35.7 ± 5.3 11.4 ± 1.2 8.0 ± 0.1 VNS group     
(n= 18) Day 14 33.2 ± 5.0   8.5 ± 0.9 7.9 ± 0.1 
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Vagus nerve stimulation does not affect memory in Fast rats,  
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Rationale: Using a seizure-prone Fast-kindling rat strain with known comorbid behavioral 
features, we investigated the effects of vagus nerve stimulation (VNS) on spatial memory, 
epileptogenesis, kindled seizures and body weight. 
Methods: Electrodes were implanted in both amygdalae and around the left vagus nerve of 17 
rats. After recovery, rats were first tested in the Morris water-maze (MWM) utilizing a fixed 
platform paradigm. The VNS group received 2 h of stimulation prior to entering the MWM. 
To investigate the effects of VNS on the kindling process, the VNS group received 2 h of 
stimulation prior to daily kindling stimulation. The abortive effects of acute VNS were then 
determined in fully kindled rats by applying VNS immediately after the kindling pulse. Body 
weight, water consumption and food intake were measured throughout. 
Results: Memory performance in the MWM was not different between control and VNS rats.  
Also kindling rate was unaffected by antecedent VNS; besides, pro-convulsive effects were 
noted during the stage-5 convulsions in the VNS group (p< 0.01). Still, VNS showed anti-
convulsant effects (p< 0.01) in fully kindled rats when applied immediately after the kindling 
stimulus. Body weight was significantly lower during kindling (p< 0.01) in VNS-treated rats 
compared to controls, which was associated with reduced food intake, but without difference 
in water consumption. 
Conclusion: VNS stimulation appears to be devoid of significant cognitive side effects in the 
MWM. Although VNS exhibited no prophylactic anti-epileptic effect on epileptogenesis or 
seizure severity when applied prior to the kindling stimulus, it showed significant anti-
convulsant effects in fully kindled rats when applied after seizure initiation. Lastly, VNS 
slowed the weight gain associated with kindling by reducing food intake.  
 
Key words: vagus nerve stimulation (VNS), amygdala kindling, fast rats, memory, body 
weight 
 
1. Introduction 
 Vagus nerve stimulation (VNS) is an efficacious broad-spectrum add-on treatment for 
patients with medically or surgically refractory epilepsy (Ben-Menachem, 2002). Treatment 
involves stimulation of the left vagus nerve via an implanted pulse generator in an attempt to 
reduce the frequency and severity of epileptic seizures. Controlled randomized trials with VNS 
have shown a 50% reduction in overall seizure frequency in approximately 30% of patients 
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(Salinsky, 2003). However, the mechanism of action remains unclear and basic research using 
chronic animal models of epilepsy is limited.  
 Kindling is considered to be one of the best animal models of temporal lobe epilepsy. 
Using a Fast-kindling rat strain, with known behavioral comorbidities, we investigated the 
therapeutic profile of VNS. The original Fast-kindling and Slow-kindling rat strains were 
created through selective breeding of two outbred parent strains (Long Evans Hooded and 
Wistar rats) (McIntyre et al., 1999). The selected strains demonstrate strong genetic control 
over amygdala epileptogenesis with faster rates of kindling in the Fast-kindling strain (Racine 
et al., 1999). In addition to faster kindling rates, the Fast strain shows behavioral 
comorbidities, including relatively greater impulsivity, hyperactivity and learning impairments 
compared to Slow rats (Anisman and McIntyre, 2002). Fast rats also exhibit greater body 
weights throughout development than the Slow strain. 
 Several studies have observed improved alertness, behavior and mood following VNS 
treatment in patients with refractory epilepsy, independent of changes in seizure frequency 
(Elger et al., 2000; Harden et al., 2000; Harden, 2001; Kossoff and Pyzik, 2004). In rats, as 
well as in humans, Clark and colleagues found that VNS was able to enhance memory storage 
when applied acutely during memory consolidation, which was dependent on an inverted-U 
shaped function of the stimulation current (Clark et al., 1995; Clark et al., 1998; Clark et al., 
1999). In contrast, chronic VNS application in a clinical setting did not affect cognitive 
performance in patients with epilepsy using standardized tests (Hoppe et al., 2001; Dodrill and 
Morris, 2001). As a further test of the effects of VNS on memory processes, we wanted to 
investigate the impact of VNS on spatial learning in the Morris water-maze (MWM), when 
applied prior to each learning session in seizure-prone Fast rats, which have natural learning 
problems.  
 Initial animal studies showed promising results for VNS, which reduced both seizures 
(Lockard et al., 1990; Woodbury and Woodbury, 1990; Woodbury and Woodbury, 1991; 
Zabara, 1992; Takaya et al., 1996) and interictal EEG abnormalities (McLachlan, 1993). 
Consequently, VNS was further explored as a treatment for human epilepsy. VNS efficacy in 
animals has primarily been assessed in acute models (3-mercaptopropionate, 
pentylenetetrazole, maximal electroshock, penicillin or strychnine application) utilizing 
stimulation protocols immediately before and/or after seizure induction. However, only a few 
studies have assessed the effect of VNS in chronic animal models of epilepsy (Lockard et al., 
1990; Munana et al., 2002; Dedeurwaerdere et al., 2004; Dedeurwaerdere et al., 2005). For 
instance, Fernandez-Guardiola et al. (1999) demonstrated that VNS inhibited epileptogenic 
processes during kindling in cats. Further investigation using such chronic epilepsy models 
may help to elucidate the mechanism of action of VNS, which should ultimately lead to a 
more hypothesis-driven approach to VNS clinical trials and guide the search for optimal 
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stimulation parameters and appropriate patient populations. This study was designed to 
investigate the effect of VNS on the progression of daily amygdala kindling in the Fast-
kindling rat strain and to then examine its anti-convulsant properties in fully kindled Fast rats.  
 In addition, since weight reduction has been reported in patients treated with VNS 
(Burneo et al., 2002; Kneedy-Cayem et al., 2002), we wanted to validate this observation in 
Fast rats. In a previous study using genetic absence epilepsy rats from Strasbourg (GAERS), 
we observed a significant weight reduction after two weeks of chronic VNS (Dedeurwaerdere 
et al., 2003). Because seizure-prone Fast rats exhibit increased body weight compared to 
seizure-resistant Slow rats and amygdale kindling is known to increase body weight (Loscher 
et al., 2003; Bhatt et al., 2004), we aimed to study the effects of VNS on body weight 
throughout this study. 
 
2. Methods 
2.1 Animals 
Seventeen Fast-kindling rats were bred and raised in the Life Science Animal Facility 
of Carleton University and treated in accordance with the guidelines of the Canadian Council 
on Animal Care and a protocol approved by the Carleton University Animal Care Committee. 
After weaning, rats were housed in pairs in standard opaque plastic cages (32 cm x 22 cm x 
20 cm) with free access to food and water. They were maintained on a 12 h light/dark cycle 
(lights on at 8 a.m.) at 23°C with 60% relative humidity. At the time of the experiments, rats 
weighed between 300 and 450 g and were singly housed. 
2.2. Surgery 
 After 4-7 days of daily handling, rats were anesthetized with sodium pentobarbital 
(Somnotol, 65 mg/kg) via intraperitoneal (i.p.) injection. A deep level of anesthesia during the 
surgical procedures was maintained by means of inhalation anesthesia utilizing Isoflurane 
(1%). 
2.2.1. Implantation of the vagus nerve cuff-electrode 
 A self-sizing spiral silicone cuff-electrode (inner diameter: 0.7 mm) with recessed 
platinum contacts (surface: 1 x 2 mm, stimulation poles separated by 2 mm) and with flexible 
leads was used to deliver VNS. We have previously assessed the electrophysiological 
properties of this electrode and it was able to activate different nerve fibers at intensities 
lower than when using a simple wire cuff-electrode, likely due to minimized shunting of 
current to surrounding tissue. 
 The stimulation cuff-electrode was implanted as described previously (Takaya et al., 
1996; Dedeurwaerdere et al., 2004). The cuff-electrode leads, attached to male Amphenol 
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pins, were tunneled subcutaneously towards the head and were inserted together with the EEG 
electrodes in a plastic head cap (Molino and McIntyre 1972). 
2.2.2. Implantation of the depth electrodes 
Bipolar stimulating/recording electrodes, consisting of two twisted strands of 0.127 
mm diameter Diamel-insulated Nichrome wire attached to male Amphenol pins and cut to 
approximately 9 mm, were implanted in both amygdalae. Stereotaxic coordinates for the 
implantation were 0.2 mm posterior to bregma, 4.5 mm lateral to the midline and 8.2 mm 
below the skull surface (Paxinos and Watson, 1998). Five stainless steel screws, embedded in 
the skull and secured with dental acrylic, were used to anchor the electrodes in place. The 
Amphenol pins were inserted in the plastic head cap and secured in place by dental acrylic 
according to standard procedures (Molino and McIntyre, 1972). Following surgery, rats were 
given acetaminophen rectal gel, a topical analgesic (bupivacaine) and a subcutaneous 
injection of saline (NaCl 0.9%, 2 ml/kg) and then placed in plastic cages under warming 
lamps to maintain normal body temperature until behaviorally active. Rats were then returned 
to the colony room and allowed a two week recovery period before the initiation of kindling.  
2.3. Vagus nerve stimulation 
VNS was performed by connecting the cuff-electrode to an external NeuroCybernetic 
Prosthesis device (NCP, model 100; Cyberonics Inc., USA). Similar to VNS practice, the 
output current was ramped up to a just tolerable level of stimulation (Handforth et al., 1998). 
The following stimulation parameters were used for chronic stimulation: output current: 0.25-
0.5 mA; pulse duration: 500 µs; frequency: 30 Hz; and on/off duty cycle: 30 s/ 1.1 min. When 
a stimulus of higher intensity was given, animals behaviorally reacted by flattening the ears, 
taking a fixed posture and sometimes vocalizing. A short test stimulus (output current: 1 mA; 
pulse duration: 500 µs; frequency: 30 Hz and duration: 1s), which evoked a behavioral 
response, was delivered daily in treated animals to check the integrity and impedance of the 
electrode-to-vagus nerve interface. The impedance values were always between 10 and 20 
kΩ, which was within the range to deliver output currents of 0.5 mA. 
2.4. Experiments 
2.4.1. Effect of VNS on spatial memory in the Morris water-maze 
 The Morris water maze (MWM) is frequently employed to assess working memory. 
Much is known about the behavior of Fast rats in that context (Anisman and McIntyre, 2002). 
The MWM we used was a white, circular polypropylene pool (158 cm in diameter, 60 cm in 
height) that was filled with water (21°C and 38 cm deep) made opaque by the addition of 
powdered milk. A clear Plexiglas platform (14 cm in diameter) was submerged 2 cm below 
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the surface. The laboratory contained many extra maze cues for spatial orientation and the 
experimenter remained in the same position throughout the training.  
 The MWM test requires that an animal, placed in different start positions in the maze, 
locates and ascends a submerged platform. Acquisition performances were compared between 
control (n= 10) and VNS (n= 7) groups. All rats were placed in white plexiglass cages for 2 h 
before training began in the MWM, but only the VNS group received 2 h of stimulation, using 
the parameters described above. There were four training days during which the rats received 
four trials per day in the MWM to learn the location of the submerged platform and latency to 
reach the platform was measured. The platform remained in the same location throughout the 
entire experiment, while the starting location for the rats on the four daily trials varied 
between the four maze quadrants.  
 Cumulative latency to ascend the platform per day (sum of the four trials on each 
day) and per trial (sum of each trial over the four days) was calculated. Differences between 
the control and VNS groups in cumulative latencies were assessed using ANOVA with 
repeated measures. Data are presented as mean ± standard error of the mean (SEM) and 
significance is set at p< 0.05. 
2.4.2. Effect of VNS on amygdala kindling 
- Effect of VNS on afterdischarge threshold (ADT)  
On the first day before daily kindling, initial (prekindling) ADTs and associated 
afterdischarges (AD) were determined for both amygdalae. The ADT was defined as the 
minimum stimulus intensity required to trigger a clearly discriminable, high-voltage, 
electrographic seizure event (an AD) that outlasted the stimulus by two or more seconds 
(Kelly et al., 1999). To assess the threshold, a 1 s, 60 Hz sine wave stimulus of progressively 
increasing intensity (15, 25, 35, 50, 75, 100, 150, 200, 300, 400, 500, 600 µA) was delivered 
until an AD was observed using a constant current generator. The interval between 
stimulations was 1 min. The interval between amygdala threshold determinations in the 
structure to be kindled (primary site) and contralateral amygdala was 10 min. During the ADT 
determinations, none of the animals received VNS. In one rat an AD could not be elicited and 
it was excluded from further kindling experiments. Post-kindling ADTs and associated 
behavioral profiles were also determined in both amygdalae 24 h after the last stage-5 
behavioral seizure was elicited from the primary site.  
- Effect of VNS on kindling development 
 Fast rats (n= 16) were stimulated in the amygdala once daily at their individual ADT 
intensity (Racine, 1972). During the course of kindling, if the rat failed to respond with an 
AD, it was stimulated at a higher intensity until an AD was evoked (using the increment 
technique described for ADT determination). Kindling continued until five stage-5 seizures 
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were accumulated. Kindling rate was defined as the number of AD-evoking stimulations 
necessary to develop the first stage-5 convulsion (Racine, 1972). Cumulative AD duration 
(ADD) was defined as the sum of ADDs from the primary site elicited prior to reaching the 
first stage-5 seizure. The stages of behavioral seizures were recorded and seizure severity was 
classified according to Racine (1972): Stage 1, immobility, eye closure, twitching of vibrissae, 
sniffing, facial clonus; Stage 2, head nodding associated with more severe facial clonus; Stage 
3, clonus of one forelimb; Stage 4, rearing, often accompanied by bilateral forelimb clonus; 
Stage 5, rearing with loss of balance and falling accompanied by generalized clonic seizures. 
The convulsion profile of the five stage-5 seizures was determined by measuring latency to 
rearing and bilateral forelimb clonus, the duration of the stage-5 clonus and ipsilateral and 
contralateral ADDs . 
During the kindling process, the vagus nerve was stimulated for 2 h prior to the 
kindling stimulus in the VNS group (n= 7), because it has been previously demonstrated that 
VNS has prophylactic action after prolonged stimulation (Takaya et al., 1996). In one VNS 
rat, electrical lead fracture occurred after four kindling days with VNS; hence this rat was 
excluded from the analysis. The control group (n= 8) was kindled in the same way as the VNS 
group, but did not receive VNS. 
- Anti-convulsive effect of VNS on stage-5 seizures 
 In six animals with intact cuff-electrodes, the effects of acute VNS (for 60 s initiated 
using a magnet to trigger the device) on their stage-5 seizure profile was assessed. This VNS 
stimulation was applied approximately 2 s after induction of the kindling stimulus and the 
profile of the seizure was determined. Ten ‘control’ rats received the same kindling 
stimulation, without VNS. The next day, all rats received an additional kindling stimulation, 
which was also applied without VNS, as a further control observation. To assess the effect of 
acute VNS on amygdala kindled seizures, the following parameters were determined for all 
seizures: latency to bilateral forelimb clonus, the duration of clonus and the associated AD 
duration in the ipsilateral and contralateral amygdalae. In fully kindled rats, a stage-5 
generalized convulsive seizure, characterized by forelimb clonus with rearing and falling, is 
generally evoked at the ADT. Thus, we also compared post-kindling ADTs and associated 
behavioral profiles between VNS-treated and control rats. 
- Statistical analysis 
Differences between control and VNS groups were determined using the Mann-
Whitney U test for seizure severity (behavioral score) or by the Student's t-test for all other 
dependent values. ADTs and their primary ADDs at both the primary and contralateral sites 
were also compared before and after kindling using the paired Student's t-test. To determine 
differences in the convulsion profile between both groups, ANOVA with repeated measures 
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was used. Data are presented as mean ± standard error of the mean (SEM) and significance is 
set at p< 0.05.  
2.4.3. Effect of VNS on body weight 
During the kindling experiments, all rats were weighed daily. On four consecutive 
days, food and water consumption were also measured in control and VNS groups by 
weighing the water bottles and the food. Differences in weight gain during the kindling 
process (body weight on the day of prekindling ADT determination was used as reference), 
water consumption and food intake were assessed using ANOVA with repeated 
measurements. 
2.5. Histology 
Rats were perfused 24 h following the final kindling stimulus for histological 
assessment of stimulating/recording electrode placements. Each rat was deeply anesthetized 
with 65 mg/kg sodium pentobarbital and was then perfused intracardially with saline followed 
by 10% formalin. One day later, the electrodes were removed from the cranium and the brains 
were excised and stored in 30% sucrose for at least three days before sectioning. Frozen 
sections of 40 µm were taken through the electrode tract tips and stained with cresyl violet to 
identify the kindled site. 
 
 
3. Results 
3.1. Effect of VNS on spatial memory in the Morris water-maze test 
Spatial memory was not altered in VNS Fast rats compared to control Fast rats in the 
MWM. Specifically, cumulative latencies to reach the platform over trials or days were not 
different between control and VNS groups (Figure 1). As expected, cumulative latencies to 
reach the fixed platform declined over days indicating a learning curve for both groups 
(Figure 1). Clearly, VNS stimulation had no negative impact on acquisition of learning in 
naïve seizure-prone Fast rats in the MWM. 
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3.2. Effect of VNS on amygdala kindling 
In all animals, histological examination confirmed placement of the kindling 
electrodes in the amygdala. 
3.2.1. Effect of VNS on afterdischarge threshold (ADT) 
Before kindling, no significant differences were observed between VNS and control 
groups with respect to ADTs or evoked ADDs from either the ipsilateral or contralateral 
amygdala kindling sites (Table 1). After kindling, ADTs from the kindled and contralateral 
site were again not significantly different between the groups, yet ADT stimulation evoked a 
stage-5 seizure at the primary site in all previously VNS-treated rats, whereas the mean 
seizure stage evoked in control rats surprisingly was only 3 ± 1 (p< 0.05). This might suggest 
that previous VNS treatment can render the amygdala more excitable when VNS is not 
provided shortly before the ADT testing procedure. 
As expected, ADDs were significantly prolonged in the amygdalae after kindling 
when ADTs were re-determined from both the primary (ipsilateral) and the contralateral site 
within the VNS group (p< 0.01, Table 1). This was also noted as a trend in the control group, 
but was however not significant (p< 0.085).  
Figure 1: Effect of VNS on spatial memory as tested with a fixed platform position. Cumulative 
acquisition latencies to reach the platform for the control (n= 10) and VNS group (n= 7), A: on the four
consecutive days and B: on the four daily trials. VNS was applied during 2 h before the Morris-water-
maze test in the VNS group. Data are expressed as mean ± SEM. 
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3.2.2. Effect of VNS on kindling development  
Kindling rate and cumulative ADD to the first stage-5 seizure were not different 
between control (n= 8) and VNS treated (n= 7) rats (Table 2). Notably, one rat in the VNS 
group exhibited a kindling rate (23 stimuli) that was remarkably delayed in comparison to the 
control group (5.9 ± 0.5 stimuli).  
 
Table 3: Effect of chronic VNS on kindling rate and cumulative afterdischarge duration (ADD) to 
develop stage-5 seizures in controls and VNS treated fast rats. 
Group N Kindling rate Cumulative ADD (s) to stage-5 
Control group 8 5.9 ± 0.5 275.1 ± 36.7 
VNS group 7 8.6 ± 2.5 502.0 ± 210.1 
 
Control and VNS group were stimulated once daily at afterdischarge threshold (ADT). The VNS group 
received daily VNS for 2 h before kindling. The table shows the average number of stimulation 
sessions to the first stage-5 seizure and the cumulative ADD to the first stage-5 seizure (all data with 
SEM). Cumulative ADD at the primary site was calculated by summing up the individual ADDs until 
the first stage-5 seizure.  
 
With respect to convulsion profile, no significant differences in latency to rearing 
with bilateral forelimb clonus were apparent between VNS and control groups (Table 3). 
Surprisingly, convulsion duration of the stage-5 seizures was actually longer in the VNS 
group than in the control group (p< 0.01, Table 3). Related to this, the mean ADDs of the 
ipsilateral and contralateral amygdala tended to be longer in the VNS group (p< 0.09), 
however not significantly.   
Table 4: Effect of VNS on the convulsive profile (five stage-5 seizures) in amygdala kindled fast rats. 
Group N Mean latency (s) Mean convulsion duration (s) 
Mean ADD (s) 
(ipsilateral) 
Mean ADD (s) 
(contralateral) 
Control group 8 20.3 ± 3.8 36.4 ± 4.1 76.6 ± 8.8 74.8 ± 9.2 
VNS group 7 29.0 ± 7.2 56.9 ± 5.3** 103.6 ± 12.2 102.0 ± 12.6 
 
All stimulations were carried out at ADT. Data are means and SEM of the five stage-5 seizures. Highly 
significant (p< 0.01) differences between both groups are indicated by **.  
 
3.2.3. Anti-convulsive effect of VNS on stage-5 seizures 
 Statistically, when all VNS rats were treated equally, the VNS group showed 
significantly reduced ADDs in the ipsilateral and contralateral amygdalae in the anti-
convulsive test (p< 0.01, Figure 2).  Specifically, in two out of six VNS-treated rats, the stage-
5 convulsion was completely suppressed when VNS was administered immediately after the 
kindling stimulus. Behavioral suppression in those two rats was associated with significantly 
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reduced ADDs in the ipsilateral and contralateral amygdalae. However, the other four VNS 
treated rats and all control rats (n= 10) displayed very similar generalized seizure profiles with 
respect to behavioral latencies, convulsion durations and ADDs. The next day, when VNS 
was withheld in the VNS group, no differences in behavioral stage, latency, convulsion 
duration or ADDs were evident between the two groups of rats (data not shown). 
 
3.2.4. VNS side effects 
 During the kindling experiments, several side effects of daily VNS were observed, 
including increased urination and defecation, drooling and tearing (mostly left eye and 
sometimes both eyes). 
 
3.3. Effect of VNS on body weight 
Control Fast rats showed a gradual weight gain while the VNS group remained at a 
relatively stable weight throughout the kindling process (Figure 3). Hence, body weight was 
significantly (p< 0.05) lower in the VNS group throughout the majority of the kindling 
process. Accordingly, food consumption was significantly reduced in the VNS group 
compared to control Fast rats (p< 0.05, Figure 3). On the other hand, no difference in water 
consumption was observed between the two groups (data not shown).  
 
 
 
 
 
Figure 2:  Anti-convulsive effect of acute VNS on stage-5 seizures in amygdala kindled Fast rats. After 
all animals had displayed five stage-5 seizures (fully kindled), anti-convulsive effects of VNS were tested 
by applying a 60 s VNS train immediately after the kindling stimulus was initiated in the VNS group (n=
6). Only the kindling pulse was administered to the control group (n= 10).  Data are expressed as mean ± 
SEM, significance is set at p< 0.05, ** p< 0.01 and a p= 0.059 (borderline missed significance). 
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4. Discussion 
The present study investigated the effect of VNS on spatial memory, development of 
amygdala kindling, the profile of generalized convulsions and weight gain in a highly seizure-
prone rat strain (Fast rats) with natural comorbid learning impairments.  
4.1. Effect of VNS on spatial memory in the Morris water-maze test  
We found that applying VNS before daily training in the MWM did not alter 
acquisition of spatial memory of otherwise naïve Fast rats. Clearly, VNS did not negatively 
impact learning in this paradigm. While other therapeutic agents, especially AEDs, have been 
shown to exhibit mild to serious effects on cognition (Ortinski and Meador, 2004; 
Aldenkamp, 2001; Motamedi and Meador, 2004), multiple human studies have shown that 
VNS, using stimulation parameters typical of clinical settings, does not affect 
learning/memory (Hoppe et al., 2001). Similarly, we did not find changes in learning 
performance in the MWM following VNS treatment, which was in contrast to the results of 
Clark et al. (1995, 1998) who investigated rats in an avoidance test. Several factors may 
contribute to this discrepancy. We have applied VNS prior to the learning test, while Clark et 
Figure 10: Effect of chronic VNS on body weight and food intake. The figure shows changes in
body weight during the kindling experiments starting from the ADT determination until the 10th
stimulation session. Body weight on the day of ADT determination (1st stimulation) was used as a 
reference point for each group. During four consecutive days water (not shown) and food intake (g)
were measured. Data are expressed as mean ± SEM, significance is set at p< 0.05 and is indicated 
by an asterisk, * for p< 0.05 and ** for p< 0.01. 
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al. (1995, 1998), administered VNS after the test during memory consolidation. In addition, 
the stimulus current used in the various studies may also be relevant, since learning 
improvements in Clark’s study were dependent on an inverted-U shaped function of the 
output current, with only intermediate currents being effective. The stimulation parameters 
used in our study, correspond to a strong rather than intermediate stimulation regimen. As 
described in the methods, just as is done in patients (Handforth et al., 1998), the output 
current was ramped up to the tolerance limit of the rat, which is the intensity believed to exert 
anti-epileptic effects.  
4.2. Effect of VNS on amygdala kindling 
An acute VNS train administered after the kindling stimulus in fully kindled Fast rats 
completely suppressed seizure severity in two of six rats and collectively shortened ADDs in 
our chronic amygdala kindling model of temporal lobe epilepsy. Other animal studies using 
acute seizure models have also observed this anti-convulsant effect of acute VNS (Woodbury 
and Woodbury, 1990; Woodbury and Woodbury, 1991; Zabara, 1992; McLachlan, 1993). In 
humans, 50-60% of patients who use the magnet to activate the VNS pulse generator benefit 
from magnet-induced VNS (Boon et al., 2001; Morris III, 2003). Our findings demonstrate 
VNS benefit in only a subpopulation of our Fast rats while other rats appeared relatively 
unaffected. Further research directed towards identification of critical criteria that leads to 
success for VNS application is warranted.   
The mechanism through which acute VNS produces its anti-convulsant effect is not 
yet understood. However, some authors hypothesize possible involvement of non-specific 
arousal (Rutecki, 1990; McLachlan, 1993; Fanselow et al., 2000). For instance, McLachlan et 
al. (1993) observed that similar reductions in spike frequency were obtained by VNS 
application and by an arousing sensory stimulation treatment involving thermal stimulation of 
the tail. When acute VNS was applied at high intensity during absence seizures in GAERS, 
spike and wave discharges (SWDs) were stopped (Dedeurwaerdere et al. 2005).  Indeed, 
absence seizures are often aborted by unexpected sensory stimuli (e.g. noise, touching the 
animal) in GAERS (Danober et al., 1998). On the other hand, when VNS was applied at a 
lower intensity, presumably not perceptible by the animal (indicated by no evidence of 
recognition), seizures were not interrupted by the stimulation and were even prolonged 
(Dedeurwaerdere et al., 2004, Dedeurwaerdere et al., 2005). Perhaps in a similar way, kindled 
seizures can be blocked by an antecedent footshock (Pinel et al., 1973).  It has been 
demonstrated, in humans, that sensory stimulation can suppress focal spikes and absence 
seizures (Ricci et al., 1972; Rajna and Lona, 1989). Thus, beneficial effects from acute VNS 
could be mediated via nonspecific arousal, although other possible mechanisms of action 
cannot be excluded.   
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VNS did not affect kindling epileptogenesis in seizure-prone rats as evidenced by 
similar kindling rates and cumulative ADDs to the first stage-5 seizure in control and VNS 
groups. In apparent contrast, Fernandez-Guardiola et al. (1999) demonstrated that daily 
amygdala kindling (AK) was delayed in VNS treated cats. Stimulation parameters used in our 
study and the one of Fernandez-Guardiola et al. (1999) were similar, with the exception of the 
administration protocol. In the cat study, a VNS train of 60 s was applied before kindling and 
four times thereafter with a 60 min interval. Alternatively, a more likely cause for the 
discrepant findings would be the use of initially ‘normal’ cats versus our seizure-prone rats. It 
is conceivable that VNS cannot interfere with epileptogenesis in animals with a strong genetic 
predisposition to develop epilepsy, like the Fast rats in our study. Support for this hypothesis 
comes from a previous study in GAERS, a genetic model of absence epilepsy, wherein one 
week of VNS was not enough to decrease seizures significantly from control rats 
(Dedeurwaerdere et al., 2005). However, it is noted that in the present study we saw that some 
VNS-treated rats (n= 3) showed delayed kindling rates compared to controls (n= 3) when the 
piriform cortex, rather than the amygdala, served as the kindling focus (S. Dedeurwaerdere, 
personal observations, 2004). While kindling rate in the piriform cortex is normally much 
faster than in the amygdala (McIntyre et al., 1999), VNS rats did not display stage-5 seizures 
until VNS was terminated when kindled from the piriform cortex. Therefore, the origin of 
epileptogenesis could also be an important factor in the efficacy of VNS against kindling 
processes in Fast rats.  
Two hours of VNS treatment administered prior to amygdala kindling stimulation in 
fully kindled Fast rats did not affect the latency to the stage-5 seizure between the two 
treatment groups. Surprisingly, however, convulsion duration was actually significantly 
longer in VNS-treated fully kindled animals.  Similarly, the associated ADDs were also 
longer in the VNS group when VNS was applied for two hours before the kindling stimulus. 
Seizure aggravation is rarely reported in the clinical VNS literature (Koutroumanidis et al., 
2000; Scherrmann et al., 2001; Connor et al., 2003); however increased synchronization of 
the EEG by VNS has been described (Koo, 2001). Further, Stoica and Tudor (1968) noted an 
increase in interictal spike frequency with high-voltage stimulation of the vagus nerve. In a 
previous study using GAERS, we observed a transient prolongation of SWDs associated with 
VNS treatment (Dedeurwaerdere et al., 2004; Dedeurwaerdere et al. 2005). The reports of 
seizure aggravation in humans have been anecdotally associated with higher output current 
(Koutroumanidis et al., 2000) and rapid cycling (Connor et al., 2003). However, it is generally 
assumed that increasing output current and duty cycle will improve efficacy (DeGiorgio et al., 
2001). Nevertheless, evidence is available that VNS can have both inhibitory and excitatory 
effects in the brain.  
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Pre- and post-kindling ADTs were not significantly different between control and 
VNS rats.  Ipsilaterally and contralaterally triggered ADDs were only significantly prolonged 
in the VNS group after kindling. After kindling, ipsilateral ADTs evoked stage-5 seizures in 
all VNS rats, which was not the case in the control group. Paralleling the human condition, it 
might be that if VNS therapy is discontinued after a prolonged period of treatment, there is a 
decreased capability to shut down or to control seizures. Accordingly, some patients with 
batteries reaching end of life, indicate increased seizure severity in comparison to periods 
before VNS treatment (K. Vonck pers. com.). Besides relapse of seizures, altered seizure 
patterns have also been reported (Tatum IV et al., 2004). In addition, it has been stated that 
postponing generator replacement may result in permanent loss of seizure control with VNS 
(Vonck et al., 2005). 
4.2. Effect of VNS on body weight 
Vagal afferents play a predominant role in the regulation of food intake (Schwartz, 
2000). They carry signals from the stomach that pertain to the size and chemical composition 
of a meal to nucleus tractus solitarius, information that is then transmitted to satiety centers in 
the hypothalamus (Laskiewicz et al., 2004). Several studies performed in healthy animals 
found that vagal neuromodulation results in central and peripheral effects altering food intake 
and body weight down regulation (Roslin and Kurlan, 2001; Sobocki et al., 2001; Sobocki et 
al., 2002; Laskiewicz et al., 2004).  
A basic association between amygdala kindled seizures and weight gain in rats has 
been documented (Loscher et al., 2003; Bhatt et al., 2004). In the present study we found that 
VNS treatment prevented the gradual increase in body weight observed in control rats 
throughout the kindling process. Interestingly, the amygdala has been suggested as a region 
where interactions between gustatory and vagal signs take place (Han et al., 2003). This 
reduction in amygdala kindling-induced weight gain in VNS rats was associated with reduced 
food intake compared to control kindled rats. In a previous study from our laboratory using 
GAERS, weight reduction was observed after two weeks of chronic VNS (Dedeurwaerdere et 
al., 2003). As in the kindling study the Fast rats only received two hours of VNS a day, it is 
possible that more continuous VNS would result not only in reduced weight gain, but also in 
reduced body weight as in GAERS. We are the first to report altered body weight in animal 
studies evaluating the efficacy of VNS on epilepsy likely because previous studies have 
primarily applied VNS acutely over very short time spans.  
The effects of VNS on satiety and food intake could suggest an additional anti-
convulsant mechanism of action of VNS by caloric restriction. Diets have been used for the 
treatment of intractable childhood epilepsy since the 1920s and are re-emerging as a treatment 
option (Kossoff, 2004), although the mechanism of action of these diets may be related to 
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induced ketosis. It has also been quoted that acute VNS could result in hemodynamically-
induced hypoperfusion creating a relative deficit of energetic substrates (Sunderam et al., 
2001). 
 
 
5. Conclusion 
 In the present study we found that VNS with high-intensity stimulation parameters 
used in clinical settings does not affect spatial mapping memory in seizure-prone rats. When a 
VNS train was applied after the kindling pulse with the same stimulation parameters, stage-5 
seizures could successfully be altered in some animals. However, VNS applied prior to the 
kindling stimulus was not able to prevent kindling epileptogenesis and had no prophylactic 
anti-convulsive effect on stage-5 seizures. In fact, seizure profiles in fully kindled Fast rats 
were worsened in the VNS-treated group. Finally, VNS treatment prevented weight gain 
associated with the kindling process presumably via the observed reduction in food intake. 
Clearly, the complexities of VNS treatment should be further investigated in order to optimize 
treatment in patients with refractory epilepsy. 
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Vagus nerve stimulation (VNS) is a neurophysiological treatment for patients with medically 
or surgically refractory epilepsy. Since the first human implant in 1989, more than 10 000 
patients have been treated with VNS. The precise mechanism of action remains to be 
elucidated. Animal experiments with VNS were initially performed to demonstrate efficacy 
and safety preceding the clinical trials in human patients. Mechanism of action research 
involving animal experiments can provide essential clues. Animal experiments are often 
labor-intensive even in the hands of experienced researchers, however and the results remain 
only a reflection of the complicated pathophysiological systems of the human brain. 
Mechanism of action research in human patients treated with VNS is particularly challenging 
because of safety concerns, the large number of patients required and the heterogeneous 
nature of various small patient series. This study provides an overview of the progress that has 
been made in the past 10 years through neurophysiological, neuroanatomic, neurochemical 
and cerebral blood flow studies in animals and patients treated with VNS. Further elucidation 
of the mechanism of action of VNS may increase its clinical efficacy. It may also provide 
inspiration for the development of new therapeutic modalities for refractory epilepsy.  
 
Key Words: Vagus nerve stimulation—Mechanism of action— Refractory epilepsy.  
 
 
1. Introduction 
 When epileptic seizures are uncontrolled, diagnostic and therapeutic evaluation in a 
specialized setting is warranted. Alternative treatment modalities for patients with refractory 
epilepsy include trials with newly developed anti-epileptic drugs, epilepsy surgery and 
neurostimulation.  
 The introduction of a new anti-epileptic drug in the medication regimen of refractory 
patients results in seizure freedom in only a small percentage of patients (Fisher, 1993). 
Repeated inclusion in trials with novel anti-epileptic drugs may be associated with a low 
quality of life.   
 Epilepsy surgery is an alternative treatment for patients with medically refractory 
epilepsy in whom the “epileptogenic zone” can be identified and resected. Only 30% to 50% 
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of surgical candidates who are enrolled in the presurgical evaluation protocol eventually 
undergo surgery (Boon et al., 1999). For the remaining patients, there are few therapeutic 
options left.  
 The inability to provide adequate treatment for refractory patients with multifocal 
epilepsy provides an impetus to develop novel therapies. One such type of treatment is the 
electrical stimulation of nervous tissue to suppress seizure generation. Electrical stimulation 
of the vagus nerve is a neurophysiological treatment that was developed in the late 1980s and 
is currently available in specialized epilepsy centers worldwide (Handforth et al., 1998). Deep 
brain stimulation for epilepsy using electrical stimulation of areas within the brain is currently 
in the pilot study phase and is beyond the scope of this review.  
 The precise mechanism of action (MOA) of vagus nerve stimulation (VNS) and how 
it suppresses seizures remains to be elucidated. Most specialists in the field believe that 
greater insight in the MOA might help to identify certain seizure types or epileptic syndromes 
that respond better to VNS. It may also guide the search for optimal stimulation parameters 
leading to an increase in clinical efficacy. It may even lead to the development of new 
therapies (e.g., the identification of optimal stimulation targets for peripheral stimulation or 
deep brain stimulation). The purpose of this review is to provide an overview of the currently 
available data on MOA research in VNS.  
 
2. History  
 The first vagus nerve stimulator was implanted in a human subject in 1989; however, 
the historical basis of peripheral stimulation for treating seizures dates back centuries. In the 
sixteenth and seventeenth centuries, physicians described the use of a ligature around the limb 
from which a seizure had started so as to arrest its progress. The method had been described 
many centuries before by Pelops, an ancient Greek author. He believed this observation was 
proof that epileptic fits originated from the limb itself. The hypothesis was reviewed in the 
beginning of the nineteenth century when Odier (1811) showed that ligatures were equally 
efficacious in arresting seizures caused by organic brain disease (e.g., a brain tumor). At the 
end of that century, Gowers (1881) attributed these findings to raised resistance in the sensory 
and motor nerve cells in the brain corresponding to the limb involved. This change of 
resistance, in turn, would arrest the spread of the epileptic discharge.  
 Gowers (1881) also reported several other ways by which sensory stimulation could 
prevent seizures from spreading (e.g., pinching of the skin and inhalation of ammonia). 
Almost a hundred years later, Rajna and Lona (1989) demonstrated that afferent sensory 
stimuli could abort epileptic paroxysms in human beings.  
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3. Anatomic basis 
 The vagus nerve is a mixed cranial nerve that consists of ~80% afferent fibers 
originating from the heart, aorta, lungs and gastrointestinal tract. Approximately 20% of these 
efferent fibers provide parasympathetic innervation of these structures and also innervate the 
voluntary striated muscles of the larynx and the pharynx (Agostini et al., 1957; Foley and 
DuBois, 1937; Paintal 1973). Cell bodies of the efferent fibers are located in the dorsal motor 
nucleus and nucleus ambiguous respectively. Afferent fibers have their origin in the nodose 
ganglion and primarily project to the nucleus of the solitary tract (NST). At the cervical level, 
the vagus nerve mainly consists of small-diameter unmyelinated C fibers (65% to 80%) and a 
smaller portion of intermediate-diameter myelinated B fibers and large-diameter myelinated 
A fibers. The NST has widespread projections to numerous areas in the forebrain as well as in 
the brainstem, including important areas for epileptogenesis such as the amygdala and 
thalamus. There are direct neural projections into the raphe nucleus, which is a major source 
of serotonergic neurons and indirect projections to the locus coeruleus and A5 nuclei which 
contain noradrenergic neurons. Finally, there are numerous diffuse cortical connections.  
 The diffuse pathways of the vagus nerve mediate important visceral reflexes such as 
coughing, vomiting, swallowing, control of blood pressure and heart rate. Heart rate is mostly 
influenced by the right vagus nerve, which has dense projections primarily to the atria of the 
heart (Saper et al., 1990).  
 
4. Animal experiments  
 Early animal experiments investigated the effect of stimulation of the cervical vagus 
nerve on EEG. Depending on the level of anesthesia and the stimulus parameters used, VNS 
can induce EEG synchronization, EEG desynchronization, rapid eye movement and sleep or 
slow wave sleep in animals (Chase et al., 1966, 1967; Zanchetti et al., 1952). This was 
explained by the fact that different types of nerve fibers in the vagus nerve are activated when 
different stimulus parameters (frequency and intensity) are used. Desynchronization results 
from high-intensity and high-frequency (> 70 Hz) stimuli activating unmyelinated C fibers. 
Lower intensity high-frequency (> 70 Hz) stimulation induces synchronization because of 
activation of myelinated A and B fibers. Desynchronization may also be caused by high-
intensity slower stimulation in the range of 20 to 50 Hz. Magnes et al. (1961) evaluated EEG 
changes induced by stimulation of the NST and found desynchronization when using 
frequencies above 30 Hz and synchronization when using a lower stimulation frequency in 
the range of 1 to 17 Hz. Because epileptic seizures are characterized by a paroxysmal 
abnormal synchronicity of EEG, it was believed that VNS could suppress seizures by 
desynchronizing the EEG.  
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 Following up on this idea, the effect of VNS on clinical behavior and EEG epileptic 
activity in different animal models was studied. Vagus nerve stimulation blocks interictal 
spike activity induced by strychnine applied to the cortex of the cat (Zanchetti et al., 1952). 
Zabara (1992) found that generalized seizures in dogs induced by pentylenetetrazole and 
strychnine were inhibited by VNS and he made estimation about optimal stimulation 
parameters. These were found to be 20 to 30 Hz in frequency, 3.5 to 7 mA in output current 
and 0.2 ms in stimulus duration (Zabara, 1992). Woodbury and Woodbury (1990) established 
the anti-convulsant efficacy of VNS using frequencies greater than 4 Hz in rats after induction 
of seizures with pentylenetetrazole, 3-mercaptoproprionate and maximal electroshock. 
According to their research, the anti-convulsant effect is directly related to the fraction of 
unmyelinated C fibers stimulated. Chronic VNS also reduced the frequency of recurrent 
spontaneous seizures in monkeys with alumina gel foci (Lockard et al., 1990).  
 The results of these animal studies led to the development of an implantable device 
for human use and the first human trials for the treatment of epilepsy. Since 1989, more than 
10 000 patients have been treated with VNS. This growing number of patients has aroused 
further interest in MOA research.  
 Other work has concentrated on the identification of anatomic brain structures that are 
potential mediators of the anti-seizure effect of VNS. Using c-fos, a nuclear protein that is 
expressed in neurons as a result of high neuronal activity, Naritoku et al. (1995) were the first 
to identify some key structures in the neuronal network between the brainstem and forebrain 
that are activated during VNS. Vagus nerve stimulation induced severe staining in limbic 
structures such as the amygdala, a highly epileptogenic region that plays a role in the 
generalization of seizures. The habenula and posteromedian nucleus of the thalamus, 
structures implicated in seizure regulation, also showed intense c-fos immunoreactivity. 
Support for a role of monoamines in the MOA of VNS was found through VNS-induced c-fos 
activation in the locus coeruleus and A5 nuclei of the brainstem. These two noradrenergic 
nuclei receive indirect projections from the nucleus tractus solitarius, the main efferent 
nucleus for the vagus nerve. Vagus nerve stimulation was shown to produce bilateral 
symmetric labeling in the previously mentioned brain structures, supporting the existence of a 
bilateral anti-convulsant effect despite unilateral left-sided stimulation. Because c-fos is a 
protein that signals transcription of other genes, VNS efficacy may be based on long-term 
neuronal changes. This hypothesis was confirmed by Takaya et al. (1996), who showed that 
the anti-seizure effect of VNS outlasts the duration of the stimulation train and that repetition 
of stimuli increases VNS efficacy. Inspired by the results from earlier studies on the circuitry 
involved in the anti-nociceptive effect and seizure-modulating effect of the locus coeruleus, 
Krahl et al. (1998) performed bilateral lesioning of the locus coeruleus in rats. As a result, 
seizure-suppressing effects of VNS in these animals were lost when treated with convulsant 
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chemicals. The authors claimed that lesioning of the locus coeruleus blocks the anti-
convulsant effects of VNS by preventing VNS-induced norepinephrine release either globally 
or in some specific brain site.  
 Further investigation of neurotransmission on a neurochemical level was performed 
by Walker et al. (1999). These authors tried to establish the seizure-regulating influence of 
medullary nuclei by further investigating the role of gamma-aminobutyric acid (GABA) and 
glutamate synaptic transmission within the NST with respect to regulation of susceptibility to 
seizures of forebrain origin (Walker et al., 1999). They concluded that an increase in GABA 
or a decrease in glutamate transmission in the rat NST reduces the severity of limbic seizures. 
Vagus nerve stimulation may therefore exert its anti-seizure effect by inhibition of ascending 
outputs from the NST that project via various anatomic connections to the forebrain.  
 The early hypothesis of cortical desynchronization induced by activation of 
unmyelinated afferent vagal C fibers through the reticular activating system was further 
investigated by three different research groups. In human beings, effective therapeutic 
stimulation parameters are subthreshold for C fibers. Krahl et al. (2001) found strong 
evidence that vagal C fibers are neither responsible nor necessary for the seizure-suppressing 
effect of VNS. According to their experiments in awake and freely moving rats, activation of 
myelinated A and B fibers was shown to be responsible for seizure suppression.  
 Zagon and Kemeny (2000) performed animal studies at a cellular level. They 
particularly looked at the effects of the “weak stimuli” that predominantly activate the 
myelinated vagal afferents and are produced in cortical pyramidal neurons of the parietal 
cortex. They confirmed the findings by Krahl et al. (2001) on the role of myelinated afferent 
vagal fibers. Moreover, they showed that trains of vagal stimuli lead to prominent slow 
hyperpolarization of pyramidal cell membranes, reducing excitability. According to these 
findings, VNS is more likely to suppress neuronal excitability in cortical neurons, which may 
contribute to epileptic discharges, than to interfere with the synchronization of ongoing 
neuronal activity. Vagus nerve stimulation at low intensity repeated at such a rate that a 
second inhibition is initiated before the end of the previous inhibitory response may achieve 
sustained inhibition of the activity of involved cortical neurons.  
 Fanselow et al. (2000) investigated the effect of trigeminal nerve stimulation on 
seizures. They showed that stimulation of the infraorbital branch of the trigeminal nerve 
effectively reduces pentylenetetrazole-induced seizures in awake rats. Effective stimulation 
frequency (100 to 333 Hz) and current (9 to 11 mA) were higher when compared with 
parameters used in VNS. They believe that stimulation of cranial nerves suppresses seizures 
by activating the midbrain reticular formation and that this activation results in general 
arousal via the reticular activating system.  
 The efficacy and mode of action of VNS have mainly been studied in acute animal 
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models of epilepsy. Fernandez-Guardiola et al. (1999) performed VNS studies in electrically 
kindled cats, a model for chronic epilepsy. Their results showed that VNS delays the 
development of seizures induced by electrical kindling in the amygdala, suggesting a possible 
preventative effect of VNS on epileptogenesis. These results were confirmed by Naritoku and 
Mikels (1996, 1997), who evaluated the effects of VNS in electrically kindled rats.  
 To date, no results of studies in animal models with spontaneous primary generalized 
epilepsy have been published. Preliminary results from our group at Ghent University 
Hospital, who studied VNS efficacy in genetic absence epilepsy rats from Strasbourg, suggest 
that short-term VNS (3 h of stimulation, 1.5 mA, 30 Hz, 500 µs, 30 s on/5 min off during five 
consecutive days) does not reduce the frequency or duration of absence seizures 
(Dedeurwaerdere et al., 2004). Further studies using chronic stimulation need to be 
undertaken.  
 
5. Research in human beings  
 The first experimental work in human beings aimed to reproduce EEG findings from 
animal experiments. Vagus nerve stimulation–induced suppression of interictal epileptic 
activity recorded by scalp EEG could not be demonstrated (Hammond et al., 1992a). In one 
patient, ictal EEG activity was abruptly terminated by acute VNS. In another patient, bilateral 
rhythmic δ activity during an aura was also interrupted by acute VNS. In three other patients, 
acute VNS delivered well into an ongoing seizure did not have any influence on the EEG or 
behavioral symptoms. Using fast-Fourier EEG analysis, no changes of normal background 
EEG during wakefulness, sleep or anesthesia were found.  
 Another study assessed the acute effects of VNS on background EEG activity using 
magnet mode activation (Salinsky and Burchiel, 1993). Epochs of 3 min of EEG were 
analyzed: 60 s before and after a VNS stimulation train and 60 s between during stimulation. 
Quantitative analysis did not reveal any changes in EEG background activity.  
 Other neurophysiological studies investigated VNS-induced vagal nerve evoked 
potentials (EPs) and the interference of VNS with clinically used EPs for diagnostic reasons. 
Vagus nerve stimulation induces a high-amplitude EP with a widespread scalp distribution 
(Hammond et al., 1992b). In one patient who was given a muscle-paralyzing agent during 
anesthesia, the vagus nerve EP was abolished. This suggested the presence of a myogenic EP 
rather than a true cortical EP, which was believed to be generated through activation of the 
recurrent laryngeal nerve. In this study, acute or chronic VNS did not have any influence on 
the different diagnostic EPs (visual, auditory brainstem, auditory 40 Hz and long-latency 
cognitive).  
 Naritoku et al. (1992) performed brainstem auditory EPs and somatosensory EPs to 
determine if chronic VNS results in electrophysiologically measurable changes. There was no 
Mechanism of action of vagus nerve stimulation                                                                       Chapter 5 
 111
influence on brainstem auditory EPs. There was a significant increase in the interval between 
cervicomedullary and thalamocortical potentials (N13 to N20 interval) when three VNS 
patients were compared after one month of stimulation with three normal individuals and with 
baseline findings before VNS. An increase of somatosensory EP interpeak latencies has also 
been described in patients treated with phenytoin and carbamazepine. The prolongation of the 
interpeak latency may be related to the anti-epileptic effect of VNS. According to these 
authors, their findings support the hypothesis that VNS has effects on neuronal mechanisms 
that extend beyond structures immediately associated with the vagus nerve. The number of 
responders was too small (two responders) to allow meaningful conclusions on the prognostic 
value of these EP findings. The findings by Naritoku et al. (1992) were confirmed in another 
study that showed delays in latencies of evoked responses induced by direct esophageal 
stimulation in VNS-treated patients (Tougas et al., 1993). 
 Neurochemical studies quantified amino acid and neurotransmitter metabolite 
concentrations in cerebrospinal fluid (CSF) samples before and after VNS to clarify the 
hypothesis that VNS might act through the release of neurotransmitters and other compounds 
at the projection site of the vagus nerve (Ben-Menachem et al., 1995; Hammond et al., 
1992c). The first study revealed selective increases in 5-hydroxyindoleacetic acid and ho-
movanillic acid, metabolites of serotonin and dopamine, respectively. Also, a significant 
decrease in the levels of aspartate was found, correlating with better seizure control. The 
second study revealed increased GABA and ethanolamine levels. Although serotoninergic as 
well as dopaminergic systems have been found to have anti-convulsant effects in animal and 
human studies of various types of epilepsy, it remains to be clarified whether these findings 
are epiphenomena or findings directly related to VNS.  
 Finally, the effect of VNS on human central nervous system structures has been 
studied through cerebral blood flow (CBF) studies. Various changes in supratentorial and 
cerebellar CSF caused by acute and chronic VNS have been reported.  
 The first study was published by Garnett et al. (1992), who found ipsilateral 
activation in the thalamus and cingulate gyrus in five patients. A study by Ko et al. (1996) in 
three patients reported increased CBF in the left posterior cerebellum and putamen and in the 
right medial temporal gyrus and thalamus. The main conclusion was that VNS induces 
measurable CBF changes in anatomic structures that are part of the diffuse vagus nerve 
pathways. Occurrence of (subclinical) seizures during scanning and previous resective 
surgery in these early studies may have influenced the results and may account for 
discrepancies in the reported findings. Ko and his colleagues (1998) extended their original 
study and finally examined nine individuals in whom changes in CBF were correlated with 
seizure control. A reduction in seizure frequency best correlated with decreased CBF in the 
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right fusiform gyrus. Vagus nerve stimulation was also shown to exert an effect on CBF 
longer than the duration of the stimulation train.  
 The first positron emission tomography study of acute VNS showed diffuse CBF 
changes (Henry et al., 1998). Acute CBF changes were correlated with seizure control after 
three months of VNS (three responders versus 11 non-responders). Bilateral thalamic 
hyperperfusion correlated most significantly with a decrease in seizure frequency, suggesting 
that alterations in thalamic activity may contribute to anti-seizure effects of VNS. Repeated 
positron emission tomography studies in the same patients after three months showed that 
decreased CBF in bilateral hippocampi, the amygdala and the cingulate gyrus and increased 
bilateral insular CBF found during acute VNS was no longer present (Henry, 2000).  
 Our group performed an acute 99mtechnetium single-photon emission computed 
tomography activation study in 11 patients receiving an initial stimulation train (0.25 to 0.50 
mA, 30 Hz, 500 µs, 30 seconds) that revealed ipsilateral thalamic hypoperfusion as the most 
significant finding (Vonck et al., 2000). No significant CBF increases were found. In a 
follow-up study, 23 patients underwent an acute activation paradigm and a subgroup of 10 
patients also underwent a single-photon emission computed tomography activation study after 
six months of chronic VNS. Cerebral blood flow changes were compared with clinical 
outcome (Van Laere et al., 2002). Chronic VNS (as compared to baseline CBF before 
stimulation) resulted in decreased CBF in bilateral thalami and the left caudate head. During 
the activation paradigm in a chronic situation in which the generator was activated with an 
additional 0.25 mA during 30 s, a significant left thalamic activation was found. An acute 
positron emission tomography study by the same group during the first stimulation train (0.25 
to 0.50 mA, 30 Hz, 500 µs, 30 s) in six patients (Vandekerckhove et al., 2000) showed 
significantly increased CBF in the right thalamus, somatosensory cortex and left inferior 
cerebellum. Significantly decreased CBF was found in the left fusiform gyrus and in bilateral 
dorsolateral parietal cortex. In a recent study in eight patients, Ring et al. (2000) found 
bilateral thalamic perfusion decrease after chronic intermittent stimulation.  
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6. Discussion and conclusion 
 In the past 10 years, a large body of experimental literature on the MOA of VNS has 
been published. Research has focused mainly on four topics: neurophysiological (EEG and 
EPs), neuroanatomic, neurochemical and CBF studies. When comparing animal and human 
EEG studies, there is some concern about the discrepancies that were found. Although it was 
originally believed that desynchronization of the EEG induced by C fiber activation played a 
key role in the MOA of VNS, there are now strong arguments that this is not the case. The 
finding that VNS did not change interictal EEG activity in human beings as had been 
observed in animals was quite surprising. Moreover, human efficacy data from clinical trials 
show that stimulation at levels sub-threshold for activating C fibers is efficacious. Animal 
experiments further exploring this issue confirmed that C fibers most likely did not play a 
critical role. EEG recordings in animals were performed using epidural electrodes or depth 
electrodes. Such EEG recordings in human subjects are much less available. A single-case 
study with intracranial EEG during VNS was reported. Spectral analysis showed clear 
changes in α, β and γ power (Thompson et al., 1999). It is possible that visually undetectable 
subtle changes in scalp EEG occur during VNS. Quantitative techniques such as nonlinear 
dynamic analysis may help to clarify this matter.  
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 The different level of consciousness of experimental animals in different studies also 
confounds interpretation of results. The earliest animal experiments were performed in 
anesthetized animals and differed from the studies by Krahl et al. (2001) in awake and freely 
moving animals.  
 Another point is that in the animal experiments, the effect of VNS was always 
evaluated when stimulation was performed in close relation to time of seizure onset, testing 
the anti-seizure effect of VNS. In human beings, VNS is used in an intermittent mode. 
Seizures are also suppressed when the stimulator is in the “off” mode, suggesting an anti-
epileptic effect rather than an anti-seizure effect only. This finding is supported in the animal 
studies done by Takaya et al. (1996), who demonstrated that the efficacy of VNS outlasts the 
duration of the stimulation train. There may be different pathways involved in anti-seizure 
and anti-epileptic effects. Zagon and Kemeni (2000) suggested that chronic VNS suppresses 
neuronal excitability and induces a sustained hyperpolarization in cell membranes of cortical 
neurons.  
 Findings concerning the anti-seizure effect of VNS are concordant in animals and 
human subjects. When stimulated early enough in the course of an ictal EEG discharge 
(accompanied by behavioral symptoms), the seizure can be interrupted. This is also 
concordant with data from a magnet stimulation study that is reported elsewhere in this issue. 
Some authors suggest that this anti-seizure effect is strong enough in some patients to treat 
epilepsy, assuming that seizures might be predicted early enough to trigger stimulation of 
cranial nerves (Fanselow et al., 2000).  
 Concerning neuroanatomic structures that are important in the MOA, several authors 
have shown through different kind of studies that the locus coeruleus and the NST play a 
crucial role. Neurochemical studies support the hypothesis that these structures, when 
activated through electrical stimulation of the vagus nerve, may cause release of seizure-
suppressing neurotransmitters.  
 Although CBF studies have contributed to the identification of brain structures that 
are located on the pathway from the cervical level of the vagus nerve to the cortex, their 
spatial resolution is not high enough to visualize these structures on an anatomic basis. A 
difference has to be made between structures on this pathway that may be activated during 
CBF activation studies and structures that truly play a role in the MOA of VNS. Varying 
results were found in different CBF studies, but the thalamus is most consistently involved. 
The VNS-induced CBF changes that were found suggest suppression of seizures by threshold 
modulation in structures known to play an important role in epileptogenicity. It is unclear 
whether activation of inhibitory neurons or an increase in inhibitory neurotransmitters is 
responsible for this.  
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 Further studies in different animal models may reveal important clues about the 
MOA. Some initial interesting work has been performed in kindling models during the acute 
phase of kindling itself. Exploring the effect of long-term VNS in chronic seizures after 
kindling procedures have been performed may reveal even more interesting findings.  
 Vagus nerve stimulation is a patient-friendly treatment in the sense that it requires a 
minimally invasive procedure, has few side effects and requires minimum cooperation of the 
patient, which can be an advantage in mentally retarded patients. If proven not to be 
efficacious, the generator and lead can be removed successfully (Espinosa et al., 1999). 
Conversely, the palliative character and low efficacy of VNS compared with epilepsy surgery 
have to be considered. Further elucidation of the MOA may enhance clinical efficacy or 
identify structures within the brain that are potential targets for electrical stimulation.  
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Purpose: Vagus nerve stimulation (VNS) is an effective neurophysiological treatment for 
patients with refractory epilepsy, however, the mechanism of action remains unclear. Small 
animal positron emission tomography (PET) permits the monitoring of biochemical processes 
during multiple scans in the same animal. The aim of this pilot-study was to explore the 
potential of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) PET to investigate the effect of acute 
and chronic VNS on glucose metabolism in the rat brain.  
Methods: One week after surgery, a baseline FDG-PET scan was acquired during which 
animals were not stimulated. Secondly, scans were taken after first activation of the VNS 
electrode (acute VNS) and after one week of continuous VNS (chronic VNS). Images were 
obtained in a control group at the same time as the acute and chronic VNS scans. After 
acquisition, PET images were manually fused with MRI-data. Normalized brain activities and 
left/right activity ratios of different brain structures were compared between control 
measurements and VNS group.  
Results: During acute VNS, glucose metabolism was significantly decreased in the left 
hippocampus (p< 0.05). Significant increases were found in both olfactory bulbs (p< 0.05).  
A significant decrease in left/right ratio in the striatum (p< 0.05) was found which 
corresponded with a decrease in the left striatum, which was not significant (p< 0.07).  
Conclusion: Acute and chronic VNS induced changes in glucose metabolism in regions 
important for seizure control (hippocampus, striatum). Our results are consistent with 
previous findings in patients with epilepsy using indirect perfusion markers. 
 
Key words: small animal positron emission tomography (PET), vagus nerve stimulation 
(VNS), micro-PET, mechanism of action, rat, epilepsy. 
 
 
1. Introduction 
Vagus nerve stimulation (VNS) is used to reduce the frequency and severity of 
epileptic seizures in refractory patients, although the precise mechanism of action (MOA) still 
remains to be elucidated (Vonck et al., 2001). Understanding the MOA is an important aspect 
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of clinical VNS, as identification of responder groups and optimization of stimulation 
parameters is of great interest.  
It is generally assumed that VNS exerts its effect by inducing action potentials in the afferents 
of the left vagus nerve, which has diffuse projections in the central nervous system. Several 
functional imaging studies have been conducted to investigate the activation or inhibition of 
brain structures by VNS. These studies found changes on both sides of the brain by unilateral 
left VNS and pointed out a key role for the thalamus and medial temporal lobe structures in 
the MOA of VNS (Vonck et al., 2001; Chae et al., 2003). However, there is no consensus on 
other activated structures neither on the type of changes (inhibition or excitation). This 
discrepancy can be attributed to a number of confounding factors such as imaging techniques 
used (PET, SPECT, fMRI), tracer and contrast agents, scanning protocols, stimulation 
parameters, medication regimes, course of the illness and treatment response. Heterogeneity 
of relatively small patient samples is difficult to avoid and, in addition, data gathering from 
healthy subjects is impossible for ethical reasons due to the invasiveness of VNS. 
Small animal positron emission tomography (PET) is a technique used for in vivo, 
quantitative and high-resolution spatial determination of positron emitting isotopes in small 
animal tissues. It permits the monitoring of biochemical processes over time during a dynamic 
scan period but also longitudinally across multiple scans of the same subject. This technique 
is of increasing importance as fewer animals have to be used in comparison with post-mortem 
techniques like autoradiographic methods (Phelps, 2000). Small animal PET is widely used in 
all fields of pathophysiological research such as experimental oncology, gene expression and 
CNS research and is presently also emerging in animal research on epilepsy (Kornblum, et al., 
2000). This technique could give the unique possibility to assess the effect of VNS on brain 
metabolism in healthy subjects, avoiding many of the disease-related confounding factors 
listed above.  
Some of our previous imaging studies reported a different effect of acute and chronic 
VNS on cerebral blood flow, which is ascribed to a combination of an anti-seizure and anti-
epileptic effect (Vonck et al., 2000; Van Laere et al., 2002). Therefore the aim of this study 
was to explore whether it is feasible to investigate the effect of acute and chronic effect of 
VNS on relative brain glucose metabolism in rats using micro-PET.  
 
2. Materials and Methods 
2.1 Animal preparation 
Eight male Wistar rats, weighing 300-350 g, were used in this study. The animals 
were housed under environmentally controlled conditions (12 h light/dark cycles, 20-22°C) in 
the animal facility of the Ghent University Hospital with food and water ad libitum. All 
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animals were treated according to guidelines approved by the European Ethics Committee 
(decree 86/609/EEC). The study protocol was approved by the Animal Ethical Committee of 
Ghent University Hospital (ECP 01/26).  
All animals were implanted with five epidural EEG electrodes and a stimulation cuff-
electrode around the left vagus nerve under deep ketamine/xylazine anesthesia (80 mg/kg and 
7.5 mg/kg respectively, i.p.) as previously described (Dedeurwaerdere et al., 2004). During 
surgery, additional ketamine (5 mg/kg) was given when sensorial pain prickles, by squeezing 
the foot pad, were felt. Following surgery, xylocaine (0.2 %) was applied at the incision 
wound and animals were placed under a heating lamp in their home cages to maintain normal 
body temperature until behaviorally active. The experimental period started at least one week 
after surgery and consisted of EEG recordings and repetitive scans. 
 
2.2 EEG recordings 
EEG was recorded during 3 h at the beginning and at the end of the experimental 
period to ensure that no spontaneous epileptic activity was present. For the EEG recording, a 
H2O™ portable digital 32-channel EEG recorder (Telefactor Corporation, USA) was used. 
The data were quantified by visual inspection of the EEG using TWIN™ off-line EEG 
analysis (Telefactor Corporation, USA).  
 
2.3 Small animal PET imaging 
The PET detector used for this study was the VUB-PET, developed at the University 
of Brussels (Belgium), which utilizes BaF2 scintillation crystals coupled to a position and 
photo-sensitive wire chamber, containing Tetrakis-dimethylamine-ethylene (TMAE) vapor to 
detect annihilation photons (Bruyndonckx et al., 2001). The transaxial resolution at the centre 
was 2.6 mm and at 2.5 cm from the centre the radial and tangential resolution were 
respectively 4.3 mm and 3.8 mm. Details of the VUB-PET system have been discussed at 
length previously (Bruyndonckx et al., 2001; Tavernier et al., 1992) .  
For the acquisition of the PET images, we used 2-deoxy-2[
18
F]fluoro-D-glucose 
(FDG) as a tracer, which reflects regional glucose metabolism correlating with the degree of 
neuronal activity (Kornblum et al., 2000). FDG was synthesized by a previously reported 
method that is routinely used in our facility (Hamacher et al., 1968). FDG (11.1-14.8 MBq, 
200 µl in volume) was administered i.v. through the dorsal penile vein under halothane gas 
anesthesia (5% induction and 1-1.5% for maintenance); thereafter the animals were placed 
fully awake in a dark, quiet room for 40 min. During this period, FDG is trapped in cells after 
phosphorylation by hexokinase, in a distribution reflective for conscious metabolic activity 
(Jacobs and Cherry, 2001). Brain activity initially rises rapidly; the rate of increase then 
progressively slows until activity is approximately constant between 30 and 60 min (Shimoji 
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et al., 2004). Images, acquired 45 min after FDG-injection, predominately reflect glucose 
metabolism of the first 15 min of FDG uptake. Subsequently, animals were brought under 
light anesthesia (medetomidine: 0.1 mg/kg and ketamine: 5 mg/kg, i.p.) to immobilize them in 
a fixed prone position in the centre of the scanner. Then, static PET scans in the fast and 
rotationary VUB-PET mode were performed for 10 min. No absolute quantification using 
blood sampling was carried out. Thus, we have not calculated the absolute cerebral metabolic 
rates for glucose (CMRGlc). 
Three scans were acquired in the VNS group; a first baseline scan (n= 5) was 
obtained when animals were not stimulated. Secondly, a scan was taken (n= 4), when VNS 
was activated immediately after FDG injection, to investigate the acute effect of VNS. 
Finally, to measure the chronic effect of VNS, animals were scanned after one week of VNS 
(n= 3). During the acute and chronic VNS scan, the animals were receiving VNS during the 
45 min of FDG uptake postinjection and during the scan. To compare acute and chronic VNS 
scans with a control group scans were also taken in non-stimulated control animals (n= 3) at 
the same time as the acute and chronic scan in the VNS animals. 
 
2.4 Vagus nerve stimulation 
Stimulation was performed by connecting the cuff-electrode to an external 
NeuroCybernetic Prosthesis device (NCP, model 100; Cyberonics Inc., USA). The impedance 
of the electrode-to-vagus nerve interface was measured at the beginning and end of each 
experiment; impedance values were the same before and after the experiments for all animals 
and were always between 1 and 8 kΩ. The following stimulation parameters based on 
previous studies (Dedeurwaerdere et al., 2004) were used: amplitude: 1.5 mA; frequency: 30 
Hz; pulse duration: 500 µs; on/off cycle: 30 s/ 5 min. 
 
2.5 MRI-scan 
A single male Wistar Rat (300 g) was anesthetized with medetomidine (0.1 mg/kg) 
and ketamine (5 mg/kg), i.p. for immobilization. MRI was performed on a clinical 1.5 T 
whole body system (Symphony, Siemens, Germany) and the rat was placed in a wrist coil. 
After scout images were obtained, a 3D MPRAGE (Magnetization Prepared Rapid 
Acquisition Gradient Echo) T1-weighted image of the rat brain was acquired (repetition time 
(TR)= 1100 ms, echo time (TE)= 4.45 ms, inversion time (TI)= 640, 176 x 256 matrix, slice 
thickness 0.9 mm, field of view (FOV)= 52 mm x 75 mm x 29 mm, taking 38 min 34 s). The 
obtained DICOM images were extended with empty voxels in order to yield square image 
slices before fusion to the micro-PET images.  
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2.6 Analysis of PET-data 
Data were collected in list mode and reconstructed using 2-dimensional ordered-
subset expectation maximization (2D-OSEM: 4 subsets; 2 iterations; 19 coronal slices; 128 x 
128 matrix) utilizing in house software (Bruyndonckx et al., 2001). No postsmoothing filter 
was applied. Axial (coronal) MRI-slices 
of a rat brain were used to assign 
regions of interest (ROIs) per slice (14 
slices) by means of a rat brain atlas 
(Paxinos and Watson, 1998). Eight 
areas were pointed out on each 
hemisphere: olfactory bulb, cerebral 
cortex, striatum, hippocampus, 
thalamus and hypothalamus, 
cerebellum, medulla oblongata and 
brainstem. PET and MRI images were 
manually co-registered (Figure 1) using 
the multimodality package of the 
HERMES software (HERMES, Nuclear 
Diagnostics, Sweden). ROIs were 
matched on the corresponding PET 
slices. In this way activity was 
measured for all ROIs in 14 different 
slices and a mean value of activity per 
pixel was calculated.  
 
 
The Mann-Whitney U test was used to compare whole brain normalized activities (%) 
and left/right activity ratios of the different brain structures between control measurements 
and VNS group. As control measurements, normal data were taken together from both the 
direct control group as well as the baseline measurements from each set of animals (acute 
versus chronic VNS). Statistics were calculated with SPSS (v12 for windows, SPPS Inc, 
Belgium). Significance was set at p< 0.05 (two-tailed) and data are presented as mean ± SEM 
Figure 11: Co-registration of PET and MRI images.
Coronal, axial and sagittal view of the rat brain. ROIs
indicated in red: cerebral cortices, in blue: hippocampi,
in white: thalami and hypothalami. 
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3. Results 
Ratios of glucose metabolism have been obtained in the regions of interest as 
mentioned above.  
 During acute VNS, significant changes in glucose metabolism were present in both 
olfactory bulbs (approximately 45% increased glucose uptake, p< 0.05) and in the left 
hippocampus (8% decreased glucose uptake, p< 0.05) (Figure 2). Metabolic values in the 
right hippocampus also tended to be decreased (11% decreased glucose uptake, p< 0.09) 
(Figure 2). No significant changes in left/right ratios were observed in the studied brain 
structures after acute VNS (data not shown).  
 
 
 
 
 
 
 
 
During chronic VNS, there was a tendency for an increased glucose uptake of the left 
part of the medulla oblongata (p< 0.07). There was also a trend towards a decrease of the left 
striatum (p< 0.07), which corresponded with a significant (p< 0.05) decreased left/right ratio 
(1.00 ± 0.01) compared to control measurements (1.11 ± 0.01) (Figure 3).  
Figure 12: Effect of acute and chronic VNS on glucose metabolism in rats. Control measurements (white
bars) were obtained without VNS. A. VNS was activated immediately after FDG-injection in the VNS 
group (black bars) and was on during the whole period of uptake and image acquisition. B. After one
week of chronic VNS, additional images were acquired in the VNS group (black bars). Whole brain
normalizations are shown for the eight brain regions. Plain bars are representing the left structure, dotted 
bars the right structure. Olf. Bulbs, olfactory bulbs; Th. + H-th., thalamus and hypothalamus; Hippoc., 
hippocampus; Cerebell., Cerebellum; MO, medulla oblongata. Data are expresses as mean ± SEM, 
significance is set at p< 0.05 and is indicated with an asterisk, a= p< 0.07 and b= p< 0.09. 
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4. Discussion 
 We showed that it was feasible to measure changes in glucose metabolism during 
VNS using a small animal PET-detector and a limited number of rats. Acute VNS induced a 
significant decrease in left hippocampus and an increase of glucose metabolism in both 
olfactory bulbs. Chronic VNS significantly decreased left/right striatal ratios.  
 In this animal study, the results observed are in agreement with several previous 
imaging studies in epileptic patients (Henry et al., 1998; Henry, 2000; Henry et al., 2004; Van 
Laere et al., 2002; Vonck et al., 2000). We found a decrease in the left hippocampus (trend in 
the right hippocampus), a structure known to be often involved in the generation of complex 
partial seizures in temporal lobe epilepsy. A decreased glucose metabolism in this region may 
reflect the anti-convulsant activity of acute VNS. More specifically, in patients, acute VNS 
can be triggered at seizure onset by a magnet to interfere with the seizure. In line with the 
long-term study of Henry et al. (2004), these changes in hippocampal CBF were absent after 
chronic VNS. It is believed that these differences between acute and chronic VNS reflect 
cerebral adaptation to chronic VNS (Henry, 2000). This adaptation might underlie the finding 
that therapeutic VNS often causes gradual improved seizure control over several months of 
treatment (Henry, 2000). 
 In the current study, acute VNS bilaterally increased glucose uptake in the olfactory 
bulbs. Evoked potential and unit activity recording techniques have revealed the existence of 
a vagus nerve-olfactory bulb pathway (Garcia-Diaz et al., 1984). Also in patients, VNS has 
been found to influence and modulate the processing of olfactory information (Kirchner et al., 
2004). This last neurophysiological study reported even a positive correlation between 
activation of the olfactory bulb and therapeutic benefit. As the olfactory bulb is on the 
Figure 13: Effect of chronic VNS on left/right ratio of glucose uptake in rats. Control measurements
(white bars) were obtained without VNS. After one week of chronic VNS, additional images were 
acquired in the VNS group (black bars). During the FDG uptake and image acquisition, VNS was still
turned on. Left/right ratios are shown for eight brain regions. Abbreviations: Olf. Bulbs, olfactory bulbs; 
Th. + H-th., thalamus and hypothalamus; Hippoc., hippocampus; Cerebell., Cerebellum; MO, medulla
oblongata. Data are expresses as mean ± SEM, significance is set at p< 0.05 and is indicated with an 
asterisk. 
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contrary very small in humans, it is conceivable that metabolic changes in this structure were 
not measurable in human imaging studies. 
 The increase of glucose metabolism in the left medulla oblongata after chronic VNS 
was not significant (P= 0.07) and a higher number of animals might be necessary to 
demonstrate a difference in this structure. Changes in metabolism in dorsal-rostral medulla 
during acute and chronic VNS have also been reported in CBF studies of Henry (2000). These 
findings correspond to the known anatomical connections and projections of the vagus nerve 
to the brainstem tracti and nuclei. 
 The striatum is part of the basal ganglia and consists of the caudate nucleus and 
putamen. It is fairly large (around 5 mm3) and well separated in the rat brain; because of this, 
changes can be successfully measured even at moderate 3-4 mm spatial resolution (Hume et 
al., 1996). During baseline measurements, glucose metabolism in the striatum was slightly 
higher on the left side than on the right side (ratio: 1.1). In one human study, this has also 
been observed in healthy males (Kawachi et al., 2002). After chronic VNS, we found a 
significant decreased left/right ratio in striatum in comparison with baseline and a tendency 
towards a decrease in the left striatum. This brain structure has been acknowledged to play an 
important role in the control of seizures (Deransart and Depaulis, 2002). Ictal hyperperfusion 
of the striatum was shown using single photon emission computed tomography (SPECT) in 
patients with temporal lobe epilepsy (Semah, 2002). The striatum receives indirect 
innervation from the vagus nerve via the medial reticular formation of the medulla which 
projects to the intralaminar nuclei of the thalamus (having extremely widespread projections 
to cerebral cortex and the striatum) (Henry, 2002). Moreover, in PET imaging studies in 
humans, changes in CBF have been found in the putamen due to VNS (Ko et al., 1996).  
 Our study and brain imaging studies in humans have reported changes in both 
hemispheres (Chae et al., 2003) confirming that unilateral left VNS has bilateral functional 
projections into the brain.  
 In this pilot-study we compared relative differences in glucose metabolism (whole 
brain normalizations and left/right ratios of brain structures) after acute and chronic VNS with 
control measurements. Comparison with specific reference structure such as the cerebellum 
was judged as impossible, because it is presently unknown how glucose metabolism in such a 
structure will be altered by VNS. An alternative approach to whole brain normalization could 
include the scanning of a phantom with known radioactivity together with the rat and to 
utilize brain structure/phantom ratios as dependent values. The use of relative quantitative 
values was preferred for several reasons. The performance of absolute quantitative 
longitudinal studies would require the placement of a chronic, indwelling arterial catheter, 
which would increase potential morbidity and mortality in the experimental animals 
(Kornblum et al., 2000). Recently, several studies are endeavoring to acquire absolute 
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quantification of CMRGlc necessitating measurement of plasma glucose levels and the setup 
of automated microsampling systems (Lapointe et al., 1999). Nevertheless, the blood 
sampling procedures during the FDG uptake period could affect the animals’ behavior and 
thus the results (Kornblum et al., 2000). Moreover, the comparative ease of performing 
studies using relative (as opposed to absolute) quantization can increase small animal PET’s 
accessibility to many investigators (Kornblum et al., 2000). 
 For more precise anatomical localization, autoradiography may provide functional 
data at higher spatial resolution than can be achieved with PET. Although much more animals 
are needed and comparison within the same animal is impossible, autoradiography is still the 
paramount method to detect submillimetre FDG changes in the rat brain. The resolution of the 
current VUB-PET system is limited, and therefore more subtle changes or changes in small 
structures can be missed due to the partial volume effect. Indeed, previously reported changes 
in both directions in thalamus (Henry et al., 1998; Vonck et al., 2000; Henry et al., 2004) and 
hypothalamus (Henry et al., 1998; Henry et al., 2004) (for review see Chae et al., 2003) were 
not observed in this study. The negative findings in these regions therefore do not exclude the 
presence of smaller or more localized changes and will need confirmation in a higher-
resolution acquisition or analysis. Secondly, due to the presence of Harderian glands near the 
frontal cortex, significant inscatter effects cannot be excluded, although, no changes were 
measured in glucose uptake in the Harderian glands due to acute or chronic VNS. One way to 
optimize the analysis is to incorporate partial volume correction schemes based upon high-
resolution anatomical information, which can be performed post-hoc (but then MRI scans for 
all individual animals are needed) or even partial-volume corrections during reconstruction 
(Baete et al., 2004).  
 In this study we have co-registered a single MRI template with PET images, which 
greatly improves the interpretation of the PET images. Instead of software fusion, integrated 
multimodality imaging systems e.g. combining PET with CT or MRI can obtain most 
accurate hardware fusion. Currently, hybrid systems like small animal PET/CT are being 
marketed and research is focusing on integrated (small animal) PET/MRI devices as well 
(Gaa et al., 2004). 
 In conclusion, we showed that small animal PET is a useful and promising technique 
for imaging of cerebral activation in long-term studies in rats. In this feasibility study only a 
limited group of animals were studied. In the future, it would be appropriate to further extend 
the study towards the effect of VNS on brain metabolism by using higher-resolution 
acquisition, individual MRI scans and increased numbers of animals. In addition, it would be 
of great interest to investigate VNS its properties in different animal models of epilepsy (e.g. 
genetic absence epilepsy models, status epilepticus models). These studies could be focusing 
on different stimulation parameters (high or low intensity stimulation), prolonged stimulation 
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over months, different tracers (e.g. [3H]-Flumazenil a cBZP/GABAA) or absolute CMRGlc.  
Briefly, this pilot study demonstrated with restricted means the potential of small animal PET 
as an explorative tool for studying rat brain metabolism and responses to treatments during 
several stages of VNS therapy. 
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General discussion 
Neuropharmacological therapy with levetiracetam (LEV) and vagus nerve stimulation 
(VNS) are two novel treatments for refractory epilepsy. Acute application of both treatment 
options can be very effective. LEV can act rapidly on seizures in both animals and humans. In 
addition, preclinical studies suggest that LEV may have anti-epileptogenic and 
neuroprotective effects, with the potential to slow or arrest disease progression. VNS too can 
have an immediate effect on seizures in animals and patients with in addition an important 
cumulative effect after prolonged treatment. These treatments can be considered as 
neuromodulatory, since there is evidence that changes in central nervous system function or 
organization are induced by influencing and initiating neurophysiological signals.  
In this general discussion, we will deal with different aspects of these treatments with 
regard to the results found in this Ph.D. project as well as in the light of the current literature. 
Also future perspectives will be presented for both types of treatment.   
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6.1 Levetiracetam 
Lately, several novel anti-epileptic drugs (AEDs) were added to the 
pharmacotherapeutic armamentarium. One of these drugs is LEV (ucb L059, “Keppra”) with 
a wide spectrum of anti-convulsive effects in animal models for different types of epileptic 
seizures (Loscher and Honack, 1993; Klitgaard et al., 1998; Loscher et al., 2000). Apart from 
its anti-seizure effect, there is evidence that LEV also exhibits anti-epileptogenic properties in 
the amygdala kindling model of epilepsy (Loscher et al., 1998) and the spontaneously 
epileptic rat (SER), a model of primary generalized epilepsy (Sasa et al., 2003).  
Administration of LEV suppresses the occurrence of absence seizures in genetic 
absence epilepsy rats from Strasbourg (GAERS), a validated model of absence epilepsy 
(Gower et al., 1995). The effect of LEV on the development of epilepsy in a model of primary 
generalized absence epilepsy has not been studied so far. In a pilot study in GAERS, the 
robust anti-seizure effect of LEV was confirmed and a trend towards an anti-epileptogenic 
effect was found (Boon et al., 2002). This encouraged us to further investigate the 
neuromodulatory properties of LEV in GAERS; it was felt that investigating the effect of 
chronic LEV treatment in young GAERS could provide new insights and strategies for the 
treatment of epilepsy. During this Ph.D. research, we have investigated the effect of LEV on 
the age-related development of spike and wave discharges (SWDs) in GAERS by chronic 
administration of LEV (postnatal day (PN) 23-PN60) starting before the age of occurrence of 
SWDs. The effect of early chronic LEV administration on the development of SWDs was 
evaluated in young GAERS during treatment (PN57-PN60), immediately after treatment 
termination (PN61-PN64) and two months after the last LEV injection (PN120, age four 
months), when brain maturation was achieved and SWDs recorded on cortical EEG were 
numerous.  
We found that chronic LEV administration induced a decrease in epileptiform events 
(SWDs and “short irregular SWDs”= SISWDs) in young GAERS (PN57-PN60), which 
persisted to some extent immediately following cessation of treatment (PN61-PN64), but not 
until adulthood (PN120). 
6.1.1 Clinical relevance 
The treatment of epilepsy focuses exclusively on suppressing seizures, which is one of the 
end products of epilepsy. The question is whether epileptogenesis can be prevented or 
modulated by therapeutic intervention (anti-epileptogenesis). There are several possible 
clinical roles for anti-epileptogenic compounds (Schachter, 2002): 
1. An anti-epileptogenic drug could prevent seizures in patients at high risk for developing 
epilepsy. This could include patients undergoing craniotomy, patients with stroke or 
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severe brain injury and patients with a family history of a genetically determined epilepsy 
syndrome. 
2. An anti-epileptogenic therapy could induce permanent seizure remission in patients with 
epilepsy that would persist after the drug was discontinued.  
3. An anti-epileptogenic drug could halt or reverse an increasing seizure frequency or 
severity in patients with progressive epilepsy syndromes.  
4. If epileptogenesis could not be prevented or stopped, an anti-epileptogenic drug could 
modify the disease process in such way that epilepsy would become easier to treat. 
As the underlying mechanisms of epileptogenesis are still largely unknown, 
pharmacological prophylaxis has no solid theoretical basis, but is predicted on the assumption 
that what is good for seizure control will also help to prevent the development of an epileptic 
focus. On the other hand, anti-epileptogenic drugs do not necessarily have an effect on the 
seizures themselves. 
At present, human studies have not revealed an ideal strategy for anti-epileptogenesis. A 
number of AEDs have been evaluated in clinical trials to test whether they prevent 
epileptogenesis in humans, but to date no drug has been shown to be effective in such trials. 
But we also have to keep in mind that none of the new AEDs have yet been adequately tested 
for anti-epileptogenic effects in humans (Temkin, 2001). However, animal experiments could 
give some clues on anti-epileptogenic properties of AEDs.  
6.1.2 Animal research on neuromodulatory and anti-epileptogenic properties of AEDs 
A number of AEDs have been tested in the kindling model of epilepsy for a 
pharmacological prophylactic effect (Table 1). In this model, drugs can either be tested in 
fully kindled rats for their effect on elicited seizures (anti-convulsant effect) or drugs can be 
administered during the kindling process to test whether they suppress kindling development 
(thought to reflect an anti-epileptogenic effect). Various compounds have been found to 
interfere with the kindling process (Table 1) (Loscher, 2002). 
Several studies have been performed in the status epilepticus (SE) models (Table 2). 
There are different treatment strategies in the timescale from the initial insults through the 
latent period followed by the actual onset of the seizures (Figure 1).  
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Figure 1: Epileptic processes as a treatment target during the development of acquired epilepsy (Pitkanen, 
2002). Various etiologic factors, such as genetically programmed lesions, head trauma, stroke, infection and 
SE, can cause neuronal damage in the brain. Brain injury triggers epileptogenesis in a subpopulation of 
patients during which time different neurobiological changes occur. These include acute and delayed 
neuronal loss, neurogenesis, gliosis, axonal and dendritic plasticity, angiogenesis, inflammation and 
molecular reorganization of receptors and channels. This period provides a window of opportunity for anti-
epileptogenic compounds that can either completely prevent the development of epilepsy or at least have 
disease-modifying effect. After the epileptogenic latency period, spontaneous recurrent seizures appear and 
epilepsy is diagnosed. In parallel to initial insult-induced epileptogenesis, cognitive performance might also 
decline. Good seizure control can be obtained in approximately 70% of the patients. In the remaining 
patients, molecular, cellular and network reorganization can continue even after the diagnosis of epilepsy 
because of recurrent seizures. This might have two functional consequences: worsening of epilepsy and 
further decline in cognitive functions.  
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An anti-kindling or anti-seizure effect is indicated by ‘+’; lack of such effect by ‘NE’, not effective. 
 
In the SE models, prevention of epilepsy was seen with diazepam, levetiracetam, 
valproate and topiramate (Table 2). However, the anti-epileptogenic findings of levetiracetam, 
topiramate and valproate could not be reproduced in other SE-models (Klitgaard and 
Pitkanen, 2003).  
 
 
Drug Model Prevention of epilepsy 
Reduction of 
neurodegeneration Reference 
Carbamazepine PPS n.d. NE Halonen et al., 2001a 
Caspase-inhibitors Kainate n.d. (+) Ebert et al., 2002 
Diazepam SAS + + Pitkanen et al., 2005 
Gabapentin Kainate n.d. + Cilio et al., 2001 
Ketamine Pilocarpine NE + Hort et al., 1999 
Lamotrigine PPS n.d. + Halonen et al., 2001a 
Levetiracetam Pilocarpine NE + Klitgaard et al., 2001 
Levetiracetam PPS + n.d. Mazarati et al., 2003 
MK-801 Kainate NE + Ebert et al., 2002 
Phenobarbital Kainate NE NE Bolanos et al., 1998 
Remacemide PPS n.d. NE Halonen et al., 1999 
Retigabine Kainate n.d. (+) Ebert et al., 2002 
Topiramate Pilocarpine + + DeLorenzo et al., 2002 
Topiramate SHS n.d. + Niebauer and 
Gruenthal, 1999 
Topiramate SAS NE NE Pitkanen, 2002 
Valproate Kainate + + Bolanos et al., 1998 
Valproate Pilocarpine NE n.d. Klitgaard and Pitkanen, 
2003 
Vigabatrin SAS NE NE Halonen et al., 2001b 
Vigabatrin Pilocarpine NE + Andre et al., 2001 
Vigabatrin Kainate n.d. NE Pitkanen et al., 1999 
Only studies are shown in which drugs were given after a status of sufficient length to induce epilepsy 
and brain damage. An anti-epileptogenic or neuroprotective effect is indicated by ‘+’, lack of such 
effects by ‘NE’, not effective; weak effect by ‘(+)’; not determined by ‘n.d.’. Abbreviations: SAS, 
sustained amygdala stimulation; SHS, sustained hippocampal stimulation; PPS, perforant path 
stimulation. 
Drug Suppression of kindling development 
Suppression of fully kindled 
seizures 
Valproate + + 
Phenobarbital + + 
Benzodiazepines + + 
Vigabatrin + + 
Topiramate + + 
Levetiracetam + + 
Lamotrigine + + 
Carbamazepine NE + 
Phenytoin NE + 
NMDA antagonists + NE 
Table 2: Overview of anti-epileptogenesis studies in SE models adapted from Loscher (2002). 
Table 1: Effects of AEDs in the amygdala kindling model in rats (Loscher, 2002). 
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Discrepancies between studies using the kindling model and studies using the SE 
model indicate that mechanisms underlying development of epilepsy in different animal 
models might not be the same (Loscher, 2002). In addition, there is a lack of data from other 
models of epileptogenesis and it is difficult to extrapolate the data of kindling and SE models 
to other epileptogenic etiologies such as stroke- or head trauma-induced epileptogenesis.  
Animal models of genetic idiopathic epilepsy have only been used scarcely. Absence 
seizures, a type of idiopathic epilepsy in humans, are usually a benign form of epilepsy (Wolf, 
1984). Despite the good pharmacological response in this form of epilepsy, investigating the 
anti-epileptogenic properties of AEDs in GAERS could provide new insights and strategies 
for epilepsy treatment. In GAERS, spontaneous absence seizures develop progressively. 
Therefore, it is an excellent model to study epileptogenesis and interference with 
epileptogenesis by neuromodulation. To our knowledge, there is only one study that 
chronically administered an AED i.e. remacemide in young GAERS (PN7-PN25) to establish 
its effect on SWD development (Nehlig and Boehrer, 2003). This study failed to demonstrate 
an effect of early remacemide treatment on the expression of SWDs in adult GAERS. 
6.1.3 Animal research on levetiracetam 
LEV has an anti-epileptic effect in a broad range of animal models mimicking both 
partial (Loscher and Honack, 1993; Klitgaard et al., 1998; Loscher et al., 2000; Glien et al., 
2002) and generalized epilepsy in man (Loscher and Honack, 1993; Klitgaard et al., 1998) 
including GAERS (Gower et al., 1995). In contrast, LEV revealed no effect in the two 
conventional screening tests, namely the maximal electroshock and pentylenetetrazole models 
(Klitgaard et al., 1998; Loscher and Honack, 1993). 
The anti-seizure effect of LEV has mainly been established after a single injection of 
LEV. However, in several studies LEV was administered during prolonged periods (Loscher 
et al., 1998; Loscher and Honack, 2000; Glien et al., 2002; Stratton et al., 2003). We found 
that chronic LEV treatment significantly suppressed (average difference of 62%) epileptiform 
events in young GAERS (PN57-PN60) in comparison with control animals (Dedeurwaerdere 
et al., 2005). LEV was administered daily by i.p. injection and its effect was investigated 
during treatment (3 h a day for four consecutive days) and immediately after termination of 
the treatment (3 h a day for four consecutive days) in young animals. Young GAERS have 
few SWDs; therefore the more frequent SWD-like events were also taken into account. These 
were defined as short irregular SWDs (SISWDs) with clear spike and wave aspects 
characterized by lower amplitude (< 3 times baseline amplitude) or lower peak frequency (5-7 
Hz) and shorter in duration (< 2 s) (Dedeurwaerdere et al., 2005). The LEV treated animals 
displayed less SWD-like events (up to 81%) than the control group even in the pre-injection 
hours. This could suggest that there was a slowing down of the epileptogenic processes by 
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early chronic treatment (PN23-PN60) with LEV. Yet, the lower number in the pre-injection 
hours might also be caused by retention of LEV in the brain from previous injections, 
although LEV was already eliminated from the blood plasma.  
Interestingly, there was no acute decrease in SISWDs after injection of LEV (PN57-
PN60) (Dedeurwaerdere et al., 2005). This is in contrast with previous acute experiments in 
adult GAERS, in which a clear decrease in SWDs could be observed after a single LEV 
injection (Gower et al., 1995; Boon et al., 2002; Bouwman and van Rijn, 2004). These 
studies, which were performed in adult GAERS, report the effect of a first and single LEV 
injection, while the effect of chronic LEV administration was not investigated. Moreover, 
several studies dealing with the chronic administration of LEV in animal models of temporal 
lobe epilepsy report increased functional tolerance towards LEV and some loss of efficacy 
after prolonged administration (Loscher et al., 1998; Loscher and Honack, 2000; Glien et al., 
2002). This increased tolerance could provide a possible reason for the lack of an acute 
decrease in SISWDs in GAERS that were already pretreated.  
When treatment was stopped, there was no sudden increase in epileptiform events 
(SWDs and SISWDs) (Dedeurwaerdere et al., 2005). This is in line with previously 
performed rat and mouse experiments in which chronic treatment with LEV did not lead to 
withdrawal hyperexcitability (Klitgaard et al., 1998; Loscher and Honack, 2000). Moreover, 
there was a trend (p= 0.064) towards a lower number of epileptiform events (an average 
difference of 53%) in the young LEV pretreated GAERS. In the study of Glien et al. (2002) 
LEV was administered during two weeks in the pilocarpine model of temporal lobe epilepsy. 
Some animals still had less spontaneous partial seizures one week after terminating LEV 
treatment and this was described as a carryover effect (Glien et al., 2002).  
Neuroprotective and anti-epileptogenic properties of LEV have been reported in 
several animal models of epilepsy. LEV induces neuroprotection in a rat model of focal 
cerebral ischemia (Hanon and Klitgaard, 2001). Recent observations showed that LEV 
attenuates both hippocampal cell death and enhancement in hippocampal excitability 
following a pilocarpine induced SE (Klitgaard et al., 2001). Another study demonstrated that 
chronic levetiracetam treatment has a mild neuroprotective effect on hippocampal principal 
cells and interneurons after pilocarpine-induced SE (Pitkanen and Kubova, 2004).  
These neuroprotective properties may be relevant to its anti-epileptogenic action. 
Klitgaard et al. (2001) induced pilocarpine-induced SE in rats and terminated it with 
diazepam 30 min after the beginning of SE. Thereafter, levetiracetam treatment was initiated 
and continued for the next 21 days. Continuous video-EEG monitoring (72 h) three days after 
drug cessation revealed, however, no differences in the percentage of pretreated rats with 
spontaneous seizures compared to a vehicle group. Mazarati et al. (2003) started 
levetiracetam treatment 1, 3 and 6 h after PPS and continued it for 29 days via subcutaneous 
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osmotic minipumps. Two weeks after treatment discontinuation, seizures were analyzed using 
video-EEG monitoring. Seizure frequency was reduced and the number of seizure free days 
was greater in the levetiracetam group compared to the vehicle group.  
In the amygdala kindling model, LEV suppressed kindling development at doses 
devoid of adverse effects with persistent reduction in afterdischarge duration after termination 
of treatment (Loscher et al., 1998). These findings have recently been confirmed (Stratton et 
al., 2003; Zhang et al., 2003). The ability of LEV to delay the development of kindling 
suggests that it has the potential to interfere with the epileptic circuitry modifying seizure 
recruitment and projection properties of the epileptic network (Loscher et al., 1998). 
However, LEV has been administered before the kindling stimulus was given. There are some 
controversies whether or not its anti-convulsant action might have prevented the development 
of kindling by reducing the expression of the evoked seizures rather than affecting the 
processes underlying the hyperexcitibility of the fully kindled state. We have put up a pilot 
study in which LEV (54 mg/kg i.p.) and/or valproate (200 mg/kg i.p.) was administered daily 
for 24 consecutive days before kindling (De Smedt et al., 2003). One week after the last 
injection, kindling procedures were applied according to the “rapid kindling with recurrent 
hippocampal seizures (RKRHS) model”. Preliminary results did not show differences in 
kindling rate or seizures expression from the vehicle group.   
The anti-epileptogenic potential of LEV has also been supported in the genetic SER 
model characterized by spontaneous tonic convulsions and absence seizures (Sasa et al., 
2003). LEV was administered during weeks 5–9 after birth before the appearance of 
spontaneous seizures and was terminated at the expected age for seizure expression, which 
resulted in a decrease in the frequency of both tonic and absence seizures in pre-treated 
animals. Also, the duration of both tonic convulsions and absence seizures was shorter than in 
controls.  
In a previous study, we found an indication for such an anti-epileptogenic effect in 
the GAERS model (Boon et al., 2002). Recently, we found that epileptiform events tended 
(p= 0.064) to be less frequent (up to 60%) in LEV pretreated (PN23-PN60) GAERS during 
the four observation days after treatment cessation in comparison with the control group 
(Dedeurwaerdere et al., 2005). The major metabolite of LEV is pharmacologically inactive 
and other metabolites are produced at levels below those that are relevant for pharmacological 
activities (Loscher et al., 1998). LEV does not interfere with enzyme systems (Patsalos, 2000; 
Benedetti, 2000) and is washed out rapidly (half-live ~2-3 h) after stopping the treatment 
(Loscher et al., 1998). The decrease in epileptiform events on the first two recording days 
after treatment cessation might be due to retention of LEV or other metabolites in the brain; 
however, this is unlikely for the last two recording days. Early chronic treatment with LEV in 
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young GAERS might have caused an initial slowing down of the epileptogenic processes, but 
had no effect on the later expression of SWDs (age of four months).  
It is clear that LEV can have a lasting and sometimes even permanent 
neuromodulatory effect on the epileptic central nervous system. Chronic treatment is probably 
not just a summation of several single administrations of LEV. Additional phenomena appear 
like prolonged effect after treatment for days (Dedeurwaerdere et al., 2005), a week (Glien et 
al., 2002) and even permanent modifications of the epileptic network occur (Loscher et al., 
1998). Nevertheless, undesired effects like functional tolerance have also been described after 
chronic treatment (Loscher and Honack, 2000; Zhang et al., 2003). 
6.1.4 Mechanisms of action of levetiracetam  
Until now, it is not described in what manner LEV exerts its effect on absence 
seizures in GAERS. A possible effect of LEV that might contribute to its action against 
SWDs in GAERS could be by progressively decreased firing of neurons of the substantia 
nigra pars reticulata (Loscher et al., 1996). A reduction in the firing rate of these neurons has 
been shown to result in anti-convulsant activity (Loscher and Ebert, 1996). In addition, direct 
micro-injection of LEV into the SNR induces seizure protection in the pilocarpine model of 
temporal lobe epilepsy (Klitgaard et al., 2003). The SNR is not part of the epileptic circuit 
underlying absence seizures, but it may belong to a system participating in a remote control 
over seizures (Danober et al., 1998). Indeed, high frequency stimulation of the SNR has been 
shown to interrupt SWDs in GAERS (Feddersen et al., 2004) and intracerebral micro-
injections of GABA mimetics in the SNR suppress absence seizures (Danober et al., 1998). In 
line with this, Klitgaard et al. (1998, 2003) stresses that a part of LEV’s ability to suppress 
seizures may originate from its effect on neuronal firing in the SNR, but the anatomical 
network and molecular mechanisms by which this is mediated remains to be demonstrated. 
We hypothesize that LEV’s anti-epileptic action on SWDs in GAERS is mediated through an 
effect on the SNR, but it is not known if this might interfere with epileptogenesis. In GAERS 
pups, metabolic increases in the nigral inhibitory system such as SNR compared to non-
epileptic control rats were observed (Nehlig et al., 1998). Increase in these structures involved 
in the control of seizure activity was suggested to reflect a mechanism of prevention of 
epileptogenesis in GAERS.  
6.1.5 Future perspectives 
As the incidence of new epilepsy cases is between 26 and 70 per 100 000 (Hauser, 
1998), it would be favorable to not only search for treatments that suppress seizures, but also 
to seek for treatments that tackle the underlying pathophysiology of epilepsy itself. A new 
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approach to drug screening, including the process of epileptogenesis, may identify new 
classes of drugs (Kupferberg, 2001; Klitgaard and Pitkanen, 2003). LEV is a novel AED with 
potential anti-epileptogenic properties, which was discovered using non-conventional drug 
screening. Not only the properties of the drug itself, but also the time frame during which it is 
applied is of great importance. More research is required to determine the optimal time 
windows for preventing epileptogenesis in several animal models of epilepsy. 
In the SE model, it has been shown by several investigators that the optimal time 
window to pharmacologically intervene with the initial insult (SE) is within 2 h (Brandt et al., 
2003; Pitkanen et al., 2005). Pretreatment with LEV by i.v. injection via the tail vein reduced 
or prevented (higher doses) the development of self-sustaining seizures (Mazarati et al., 
2004). Treatment during the maintenance phase of self-sustaining status epilepticus 
diminished or aborted seizures (higher doses) (Mazarati et al., 2004). The authors, however, 
did not mention whether these animals were further monitored to investigate the development 
of seizures and to assess the neural damage, which would have been of interest. In some 
studies this initial interference was extended by continuing treatment during the latent period 
(Klitgaard et al., 2001; Mazarati et al., 2003; Pitkanen and Kubova, 2004). This approach has 
been shown to induce mild neuroprotection and to interfere with epileptogenesis in the PSS 
induced SE model, but not in the pilocarpine SE model. It has not been assessed whether 
seizures are easier to treat when epilepsy was not prevented, but delayed or reduced in 
severity.  
In the amygdala kindling model, LEV had anti-epileptogenic properties when applied 
before the kindling stimulus. In a pilot-study we performed, epileptogenesis was not altered 
when chronic LEV treatment was applied before the kindling procedure was started (De 
Smedt et al., 2003). Another interesting strategy would be to apply the AED immediately 
after the evoked seizure to interfere with processes underlying epilepsy development during 
kindling. In our laboratory, a new experimental design has been set up to further investigate 
the anti-epileptogenic properties of LEV on kindling development. An alternative of the 
RKRHS model, which does not lead to permanent hyperexcitibility (Lothman and 
Williamson, 1994) is the RKRHS model with alternate day kindling. In this model, kindling is 
performed every two days during eight days. During the subsequent week, epileptogenic 
processes are indelibly imprinted into the brain resulting in a permanent hyperexcitibility 
(Lothman and Williamson, 1994). The week of epileptogenesis can be regarded as a “latent 
period”, enabling to interact with epileptogenesis without interfering with the kindling 
seizures themselves (pers. com. T. De Smedt). If permanent hyperexcitibility is affected by 
treatment during this week, this would provide evidence of an anti-epileptogenic effect of the 
tested compound. 
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Animal models of genetic idiopathic epilepsy have only just been used in anti-
epileptogenesis research. In GAERS, therapy was started (PN23) before seizures became 
apparent to interfere directly or indirectly with early pathological changes. Although there 
was a temporal effect of LEV on seizures immediately after treatment discontinuation, seizure 
expression was not altered during adulthood. It is known that important pathophysiological 
changes (T-type calcium conductance of reticular thalamic neurons, glucose metabolism, 
astrocytic modifications and glutamate transporters) in GAERS emerge early in life, before 
the appearance of spontaneous absence seizures (Dutuit et al., 2000; Dutuit et al., 2002; 
Tsakiridou et al., 1995; Vergnes et al., 2003). Some of these neuropathological and 
neurophysiological changes take place before we started the treatment in this study (Vergnes 
et al., 2003). Therefore, it could be possible that earlier initiation of LEV treatment, e.g. 
beginning at birth, could lead to a more sustained effect. The chronic delivery of LEV did not 
interfere with normal development and body weight of the animals. Clinical findings suggest 
that LEV is a well-tolerated and safe treatment option for pediatric patients with epilepsy 
(Patsalos, 2000; Coppola et al., 2004). Importantly, Bittigau et al. (2003) has, however, 
demonstrated that the same AEDs, including diazepam, clonazepam, phenytoin, 
phenobarbital, valproate and vigabatrin, can induce apoptotic neurodegeneration in the 
developing brain in clinically relevant doses. Pitkanen et al. (2004) commented that 
extrapolation of data obtained in mature brain to immature brain should be done with caution, 
hence, neuroprotection in the immature brain remains a challenge. 
As we used a relatively high dose to inject and LEV is already effective in low doses 
in GAERS (Gower et al., 1995), we expect that relevant therapeutic concentrations are 
present in the blood plasma for 8 h. However, more continuous administration of the drug 
should be considered. This could be done by the implantation of an osmotic mini-pump that 
provides a continuous release and thereby more steady plasma exposure with LEV.  
An interesting feature not investigated in the present GAERS study, is whether 
prolonged LEV treatment early in life would have modified the response to AED treatment 
during adulthood. In addition, also the effect of chronic LEV in adult animals could be of 
interest to investigate whether LEV has disease modifying properties in adult GAERS. 
More recently, Krupp et al. (2000) raised the question whether treatment with AEDs 
during epileptogenesis induces development of drug-refractory seizures if the prevention of 
epileptogenesis fails. Although LEV shows potent anti-epileptogenic and anti-convulsant 
effects in amygdala-kindled rats, repeated treatment induces anti-convulsant tolerance and 
unidirectional cross-tolerance to carbamazepine administered subsequently (Zhang et al., 
2003). The consequences of anti-epileptogenic treatment on the later response to AEDs in 
animals in which the treatment fails present a challenge that needs to be addressed in anti-
epileptogenesis studies (Pitkanen and Kubova, 2004). 
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We hypothesized that the effect of LEV on absence seizures in GAERS could be 
manifested through an effect on the SNR. However, this hypothesis is based on indirect 
evidence from related studies. Therefore, it would be interesting to set up an experiment 
which determines the anatomical network and molecular mechanisms by which this effect of 
LEV on SNR neurons is mediated in GAERS. 
Finally, future perspectives must not be limited to LEV, several other AEDs on the 
market should be considered. For instance valproate, lamotrigine, topiramate and zonisamide 
have been shown to possess interesting features potentially being anti-epileptogenic (Bolanos 
et al., 1998; Halonen et al., 2001a; DeLorenzo et al., 2002; Hashimoto et al., 2003). However, 
at present, none of these compounds has been shown to completely protect against 
epileptogenesis. Of course, these drugs have been selected for their ability to block seizures. It 
is not known whether there is a pivotal correlation between anti-seizure capability and the 
effect on epileptogenesis. Therefore new screening procedures, testing for effects on the 
processes of epileptogenesis, could reveal new classes of drugs. 
Clearly, serious efforts have already been made to understand epileptogenesis and 
anti-epileptogenesis; however, we still have a long way to go to find the ultimate compounds 
and treatment strategies. 
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6.2. Vagus nerve stimulation 
During the current research, several aspects of VNS have been approached using 
animal models of epilepsy. In a chronic model of primary generalized epilepsy, namely 
GAERS, we investigated the effect of both acute and chronic VNS. In a chronic model of 
partial epilepsy (kindling in Fast rats), we investigated several therapeutic properties of VNS 
like the acute abortive effect of VNS on generalized convulsions, chronic effects of VNS on 
the development of epilepsy, cognitive effects and effects on body weight regulation. In 
addition, we were able to detect changes in glucose metabolism after acute and chronic VNS 
in healthy rats, providing a tool to further elucidate the mechanism of action (MOA) of VNS. 
6.2.1 Efficacy of VNS in animal models of epilepsy 
Jacob Zabara published two abstracts in Epilepsia in 1985 on the efficacy of VNS, 
which unleashed further research on VNS as a new therapeutic approach to treat epilepsy. He 
found a reduction in seizure duration and severity when stimulating the vagus nerve in dogs. 
One year later, Joan Lockard (1986) showed that is was feasible to implant a VNS cuff-
electrode and stimulating device in a monkey model of epilepsy on a long-term basis.  
At present, VNS is an efficacious broad-spectrum add-on treatment for patients with 
medically or surgically refractory epilepsy (Ben-Menachem, 2002). Treatment involves 
stimulation of the left vagus nerve via an implanted pulse generator in an attempt to reduce 
the frequency and severity of epileptic seizures. Controlled randomized trials using this 
treatment strategy have shown a 50% reduction in overall seizure frequency in approximately 
30% of patients (Salinsky, 2003). In addition, VNS seems to have effects on interictal 
epileptiform discharges (IED). Koo (2001) observed a decrease in interictal spikes, which was 
later on confirmed (Kuba et al., 2002).  
The benefits of VNS as a form of seizure control are numerous. Firstly, adverse 
effects are minimal and not additive with those frequently encountered with AEDs such as 
sedation and ataxia. Problems of drug toxicity, inherent to chronic medical therapy and 
rapidly increasing with polytherapy are avoided with VNS. Secondly, because the device is 
programmed to deliver continuous intermittent stimulation, there is never an issue with 
respect to treatment compliance. Thirdly, unlike many AEDs, the effectiveness of VNS is 
maintained during prolonged treatment without development of tolerance or becoming 
refractory to treatment. Lastly, VNS does not seem to oppose the action of additional AEDs. 
Initially, animal studies on VNS preceded the use of VNS in humans, but currently, 
animal experiments are still ongoing trying to optimize VNS therapy and to elucidate the 
MOA. A chronological overview of these studies is presented in table 1. Mostly, acute VNS 
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studies were performed utilizing application protocols immediately before, during and/or after 
seizure provocation.  
 
Table 5: Chronological overview of the efficacy of VNS in animal models of epilepsy. 
Date Researcher Model Animal Result 
1952 Zanchetti et al. Strychnine Cats Blocking of IED and desynchronization of 
the cortical EEG. 
1967, 
1968 
Stoica and Tudor Strychnine Cats Decrease of IED and prevention of spreading 
to the contralateral side by VNS.  
Increase of IED by high-intensity VNS. 
1990, 
1991 
Woodbury and 
Woodbury 
3-MPA/ PTZ/ 
MES 
Rats Interruption of seizures, abortive effect. 
1990 Lockard et al. Alumina gel Rhesus 
monkeys 
Reduction of the number of seizures, 
prophylactic effect by chronic high-intensity 
VNS. 
1992 Zabara Strychnine/ 
PTZ 
Dogs Inhibition of generalized seizures by high-
intensity VNS. 
1993 McLachlan Penicillin/ 
PTZ 
Rats Decrease of IED and seizure duration, 
abortive effect. 
1996 Takaya et al. MES Rats Dose response and prophylactic effect. 
1997 Naritoku and 
Mikels 
Kindling Rats Delay of kindling development. 
1999 Fernandez-
Guardiola 
et al. 
Kindling Cats Delay of kindling development. 
2001 Sunderam et al. 3-MPA Rats Moderate anti-seizure effect. 
2002 Munana et al. Refractory 
epilepsy 
Dog Cumulative efficacy of chronic VNS after 
long-term treatment. 
2004 Dedeurwaerdere 
et al. 
GAERS Rats VNS can prolong SWDs.  
Sub-acute VNS had no effect. 
2005a Dedeurwaerdere 
et al. 
GAERS Rats High-intensity (perceptible) VNS aborts 
SWDs. 
One week of VNS does not suppress SWDs. 
Submitted
(a) 
Dedeurwaerdere 
et al. 
Kindling  
in Fast rats 
Rats Prevention of seizures and reduced ADD 
when VNS is applied after the kindling 
stimulus. 
No delay of kindling development and 
prolongation of convulsions when VNS is 
applied for 2 h before the kindling stimulus.  
Abstracts are only included if they are not published later on in full article format. Abbreviations: IED, 
interictal epileptiform discharges; VNS, vagus nerve stimulation; 3-MPA, 3-mercaptoproprionate; 
PTZ, pentylenetetrazol; MES, maximal electroshock seizure; SWDs, spike and wave discharges; ADD, 
afterdischarge duration. 
 
Zanchetti et al. (1952) were among the first to experiment with the anti-convulsive 
properties of VNS. They showed that interictal spikes, produced by topical application of 
strychnine to the cerebral cortex of the cat, were blocked by low-intensity VNS (output 
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current: 1-2 V, pulse duration: 0.5 ms and frequency 50 Hz). Similarly, Stoica and Tudor 
(1967, 1968) found that low-intensity VNS (output current: 1-4 V, pulse duration: 0.3 ms and 
frequency: 30 Hz) decreased the frequency of spiking activity by about 34% induced by 
strychnine applied topically to the coronal, anterior sigmoid, suprasylvian or medial marginal 
gyri of the cat. Spread to the contralateral side was also inhibited by VNS. Stoica and Tudor 
(1968) stated that the vagal afferent projections to these areas are diffuse and non-specific and 
that a different number of fibers project to each area. On the contrary, they also noted an 
increase in interictal spike frequency when high-intensity stimulation of the vagus nerve was 
performed (Stoica and Tudor, 1968). Two decades later, Woodbury and Woodbury (1990, 
1991) reported that acute high-intensity stimulation at frequencies greater than 4 Hz 
prevented or reduced chemically (3-mercaptoproprionate, 3-MPA and pentylenetetrazole, 
PTZ) induced clonic convulsions in anesthetized rats and electrically (maximal electroshock 
seizure, MES) induced clonic and tonic clonic seizures in awake rats. This effect was 
attributed directly to the fraction of C fibers stimulated. It was observed that VNS shortened, 
but did not shut down a chemically induced seizure once it had begun. Optimal stimulation 
parameters were described as: output current 0.2-0.5 mA/mm² of nerve cross-section, pulse 
duration 0.5-1 ms and frequency 10-20 Hz. In 1992, Zabara published his work in manuscript 
form on the anti-convulsant effect of VNS in epileptic dogs. He found that high-intensity 
VNS could interrupt or terminate strychnine-induced seizures and PTZ-induced tremors in 
anesthetized dogs. Inhibitory effects of VNS persisted for a considerable time after 
termination of stimulation. It was suggested that small unmyelinated nerve fibers must be 
stimulated and that the optimum parameters were: output current 10-20 V (~3-20 mA), pulse 
duration 0.2 ms and frequency 20-30 Hz. McLachlan (1993) found that low-intensity VNS 
not only suppressed PTZ-induced seizures (within 3 s after seizure onset), but also reduced 
(by 33%) focal interictal spikes produced by penicillin in anesthetized rats. Interictal spikes 
could already been suppressed at 0.2 mA; however, higher currents > 0.8 mA (pulse duration: 
0.5 ms and frequencies 20-50 Hz) produced a more consistent response and persisted up to 20 
s after stimulation. Vagal stimulation caused no change in seizure duration in high-dose PTZ 
induced seizures, which was explained by a more intense ictal involvement of the brainstem 
reticular system. Takaya et al. (1996) found that VNS pretreatment (output current: 1 mA, 
pulse duration: 0.5 ms and frequency: 30 Hz continuously for 0.1 or 60 min or intermittently - 
30 s/5 min on/off - for 60 min) induced a sustained anti-convulsive effect on PTZ-induced 
seizures in awake animals, which efficacy was dependent on the cumulative stimulus 
duration. Sunderam et al., (2001) reported the effect of left VNS (output current: 1.4 mA, 
pulse duration:  0.5 ms, frequency: 20 Hz and duty cycle: 30 s/3 min on/off) and left sciatic 
nerve stimulation on 3-MPA-induced seizures using a highly complicated study design. VNS 
only had a small anti-seizure effect, which the authors ascribed to a hemodynamically-
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induced deficit in energy substrates. In a chronic model of spontaneous absence epilepsy 
namely GAERS, we showed a transient increase in seizure duration following acute VNS 
(output current: 3 V, pulse duration: 0.5 ms and frequency: 30 Hz), which disappeared in a 
sub-acute setting (Dedeurwaerdere et al., 2004). However, when VNS was applied at higher 
intensities (5-10 V) perceptible for the animals, the typical spike and wave discharges 
(SWDs) were shut down immediately (Dedeurwaerdere et al., 2005a). In amygdala kindled 
Fast rats (genetic strain of seizure prone rats), acute VNS (output current: 0.5 mA, pulse 
duration:  0.5 ms, frequency: 30 Hz for 60 s) showed clear anti-convulsant effects in a subset 
of animals when applied immediately after the kindling stimulus. However, when VNS (duty 
cycle: 30 s/1.1 min on/off) was applied for two hours before the kindling pulse, generalized 
convulsions were prolonged.  
Only a few studies have assessed the effect of chronic VNS in animal models of 
epilepsy (Lockard et al., 1990; Munana et al., 2002; Dedeurwaerdere et al., 2005a). A 
possible reason for this is that long-term research on VNS in laboratory animals like rats has 
some practical implications. Firstly, chronic studies are laborious and time consuming, 
because they require long-term monitoring of the animal and subsequent analysis of all data. 
Secondly, there are also technical aspects, which make chronic VNS stimulation difficult to 
apply in small animals. To deliver chronic VNS, a pulse generator has to be implanted or 
VNS has to be delivered via flexible leads connected to an external stimulator. Because the 
Cyberonics stimulating device is rather big to implant in a rat, we chose for the latter option. 
We have constructed a long-term video EEG monitoring unit equipped with spring covered 
flexible leads (to avoid gnawing at the leads by the rat), a spring (allows up and down 
movements of the rat) and a communicator or swivel (allows the rat to walk around freely in 
the cage). The lead ends of the cuff-electrode have to be easily accessible, to connect the rat 
to the VNS pulse generator without difficulties. In addition, these lead ends have to be safely 
secured in a way that the animals cannot pull or move the leads. Therefore, we have fixated 
the lead ends together with the EEG electrodes with dental acrylic on the head of the rat. 
Finally, VNS necessitates implantation of a cuff-electrode, which is well tolerated by the 
animals, does not induce nerve damage and stays functional over prolonged periods. In our 
laboratory, such a stimulation electrode is available now (Dedeurwaerdere et al., 2005b).  
A study in rhesus monkeys showed that chronic VNS was feasible and that epileptic 
processes are influenced (Lockard et al., 1990). However, at that time, the authors stated that 
safety and efficacy of the procedure were still in question. Munana et al. (2002) evaluated the 
use of VNS (output current: 0.25-1 mA, pulse duration: 0.5 ms, frequency: 30 Hz and on/off 
cycle: 30 s/ 5 min) as a treatment for refractory epilepsy in dogs. No significant difference in 
seizure frequency, duration or severity was detected between overall 13-week treatment and 
control periods. However, during the final four weeks of the treatment period, a significant 
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decrease in mean seizure frequency (34.4%) was found, compared with the control group. 
This may reflect an increase in the efficacy of VNS over time. When chronic VNS (output 
current: 1.5 mA, pulse duration:  0.5 ms, frequency: 30 Hz and duty cycle: 60 s/12 s on/off) 
was applied during one week in GAERS, the decrease in SWDs did not significantly differ 
from the control group (Dedeurwaerdere et al., 2005a). It can be hypothesized that a longer 
period of VNS or earlier intervention during life might be required to affect an already 
established absence epilepsy syndrome. 
The effect of VNS on epileptogenesis has been investigated in the amygdala kindling 
model of temporal lobe epilepsy. During the kindling process seizure severity and duration 
gradually progress. It offers the advantage that seizures can be elicited at will and that it 
allows detailed study of the events associated with the epileptogenic process. In cats, it was 
found that VNS trains (output current: 1.2-2 mA, pulse duration: 0.5 ms and frequency: 30 Hz 
for 1 min) before and four times after the kindling stimulus interfered with epileptogenesis 
(Fernandez-Guardiola et al., 1999). These findings were confirmed in a previous abstract of 
Naritoku and Mikels (1997) in rats, who showed that VNS before each kindling stimulus 
delays the completion of kindling. However, we could not reproduce these observations using 
a genetic seizure prone rat strain. Kindling rate was not delayed by VNS (output current: 0.5 
mA, pulse duration:  0.5 ms, frequency: 30 Hz and duty cycle: 30 s/1.1 min on/off) and during 
the stage-5 convulsions evidence of hyperexcitability was even noted in the VNS group 
(Dedeurwaerdere et al, submitted). It is conceivable that VNS cannot interfere with 
epileptogenesis in individuals with a strong genetic predisposition to develop epilepsy, like 
the Fast rats in our study. Moreover, kindling might involve different mechanisms in Fast rats 
compared to healthy animals. It is noted that in this study we saw that some VNS-treated rats 
(n= 3) showed delayed kindling rates compared to controls (n= 3) when the piriform cortex, 
rather than the amygdala, served as the kindling focus (S. Dedeurwaerdere, personal 
observations, 2004). Although, kindling rate in the piriform cortex is faster than in the 
amygdala (McIntyre et al., 1999), VNS rats did not display stage-5 seizures unless VNS was 
terminated (by lead fracture). Therefore, the origin of epileptogenesis and seizure generation 
could also be an influencing factor whether VNS can act on kindling development in Fast 
rats. 
It is impossible to extract an ideal set of stimulation parameters from these studies. 
Most studies use frequencies between 20 and 30 Hz and a pulse duration of 0.5 ms. However, 
the probably most crucial parameter namely the output current is difficult to evaluate. The 
actual current delivered to the nerve is depending on the construction of the electrode. 
Different electrode types have been used and in addition, studies have been performed in 
anesthetized animals as well as in awake animals. In human, output current is increased till 
tolerability level. 
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Zabara (1992) observed that right or left vagal stimulation is equally effective in 
controlling motor seizures, but bilateral vagal stimulation produced no measurable greater 
effect than did unilateral stimulation. Krahl et al. (2003) confirmed that right-sided VNS was 
just as effective as left-sided VNS in reducing the severity of PTZ-induced seizures. They, 
however, speculated that stimulation of both vagus nerves may affect a larger portion of the 
brain than unilateral VNS. This was the case for trigeminal nerve stimulation (Fanselow et al., 
2000), though was not observed by Zabara in earlier VNS studies using anesthetized dogs. 
Stimulation of the right or left nerve of Hering (ninth cranial nerve) can also successfully 
control focal seizure activity, whereas stimulation of the twelfth cranial nerve fails to suppress 
seizure activity (Patwardhan et al., 2002). 
6.2.2 Emerging indications for VNS treatment 
Vagal stimulation may affect numerous brain structures involved in the regulation of 
mood and cognition (Schachter, 2004). Several studies report improved alertness, behavior 
and mood following VNS independent of changes in seizure frequency (Elger et al., 2000; 
Harden et al., 2000; Harden, 2001; Kossoff and Pyzik, 2004). Accordingly, VNS has been 
explored as a treatment for depression (Rush et al., 2000; Sackeim et al., 2001a; Sackeim et 
al., 2001b; Sjogren et al., 2002). Also in animal studies, VNS has shown to be an effective 
antidepressant in the forced-swim test in rats (Krahl et al., 2004).  
An open-label pilot study suggested a positive effect on cognition of VNS treatment 
for patients with Alzheimer’s disease (Sjogren et al., 2002). Clark et al. (1995) hypothesized 
that vagal afferents affect central operations involved in the modulation of memory 
consolidation processes. In rats and humans, they reported that VNS was able to enhance 
memory storage when applied during memory consolidation, which was dependent on an 
inverted-U shaped function of output current (Clark et al., 1995; Clark et al., 1998; Clark et 
al., 1999). In contrast, chronic VNS application in a clinical setting has not been found to 
affect cognitive performance in patients with epilepsy since standardized tests have not 
identified systematic positive or negative changes in attention, motor function, short-term 
memory, learning and memory or executive functions following chronic VNS (Hoppe et al., 
2001; Dodrill and Morris, 2001). Therapeutic agents such as AEDs, on the contrary, often 
exhibit mild to serious effects on cognition (Ortinski and Meador, 2004). In Fast rats, a 
genetic strain with learning impairment, we found that VNS stimulation was devoid of 
cognitive side effects in the Morris water maze, which is used to investigate spatial memory 
in rats. In the Alzheimer study and the studies of Clark et al. (1995, 1998, 1999) intermediate 
stimulation parameters were used, whereas our study and those performed in patients with 
epilepsy (Hoppe et al., 2001; Dodrill and Morris, 2001) used high stimulation parameters (up 
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to tolerability level), which are believed to have anti-epileptic effects. Therefore, different 
stimulation parameters may result in a different therapeutic effect. 
Obesity is the most significant health problem facing westernized societies being the 
primary risk factor for diabetes and obstructive sleep apnea (Roslin and Kurlan, 2001). In 
addition, it increases the risks for heart disease, pulmonary disease, infertility, osteoarthritis, 
cholecystitis and several major cancers, including breast and colon cancers (Roslin and 
Kurlan, 2001). It is estimated that 50 to 60% of the population is obese or overweight of 
whom 5 to 6% are considered morbidly obese (Roslin and Kurlan, 2001). Surgical procedures 
for morbid obesity are becoming more common because of long-term successful results 
(Mason, 1992). However, optimal treatment for morbid obesity is not yet at hand (Roslin and 
Kurlan, 2001).  
Weight reduction has been reported in patients treated with VNS (Burneo et al., 2002; 
Kneedy-Cayem et al., 2002). Vagal afferents play a predominant role in the regulation of food 
intake (Schwartz, 2000). They conduct signals from the stomach to the nucleus of the solitary 
tract (NST) carrying information about the size and chemical composition of a meal, which is 
transmitted by other specific connections to the satiety center in the hypothalamus and the 
collateral ventro-medial nucleus (Laskiewicz et al., 2004). A pilot-study in humans has been 
set up with subdiaphragmatic stimulation of the vagus nerve. This study was based on the 
finding in dogs that chronic bilateral VNS induced a decrease in weight, which was suggested 
to result from changes in the central nervous system and a secondary alteration of food intake 
by VNS.  
In a study in GAERS, we found a significant weight reduction after two weeks of 
chronic VNS (Dedeurwaerdere et al., 2003). In addition, we found that VNS treatment 
prevented the gradual increase in body weight observed in control rats throughout the 
kindling process. A basic association between amygdala kindled seizures and weight gain in 
rats has been documented (Loscher et al., 2003; Bhatt et al., 2004). Interestingly, the 
amygdala has been suggested as a region where interactions between gustatory and vagal 
input take place (Han et al., 2003). This reduction in kindling-induced weight gain in VNS 
rats was associated with reduced food intake compared to control kindled rats. As in the 
kindling study the Fast rats only received two hours of VNS a day, it is possible that more 
continuous VNS would result not only in reduced weight gain, but also in reduced body 
weight as in GAERS. We are the first to report altered body weight in animal studies 
evaluating the efficacy of VNS on epilepsy likely because previous studies have primarily 
applied VNS acutely over very short time spans. In addition, our studies showed that in 
animals, weight can be regulated by chronic unilateral left VNS applied through the vagus 
nerve in the neck. 
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6.2.3 Mechanism of action of VNS 
Desynchronization of the background EEG by stimulation of vagal C fibers 
The idea of using VNS to suppress epileptic seizures arose from early animal 
experiments in which background EEG was desynchronized by VNS. As seizures result from 
hypersynchronous firing of a group of neurons, it was hypothesized that stimuli that produced 
desynchronization of the EEG may have anti-epileptic properties.  
Experiments on “encéphale isolé” cats showed that stimulation of the vagus reduced 
the amplitude of the EEG background, produced EEG desynchronization and blocked sleep 
spindles during slow wave sleep (Zanchetti et al., 1952). However, these effects were not 
obtained in animals without spindling and the effect was similar to that of other alerting 
stimuli (nose rubbing, whistling). Forty years later, unilateral and bilateral VNS in cats 
induced, within less than 5 s, changes in the pattern and periodicity of EEG spindles, 
associated with depressed background rhythms or rhythmic EEG activities (Balzamo et al., 
1990). 
In apparent contrast, several studies observed VNS induced synchronization of the 
EEG. As early as 1938, Bailey and Bremer reported that VNS in the cat elicited synchronized 
activity on the orbital-frontal cortex EEG. Rojas (1964) showed that direct current stimulation 
(15-60 s) of the vagus nerve first produced EEG desynchronization with subsequent 
synchronization. Also Puizillout and Foutz (1974) reported that VNS produced 
synchronization of the EEG. McLachlan (1993) observed that background rhythms were not 
altered by VNS in the majority of the animals, however, in a few animals a slight increase in 
synchrony was noted after low-intensity and low-frequency (2-3 Hz) stimulation (McLachlan, 
1993). 
Stimulation of the solitary tract, which receives projections of the vagus nerve, at low 
frequencies (1-16 Hz) produced EEG synchronization, whereas high-frequency (> 30 Hz) 
stimulation results in EEG desynchronization from a sleep spindle like background also 
comparable to that observed with tactile or auditory stimuli (Magnes et al., 1961). Neither 
synchronization nor desynchronization could be elicited when the EEG background was that 
of arousal. Chase and colleagues (1966) performed more detailed experiments and showed a 
complex relation between VNS and EEG rhythmicity associated with the activation of 
specific nerve fiber types of the vagus. In encéphale isolé cat preparations, stimulation of the 
vagus at frequencies above 20 Hz and at intensities greater than 3 V produced EEG 
desynchronization or rather a blockage from spindle like activity. At frequencies above 70 Hz 
and at intensities less than 3 V, assuming that these parameters only activate myelinated 
fibers, vagal stimulation produced EEG synchronization. However, the changes elicited were 
often inconsistent and varied with the background activity. In a study in humans, both 
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synchronization and desynchronization of the EEG was present during long-term VNS 
utilizing standard stimulation parameters, which was most prominent in patients with much 
epileptiform activity (Koo, 2001). 
The vagus nerve mainly consists of unmyelinated C fibers (65-80%) and a smaller 
portion myelinated A and B fibers (Rutecki, 1990). It was assumed that high-intensity and 
high-frequency (20-70 Hz) stimuli induce desynchronization resulting from the activation of 
unmyelinated C fibers, whereas, low-intensity high-frequency stimulation induces 
synchronization by activating myelinated A and B fibers only. However, this supposition is 
most likely oversimplified, because several studies contradict and the distinction between 
low- versus high-intensity and low- versus high-frequency stimulation is often vague. 
In the study of Takaya et al. (1996), using awake and freely moving animals, no 
obvious VNS-induced changes in background EEG activity were observed. In addition, early 
studies in humans revealed that VNS induces little if any effect on EEG background rhythms. 
(Hammond et al., 1992a; Salinsky and Burchiel, 1993). Hence, it was hypothesized that acute 
desynchronization of background EEG activity is not a prominent feature of VNS when 
administered during physiologic wakefulness and sleep, nor does it explain the anti-
convulsant effect of VNS. In these studies C fibers were probably not affected and this could 
be a reason why desynchronization of the EEG was not observed. Indeed, effective 
therapeutic stimulation parameters appear to be subthreshold for vagal C fibers in humans as 
there are no clinical reports of autonomic side effects (significant gastrointestinal, cardiac or 
respiratory effects), which would arise from C fiber stimulation (Krahl et al., 2001). These 
findings were supported by studies in humans who performed intraoperative nerve potential 
recordings (Koo et al., 2001; Evans et al., 2004). Their results showed that predominantly A 
and B fibers and not C fibers are activated by the stimulation output currents used in humans. 
Therefore, C fiber activation cannot fully explain the MOA of VNS. Moreover, Krahl et al. 
(2001) showed that selective destruction of capsaicin-sensitive C fibers did not affect the anti-
convulsive effects of VNS on PTZ-induced seizures in rats.  
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Anatomical and functional projections of the vagus nerve into the cerebral hemispheres 
The vagus nerve is a mixed cranial nerve that consists of ~80% afferent fibers and 
20% efferent fibers parasympathically innervating heart, lungs and gastrointestinal tract 
(Figure 1). Mechanistic VNS research generally presumes that VNS exerts its effect through 
the induction of action potentials in the afferent fibers of the left vagus nerve (Zagon et al., 
1999; Henry, 2002). Indeed, the anatomical diffuse projections of the vagus nerve in the 
cerebral hemispheres would support a broad effect for VNS on neural excitability (Rutecki, 
1990) (Figure 1).  
Moreover, vagal stimulation produces evoked potentials (EPs) which have been 
recorded from several brain regions. In the parietal association cortex, VNS evoked slow 
hyperpolarization in the pyramidal neurons (Zagon and Kemeny, 2000). This 
hyperpolarization of the membrane could reduce the excitability of these neurons. In these 
anesthetized rats, stimulus intensities that predominantly activated myelinated fibers (less than 
200 µA) were more effective in inducing long-lasting inhibitory effects than higher stimulus 
intensities that activated unmyelinated vagal afferents. Furthermore, stimulation of the cervical 
vagus produced EPs in the cerebral cortex of several animal models (O’Brien et al., 1971; Car 
et al., 1975) and human (Tougas et al. 1993). In the cat thalamus, low-intensity vagal nerve 
stimuli facilitated cellular firing in the reticular nuclei and depressed cellular firing in the 
ventro-postero-medial nucleus of the thalamus (Car et al., 1975). Higher intensity vagal 
stimulation increased firing frequency and duration of discharges in both nuclei. EPs have also 
been measured in the brainstem (Bennett et al., 1988), cerebellum (Dell and Olsen, 1951; 
Hennemann and Rubia, 1978) and the hippocampus (Serkov and Bratus, 1970) of animals. 
 
Functional imaging of the effect of VNS 
Naritoku et al. (1995) demonstrated expression of c-fos (reflecting high neuronal 
activity) immunoreactivity in several brain regions of anesthetized rats after VNS. These 
brain regios included limbic structures, thalamic nuclei and brainstem noradrenergic nuclei 
important in the control of seizures (Naritoku et al., 1995) and supports the idea that the anti-
epileptic action of VNS involves pathways that project from brainstem to forebrain.  
Non-invasive mapping of anatomical sites of increased or decreased synaptic activity 
can be performed with functional imaging. The influence of VNS on brain activity has been 
demonstrated by imaging studies using positron emission tomography (PET), single photon 
emission computed tomography (SPECT) or functional magnetic resonance imaging (fMRI) 
techniques (Henry et al., 1998; Vonck et al., 2000; Narayanan et al., 2002; Sucholeiki et al., 
2002).  
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Figure 14: Efferent and afferent projections of the vagus nerve. A. The vagus nerve had 
efferent projections towards the pharynx, lungs, heart and gastrointestinal tract. B.
Anatomical diffuse projections of the vagus nerve to cerebral hemisphere structures adapted
from Rutecki et al. (1990). 
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These imaging studies found changes on both sides of the brain by unilateral left VNS 
and pointed out a key role for the thalamus and medial temporal lobe structures in the MOA 
of VNS. However, there is no consensus on other activated structures neither on the type of 
changes (inhibition or excitation). This discrepancy can be attributed to a number of 
confounding factors such as imaging techniques used (PET, SPECT, fMRI), tracer and 
contrast agents, scanning protocols, stimulation parameters, medication regimes, course of the 
illness and treatment response. Heterogeneity of relatively small patient samples is difficult to 
avoid. In addition, data gathering from healthy subjects is impossible for ethical reasons due 
to the invasiveness of VNS.  
We found that changes in glucose metabolism due to VNS in healthy rats can be 
monitored using small animal PET, avoiding confounding factors as described above 
(Dedeurwaerdere et al., 2005c). In this animal study, results have been observed consistent 
with several previous imaging studies in epileptic patients (Vonck et al., 2000; Van Laere et 
al., 2002; Henry et al., 1998; Henry et al., 2004). During acute VNS, we found bilateral 
decreases in the glucose metabolism of the hippocampi (tendency in the right hippocampus), 
which are known to be often involved in the generation of complex partial seizures in 
temporal lobe epilepsy. A decreased metabolism in this region may reflect the anti-convulsant 
activity of acute VNS. More specifically, in patients, acute VNS can be triggered at seizure 
onset by a magnet to interfere with the seizure. In line with the long-term study of Henry et al. 
(2004), these changes in hippocampi were absent after chronic VNS. It is believed that these 
differences between acute and chronic VNS reflect the brains adaptation to chronic VNS. At 
this moment we cannot explain these changes after chronic VNS treatment observed in 
imaging studies. Further study will be required to determine why the acute effects of VNS on 
brain blood flow differ from VNS effects after months or years of stimulation. Henry (2002) 
suggested that intrasubject differences between acute and chronic VNS activation scans may 
reveal processes of adaptation to chronic VNS, and that some of them may have an anti-
epileptic effect. These adaptation processes might underlie the finding that therapeutic VNS 
often causes gradual improved seizure control over several months of treatment (Vonck, 
2003). In this case, ‘plasticity’ instead of ‘adaptation’ could be a more suitable term as 
'adaptation' would in fact be expected to suppress the effect of VNS and therefore reduce the 
anti-convulsive effect with time 
We also observed that acute VNS bilaterally increased glucose uptake in the olfactory 
bulbs. Evoked potential and unit activity recording techniques have revealed the existence of 
a vagus nerve-olfactory bulb pathway (Garcia-Diaz et al., 1984). Also in patients, VNS has 
been found to influence and modulate the processing of olfactory information (Kirchner et al., 
2004). This neurophysiological study reported even a positive correlation between activation 
of the olfactory bulb and therapeutic benefit. As the olfactory bulb is on the contrary very 
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small in humans, it is conceivable that changes in metabolism of this structure were not 
measurable in human imaging studies.  
Chronic VNS induced an increase in metabolism in the left medulla oblongata 
(Dedeurwaerdere et al., 2005c). Changes in dorsal-rostral medulla during chronic VNS have 
also been reported in an initial study of Henry et al. (2000). These findings correspond to the 
known anatomical connections and projections of the vagus nerve to the brainstem tracti and 
nuclei.  
In addition, we found a significantly decreased left/right ratio in striatum and a 
tendency towards a decrease in glucose uptake in the left striatum after chronic VNS 
(Dedeurwaerdere et al., 2005c). This brain structure has been acknowledged to play an 
important role in the control of seizures (Deransart and Depaulis, 2002). Ictal hyperperfusion 
of the striatum was shown using single photon emission computed tomography (SPECT) in 
patients with temporal lobe epilepsy (Semah, 2002). The striatum receives indirect 
innervation from the vagus nerve via the medial reticular formation of the medulla which 
projects to the intralaminar nuclei of thalamus (having extremely widespread projections to 
cerebral cortex and the striatum) (Henry, 2002). Moreover, in a PET imaging study in 
humans, changes in glucose metabolism have been found in the putamen (Ko et al., 1996) and 
caudate nucleus (Vonck, 2003) due to VNS. 
Finally, we were not able to detect previously reported changes in thalamus (Henry et 
al., 1998; Vonck et al., 2000; Chae et al., 2003; Henry et al., 2004) and hypothalamus (Henry 
et al., 1998; Henry et al., 2004) (for review see Chae et al., 2003). The negative findings in 
these regions therefore do not exclude the presence of smaller or more localized changes. 
Further study will require higher-resolution acquisition and more advanced analysis. Imaging 
studies in patients of our group showed a decreased tracer uptake in the left thalamus during 
chronic VNS (Vonck et al., 2000; Van Laere et al., 2002; Vonck, 2003). This may 
demonstrate that VNS induces a chronic inhibitory state in this key structure for seizure 
spread, which is manifested by a decrease in blood flow. In line with this, it has been quoted 
that VNS could result in hemodynamically-induced hypoperfusion creating a relative deficit 
of energetic substrates (Sunderam et al., 2001).  
 
Changes in neurotransmission induced by VNS 
Naritoku et al. (1992) found that chronic VNS prolongs the cervicomedullary to 
thalamocortical potential interval during somatosensory evoked potential studies. It was 
concluded that chronic VNS does alter neuronal networks outside of the brain stem vagus 
system and that alteration of forebrain neurotransmission might be a primary mechanism of 
VNS.  
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Woodbury and Woodbury hypothesized that VNS appears to act via release of large 
quantities of the inhibitory mediators GABA and glycine throughout large volumes of the 
brain, because it counteracts PTZ, 3-MPA (decreases efficacy of all inhibitory synapses) and 
strychnine induced seizures (Woodbury and Woodbury, 1991). In addition, GABA-mediated 
inhibition is implicated in the anti-epileptic effect of NST stimulation in rats, which is the 
principal target of VNS (Walker et al., 1999).  
Despite these experimental observations, a direct or indirect role of GABA in the 
anti-epileptic effect of VNS in humans remains to be demonstrated. In humans, the effect of 
VNS has been examined on the concentration of amino acids and neurotransmitters in 
cerebrospinal fluid (CSF) samples and no clear effect on GABA concentrations was 
determined (Hammond et al., 1992b; Ben-Menachem et al., 1995). Nevertheless, significant 
increases were seen in homovanillic acid (metabolite of dopamine), 5-hydroxyindoleacetic 
acid (metabolite of serotonin) and ethanolamine levels. Decreases were found in the level of 
aspartate. Although serotoninergic as well as dopaminergic systems have been found to have 
anti-convulsant effects in animal and human studies of various types of epilepsies, it remains 
to be clarified whether these findings are epiphenomena or findings directly related to VNS 
(Hammond et al., 1992b).  
The integrity of an additional neurotransmitter system, namely norepinephrine 
released from the locus coeruleus, appears to play an important role in seizure suppression 
(Krahl et al., 1998). VNS results in a significant increase in the discharge rate of locus 
coeruleus neurons in rats (Groves et al., 2005). Bilateral lesions of the locus coeruleus in rats 
prevented the seizure-suppressing effects of VNS (Krahl et al., 1998). The authors claimed 
that lesioning the locus coeruleus blocks the anti-convulsant effects of VNS by preventing 
VNS-induced norepinephrine release either globally or in some specific brain sites. VNS also 
results in a long-lasting (greater than 80 min) increase in norepinephrine efflux in the 
basolateral amygdala (Hassert et al., 2004). Noradrenergic projections to the amygdala arise 
from the locus coeruleus, which is the largest population of noradrenergic neurons in the brain 
and which receives projections from the NST, thus could be modulated by the vagus (Van 
Bockstaele et al., 1999). It is hypothesized that part of the mechanism of kindling may be a 
decrease in the effects of norepinephrine (Loscher et al., 2003). Interestingly, we found that 
VNS could suppress generalized convulsions evoked by amygdala kindling in some animals 
(Dedeurwaerdere et al., submitted). Moreover, electrical stimulation of the locus coeruleus 
suppresses epileptiform activity produced by stimulation of the amygdala (Jimenez-Rivera et 
al., 1987). Taken together, these data suggest that activation of the locus coeruleus by VNS 
might be a significant factor for the attenuation of seizures.  
The decrease of norepinephrine in various forebrain regions (including the stimulated 
amygdala) due to kindling could, besides the induction of seizures, also be a possible reason 
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for kindling-induced weight gain (Loscher et al., 2003). Drugs to treat obesity include 
noradrenergic drugs that reduce food intake (Bray, 2000). This could be of possible relevance 
to the finding that VNS reduced kindling-induced weight gain in Fast rats, which was 
associated with a reduced food intake compared to control kindled rats (Dedeurwaerdere et 
al., submitted). In conclusion, an additional role of VNS-induced changes in norepinephrine 
in the amygdala could include the regulation body weight and decreased food intake. 
The effects of chronic VNS on satiety and food intake could suggest an additional 
anti-convulsant MOA of VNS by caloric restriction. Diets have been used for the treatment of 
intractable childhood epilepsy since the 1920s and are re-emerging as a treatment option 
(Kossoff, 2004), although the MOA of these diets may be related to induced ketosis.  
 
Acute and chronic VNS 
Most likely there is not one MOA of VNS, but rather a summation of several 
physiological phenomena attributing to the overall effect of VNS. This is also apparent in the 
differences between acute and chronic VNS. Acute and chronic VNS may act via two distinct 
mechanisms of action which is supported by imaging studies in humans (Vonck et al., 2000; 
Van Laere et al., 2002). 
Acute VNS could be mediated by a possible mechanism of non-specific arousal by 
stimulation of somatic sensory pathways (Rutecki, 1990; McLachlan, 1993; Fanselow et al., 
2000). McLachlan et al. (1993) observed that similar reduction in spike frequency by VNS 
was obtained by thermal stimulation of the tail. He hypothesized that VNS influences 
epileptiform activity by a nonspecific mechanism mediated through the reticular activating 
system. When acute VNS was applied during absence seizures in GAERS at high intensity, 
noticeable for the animals, SWDs were stopped (Dedeurwaerdere et al. 2005a). Indeed 
absence seizures are aborted by unexpected sensory stimuli (e.g. noise, touching the animal) 
in GAERS (Danober et al., 1998). On the other hand, when VNS was applied at lower 
intensity, not perceptible by the animal, seizures were not interrupted and even prolonged 
(Dedeurwaerdere et al., 2004, 2005a). We also found that VNS reduced amygdala evoked 
seizures (Dedeurwaerdere et al. submitted). However, it has been observed that kindling-
induced seizures can be stopped by sensory stimulation (K. Gilby, pers. com.). Moreover, 
kindled seizures can be blocked by an antecedent footshock (Pinel et al., 1973). PTZ-induced 
seizures can also be reduced by trigeminal and Hering nerve stimulation (Fanselow et al., 
2000; Patwardhan et al., 2002). In humans, it has been demonstrated that sensory stimulation 
can suppress focal spikes and absence seizures (Ricci et al., 1972; Rajna and Lona, 1989). In 
patients with VNS, output current is typically programmed higher in the magnet mode to 
obtain this arousal effect. Acute VNS could likely be mediated by nonspecific arousal, 
although other or additional mechanisms of action cannot be excluded.  
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Chronic VNS is administered in an intermittent way and it appears that seizures 
occurring during the VNS off-time are also affected. This intermittent way of stimulation is 
insufficient to explain the reduction of seizures on the basis of abortive effects alone and 
suggests a true preventative or so-called anti-epileptic effect of VNS (Vonck, 2003). 
Processes that mediate VNS-induced sustained changes are unknown, but the persistence of 
the anti-convulsant effects suggests that VNS induces long-term changes in neuronal activity 
(Takaya et al., 1996). Naritoku et al. (1995) demonstrated expression of c-fos 
immunoreactivity in several brain regions important in epileptogenesis by VNS. C-fos is a 
protein that signals transcription of other genes. Therefore, the anti-epileptic effect of VNS 
may be mediated through transcriptional events resulting into intermediate or long-term 
changes. It is reasonable that chronic VNS induces permanent changes in network 
connections as the efficacy of VNS generally increases after long-term treatment. 
  In relation to the improving long-term effect of VNS it has been reasoned out that if 
epileptic fits can induce more epileptic fits as is the case in kindling, then reducing the 
number of epileptic events (and perhaps also subclinical ones) by VNS could reduce the risk 
for more epileptic events and thus 'cure' the epilepsy. This mechanism could be seen as the 
reverse of kindling. Firstly, Gowers’ (1881) famous quotation that “seizures beget seizures” is 
still under debate (Theodore and Wasterlain, 1999; McIntosh and Berkovic, 2005). Indeed, 
experimental work in animals provided support that even single seizures are harmful 
(Bengzon et al., 1997), which may initiate or facilitate a cascade of events leading to an 
epileptogenic lesion (Briellmann et al., 2005). However, in patients inconsistent data exist. 
Moreover, human studies suggest that epilepsy is usually not a progressive disorder although 
some epilepsy syndromes (e.g. progressive myoclonic epilepsies, epileptic encephalopathies) 
do have a progressive intractable course (Berg and Shinnar, 1997). Anyway, it is probably not 
by preventing the seizures themselves that epilepsy could be cured, but rather by treating the 
underlying cause of the seizures (Berg and Shinnar, 1997). Also our own study in young 
GAERS may be relevant to this discussion. Although GAERS displayed fewer seizures 
during development of the absence epilepsy because of the chronic LEV treatment, they all 
developed a similar epilepsy profile as the control group after terminating the treatment 
(Dedeurwaerdere et al., 2005d). Nevertheless, the hypothesis that VNS unkindles epilepsy has 
been tested by Dasheiff et al., (2001). They hypothesized that the longer and more frequent a 
person has seizures, the longer it will take to unkindle them. Therefore, they have accessed 
the database of two large clinical trials and multiple types of analyses could not support their 
hypothesis. Hence they stated that VNS does not unkindle seizures. Moreover, responders to 
VNS treatment do have seizure relapse after battery failure. Hence, at this moment it does not 
seem that VNS is curing epilepsy. 
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6.2.4 Conclusion 
Left-sided VNS is an effective treatment for patients with complex partial seizures 
with or without secondary generalization who show insufficient response to anti-convulsant 
drugs and are unsuited for neurosurgical treatment. In addition it is a well-tolerated and safe 
form of neurostimulation. Indeed, we found that VNS does not induce cognitive side effects 
in Fast rats. 
Remarkably, VNS could as well prolong as shorten SWDs in GAERS depending on 
the output current used. This phenomenon was also observed on amygdala kindling induced 
seizures in Fast rats. In this study, VNS application before the induction of a seizure 
prolonged seizures while VNS applied after the kindling pulse could prevent seizures. We 
should also note that the anti-epileptic effect of VNS on amygdala kindled seizures was only 
present in a small subgroup of animals. Briefly, VNS can induce both synchronization and 
desynchronization and can result in both excitation and inhibition as supported by our studies 
in a model of generalized primary epilepsy (GAERS) and a model of partial epilepsy 
(amygdala kindling).  
Despite several discrepancies in the VNS literature, we can state that VNS activates 
and inhibits multiple brain regions thereby affecting several neurotransmitter systems. More 
specifically, in our micro-PET study we found decreased metabolism in the left hippocampus 
and left striatum and increases in glucose metabolism in olfactory bulbs and left medulla 
oblongata.  
Most likely there is not one MOA of VNS, but rather a summation of several 
physiological phenomena attributing to the overall effect of VNS. The major MOAs 
underlying the desired anti-seizure actions of VNS may be mediated by its diffuse projections 
in the cerebral hemispheres inducing i) a transient decrease in synaptic activities in the 
amygdala, hippocampus and other components of the limbic system, ii) an intermittent 
increase in release of norepinephrine in the cerebrum or iii) a change in synaptic activities in 
the thalamus and thalamocortical projection pathways bilaterally, leading to increased arousal 
and possibly to decreased synchrony of synaptic activities between and within cortical 
regions. Perhaps, these separate mechanisms of VNS can be fine tuned by combining specific 
stimulation parameters and stimulation protocols resulting in an optimal outcome.  
There is clear evidence that acute and chronic VNS differ in MOA. Whereas the anti-
convulsive effect of acute VNS could be due to an arousal effect, results from different 
studies in humans and animals are increasingly supporting the idea that the anti-epileptic 
effect of chronic VNS is based on long-term modulatory changes in synaptic transmission 
within certain neuronal network. Hence, it takes several months for these changes to be fully 
installed and expressed. 
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Besides its anti-epileptic effect, it is not surprising that VNS, which has numerous 
projections to the brain, could influence several other functions like mood, memory, feeding 
behavior. In our studies, effect on body weight induced by VNS was indicated in two animal 
models of epilepsy namely GAERS and amygdala kindled Fast rats. 
6.2.5 Future perspectives 
Vagus nerve stimulation has been used since 1988 and at present almost 30 000 
patients are being treated with VNS worldwide. Experience and knowledge about VNS is 
rapidly increasing, however several questions remain unclear. VNS is used in generalized and 
partial epilepsy (Ben-Menachem, 2002), but still responder groups have not been clearly 
identified. Currently 30% of patients treated with VNS will not benefit from VNS. A better 
understanding of VNS could improve seizure outcome by identifying specific epilepsy 
syndromes or types of epilepsy that respond well to VNS on the one hand or by optimizing 
stimulation parameters on the other hand. Future animal research is therefore crucial.  
VNS efficacy in animals has primarily been assessed in acute models utilizing 
stimulation protocols in close relation to the time of seizure onset. These studies have pointed 
out a series of stimulation parameters, although there is no agreement whether high- or low-
stimulation parameters should be used and which fiber groups are affected by such 
stimulation. Unfortunately, an adapted electrode including the measuring capability of action 
potentials of the different nerve fibers induced by VNS, is not yet available for the vagus 
nerve of rats and previous attempts were faced with lots of difficulties. However, the 
capability of the VNS electrode to selectively elicit different fibers can be first tested in a 
setup using anesthetized animals, avoiding the practical difficulties of using freely moving 
animals. After distinguishing sets of stimulation parameters (output current, pulse duration, 
frequency) that are activating different fibers, their anti-epileptic properties can be tested in a 
chronic model of epilepsy, like the kindling model in which seizures can be induced at will.  
The efficacy of chronic VNS (several weeks of stimulation) should be investigated in 
different animal models of epilepsy that are closely imitating human epilepsy such as 
GAERS, kindling model, SE model, concussion model and stroke models. This may provide 
clues on the identification of responder groups. However, responders to VNS therapy are 
perhaps not associated with a specific type of epilepsy. In a model of temporal lobe epilepsy, 
VNS benefited only a subpopulation of the amygdala kindled rats while other rats appeared 
relatively unaffected. Further research directed towards identification of essential criteria that 
leads to success for VNS application is warranted. Maybe specific genes can be identified 
which correlate with the degree of benefit from VNS. 
Presently, there are only a few guesses of which neurotransmitters contribute to the 
action of VNS. Further research should determine which neurotransmitters (e.g. GABA, 
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glutamate, norepinephrine, serotonin, dopamine) are involved in the acute and chronic effects 
of VNS. This could be realized by means of microdialysis investigating changes in 
neurotransmitters in several brain structures. Also small animal PET could be performed 
using specific tracers during different stimulation protocols. As the resolution of small animal 
PET is limited, several structures like the nucleus coeruleus cannot be visualized. Therefore, 
refining research using autoradiography and fMRI can be performed to investigate inhibition 
and excitation of anatomically small regions.  
Besides its anti-epileptic effect, VNS could also influence several other functions like 
mood, memory, feeding behavior. However, it is conceivable that different stimulation 
parameters can result in a different effect. Hence, stimulation parameters probably must be 
optimized for each target group. 
Clearly, the complexities of VNS treatment should be further investigated in order to 
optimize treatment in patients with refractory epilepsy. 
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Summary 
Epilepsy is the most common serious brain disorder affecting 0.5-1% of the general 
population. This neurological disorder consists of recurrent seizures, resulting from excessive, 
uncontrolled electrical activity in the brain. Despite the pharmacological development of new 
treatments, still one third of the epilepsy patients does not respond sufficiently to anti-
epileptic drugs (AED) and are called refractory patients. Hence, there is a constant impetus to 
search for other treatment strategies like epilepsy surgery, vagus nerve stimulation and deep 
brain stimulation. Besides the ongoing research on the efficacy of anti-epileptic treatments in 
suppressing seizures (anti-seizure effect), we want to seek for therapies that can lead to plastic 
changes in the epileptic network and in this way have a modulating effect. The impact of 
therapies which may slow down processes underlying epilepsy and which might prevent or 
even cure epilepsy cannot be overlooked.   
Neuropharmacological therapy with levetiracetam (LEV) and vagus nerve stimulation 
(VNS) are two novel treatments for refractory epilepsy. Acute application of both treatment 
options can be very effective. LEV can act rapidly on seizures in both animals and humans. In 
addition, preclinical studies suggest that LEV may have anti-epileptogenic and 
neuroprotective effects, with the potential to slow or arrest disease progression. VNS as well 
can have an immediate effect on seizures in animals and patients with in addition a 
cumulative effect after prolonged treatment. These treatments can be considered as 
neuromodulatory since there is evidence that changes in central nervous system function or 
organization are induced by influencing and initiating neurophysiological signals.  
Studies in man are hampered by the heterogeneity of patient populations (age, course 
of the epilepsy, type of epilepsy, AED regime and genetic background) and the difficulty to 
study therapy-related effects in a systematic way. Therefore, investigation was performed 
utilizing two models mimicking epilepsy in humans. They are both chronic models with 
seizures evolving from true, genetically-driven epileptogenesis. Genetic absence epilepsy rats 
from Strasbourg (GAERS) have inborn absence epilepsy and Fast rats have a genetically 
determined sensitivity for electrical amygdala kindling, which is an excellent model of 
temporal lobe epilepsy. 
Anti-epileptogenic effects of LEV in addition to anti-epileptic effects have been 
reported in the rat amygdala kindling model and the spontaneously epileptic rat (SER), a 
model of primary generalized epilepsy characterized by spontaneous tonic convulsions and 
absence seizures. Administration of LEV strongly suppresses the occurrence of absence 
seizures in GAERS. In a pilot study in GAERS, the robust anti-seizure effect of LEV was 
confirmed and a trend towards an anti-epileptogenic effect was found. This encouraged us to 
further investigate the neuromodulatory properties of LEV in GAERS; it was felt that 
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investigating the effect of chronic LEV treatment in young GAERS could provide new 
insights and strategies for the treatment of epilepsy. During the present research, we have 
investigated the effect of LEV on the age-related development of spike and wave discharges 
(SWDs) in GAERS by chronic administration of LEV (postnatal day (PN) 23-PN60) starting 
before the age of occurrence of SWDs. We found that chronic LEV administration induced a 
reduction in epileptiform events in young GAERS. This effect persisted to some extent after 
treatment cessation (PN61-PN64), which might indicate a slowing down of epileptogenic 
processes. However, this effect was only temporary, because at the age of four months all 
animals revealed a similar expression of epileptiform discharges. Further studies should 
determine the optimal time window to interfere more permanently with epileptogenesis in 
GAERS. 
VNS has been used since 1988 and at present approximately 30 000 patients are being 
treated with VNS worldwide. Experience and knowledge about VNS is rapidly increasing, 
however several questions remain unclear. VNS is used in generalized and partial epilepsy, 
although responder groups have not been clearly identified. Currently 30% of patients treated 
with VNS will not benefit from VNS. VNS is believed to induce its effect by affecting a large 
number of intracerebral structures through stimulation of the vagal fibers in the neck. The 
precise mechanism of action by which VNS exerts its anti-epileptic effect has not been 
elucidated yet. Understanding VNS could improve seizure outcome by identifying specific 
epilepsy syndromes or types of epilepsy that respond well to VNS or by optimizing 
stimulation parameters.  
Initial animal studies with VNS showed promising results in reducing both ictal and 
interictal EEG abnormalities. These findings laid the foundation for further development of 
VNS as a treatment for human epilepsy. However, VNS efficacy in animals has primarily 
been assessed in acute models (3-mercaptopropionate, pentylenetetrazole, maximal 
electroshock, penicillin or strychnine application) utilizing application protocols immediately 
before and/or after seizure provocation. Only a few studies have evaluated the effect of VNS 
in chronic animal models of epilepsy. It is clear that additional research is needed using 
chronic animal models and using both acute and chronic VNS protocols. Moreover, such 
fundamental data for idiopathic epilepsy are presently completely lacking. Information about 
the potential efficacy of VNS in GAERS, a validated animal model of absence epilepsy, could 
help to clarify the general principles that underlie VNS, although extensive therapeutic use of 
VNS in absence epilepsy is unlikely. In this chronic model of spontaneous absence epilepsy, 
we observed a transient increase in seizure duration following acute VNS, which disappeared 
in a sub-acute setting. However, when VNS was applied at higher intensities perceptible for 
the animals, the typical SWDs were shut down immediately. When chronic VNS was applied 
during one week in GAERS, the decrease in SWDs did not significantly differ from the 
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control group. It can be hypothesized that a longer period of VNS or earlier intervention 
during life might be required to affect an already established and genetically driven epilepsy 
syndrome. In a genetic seizure-prone kindling-strain, epileptogenesis was not prevented by 
two hours of daily VNS. Again both excitatory and inhibitory effects of VNS were observed. 
Seizure profiles in these fully kindled Fast rats were worsened when VNS was applied before 
the kindling pulse, whereas VNS applied immediately after the kindling pulse could 
completely prevent stage-5 seizures in a subset of animals. In addition, VNS stimulation 
appeared to be devoid of significant cognitive side effects in the Morris water maze. Finally, 
VNS reduced body weight after two weeks of treatment in GAERS and prevented weight gain 
associated with the kindling process in Fast rats presumably via the observed reduction in 
food intake. Clearly, the complexities of VNS treatment should be further investigated in 
order to optimize treatment in patients with refractory epilepsy. 
Several functional imaging studies have been conducted to investigate the activation 
or inhibition of brain structures by VNS. These studies found changes on both sides of the 
brain by unilateral left VNS and pointed out a key role for the thalamus and medial temporal 
lobe structures in the MOA of VNS. However, there is no consensus on the type of changes 
(inhibition or excitation) neither on other potentially activated structures. This discrepancy can 
be attributed to a number of confounding factors such as the differences between the imaging 
techniques used (PET, SPECT, fMRI), the contrast agents, scanning protocols, stimulation 
parameters, medication regimes, course of the illness and treatment response. Heterogeneity of 
the patient samples is difficult to avoid. In addition, data gathering from healthy subjects is 
impossible for ethical reasons as VNS is a relatively invasive procedure. Therefore, we 
explored whether it is feasible to investigate the effect of acute and chronic effect of VNS on 
brain glucose metabolism in rats using micro-PET. We showed that acute and chronic VNS 
induced changes in glucose metabolism in regions important for seizure control such as 
hippocampus and striatum. Our pilot study demonstrated that small animal PET is a useful and 
promising technique for imaging cerebral activation in long-term studies in rats.  
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Samenvatting  
Epilepsie is een ernstige neurologische aandoening die voorkomt bij 0,5 tot 1% van 
de bevolking en die gekenmerkt wordt door het herhaald en spontaan optreden van 
epileptische aanvallen. Een epileptische aanval bestaat uit een paroxysmale gedrags- en/of 
bewustzijnsverandering ten gevolge van een excessieve neuronale ontlading ter hoogte van 
een deel of de gehele hersenschors. Ondanks de farmacologische ontwikkeling van nieuwe 
anti-epileptica, reageert een derde van de patiënten onvoldoende op medicatie (refractaire 
patiënten). Er is dus een continue zoektocht naar alternatieve behandelingsmodaliteiten zoals 
epilepsie chirurgie, nervus vagus stimulatie en diepe hersenstimulatie. Naast het bestaande 
onderzoek naar de doeltreffendheid van behandelingen om aanvallen te onderdrukken, willen 
we zoeken naar therapieën die plastische veranderingen in het epileptische netwerk kunnen 
aanbrengen en hierbij een modulerend effect hebben. De impact van therapieën, die 
epileptogene processen zouden kunnen vertragen, voorkomen en eventueel zelfs epilepsie 
zouden kunnen genezen, is niet te onderschatten.  
Twee nieuwe behandelingen voor refractaire epilepsie zijn het anti-epilepticum 
levetiracetam (LEV) en nervus vagus stimulatie (NVS). LEV onderdrukt snel aanvallen zowel 
in dierstudies als in patiënten. Daarenboven suggereren preklinische studies dat LEV anti-
epileptogene en neuroprotective eigenschappen bezit. Dit houdt in dat LEV de progressie van 
epilepsie zou kunnen vertragen of zelfs de ziekte zou kunnen stoppen. Ook NVS kan een 
onmiddellijk effect hebben op aanvallen in mens en dier met bovendien een verhoogde 
doeltreffendheid op langere termijn. Deze behandelingsmodaliteiten kunnen worden 
beschouwd als neuromodulatorisch omdat er evidentie is dat ze veranderingen teweeg 
brengen in de werking en organisatie van het centrale zenuwstelsel door neurofysiologische 
signalen te beïnvloeden en te initiëren. 
Studies bij de mens worden belemmerd door de heterogeniteit van de patiënten 
populaties (leeftijd, duur van de epilepsie, type van epilepsie, medicatie en genetische 
achtergrond) en de moeilijkheid om therapie gerelateerde effecten op een systematische 
manier te onderzoeken. Daarom werd voor het huidige onderzoek gebruik gemaakt van twee 
diermodellen die dicht aansluiten bij de pathofysiologie van de mens. Het zijn beide 
chronische modellen met aanvallen die resulteren uit een ware, genetisch gedreven 
epileptogenesis. De “genetic absence epilepsy rats from Strasbourg” (GAERS) hebben een 
overerfbare vorm van absence-epilepsie en de “Fast rat strain” heeft een genetisch bepaalde 
predispositie voor het ontwikkelen van epilepsie door kindling van de amygdala, een 
uitstekend model voor temporale kwabepilepsie.  
Naast anti-epileptische effecten van LEV zijn ook anti-epileptogene eigenschappen 
geobserveerd in het amygdala kindling model en in de “spontaneously epileptic rat” (SER), 
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een model voor primair gegeneraliseerde epilepsie gekarakteriseerd door spontane, tonische 
convulsies en absences. Toediening van LEV onderdrukt krachtig het voorkomen van 
absences in GAERS. In een pilootstudie in GAERS, werd het robuuste anti-epileptische effect 
van LEV bevestigd en werd tevens een aanwijzing voor een anti-epileptogeen effect 
gevonden. Dit moedigde ons aan om de neuromodulatorische eigenschappen van LEV in 
GAERS verder te onderzoeken. Tijdens het huidige onderzoek werd het effect van LEV 
onderzocht op de leeftijdsafhankelijke ontwikkeling van “spike and wave discharges” 
(SWDs) in GAERS. Chronische administratie van LEV werd gestart vóór de leeftijd waarop 
SWDs verschijnen op het corticale EEG. Dit onderzoek toonde aan dat chronische LEV 
administratie epileptiforme hersenactiviteit in jonge GAERS onderdrukt. Daarenboven was 
dit anti-epileptische effect nog steeds aanwezig na onderbreking van de behandeling (PN61-
PN64), wat op een remming van epileptogene processen zou kunnen wijzen. Dit effect was 
slechts tijdelijk, want op de leeftijd van vier maanden (volwassenheid) vertoonden zowel de 
controle als de voordien behandelde dieren SWDs op het EEG, die niet verschilden in aantal 
of duur. Verdere studies zijn vereist om na te gaan of een optimaal tijdvenster kan bepaald 
worden waarbij een meer permanent effect op epileptogenesis in GAERS bekomen wordt.  
NVS wordt toegepast sinds 1988 en momenteel worden ongeveer 30.000 
epilepsiepatiënten over de hele wereld behandeld met NVS. De ervaring en de kennis over 
NVS groeit snel, maar verscheidene vragen blijven onbeantwoord. NVS wordt gebruikt in 
gegeneraliseerde en partiële epilepsie, hoewel “responders” niet duidelijk zijn geïdentificeerd. 
Momenteel heeft dertig procent van de patiënten behandeld met NVS geen baat bij de 
therapie. Het precieze werkingsmechanisme van NVS is nog niet volledig ontrafeld. Een beter 
begrip van het werkingsmechanisme van NVS kan de efficiëntie van de behandeling 
verbeteren door identificatie van specifieke epilepsiesyndromen of vormen van epilepsie die 
goed reageren op NVS of door optimalisatie van stimulatieparameters. De aanvankelijke 
dierstudies met NVS toonden veelbelovende resultaten met vermindering van zowel ictale als 
interictale abnormaliteiten op het EEG. Deze bevindingen legden de fundamenten voor de 
verdere ontwikkeling van NVS als behandeling voor epilepsie bij de mens. Nochtans is de 
doeltreffendheid van NVS in dieren hoofdzakelijk beoordeeld in acute modellen (3-
mercaptopropionate, pentylenetetrazol, maximale elektroshock aanvalsmodel en applicatie 
van penicilline of strychnine), waarbij stimulatieprotocollen gebruikt werden onmiddellijk 
vóór en/of na de uitlokking van aanvallen. Slechts een paar studies hebben het effect van NVS 
in chronische diermodellen voor epilepsie geëvalueerd. Het is duidelijk dat bijkomend 
proefdieronderzoek, gebruikmakend van chronische modellen en zowel acute als chronische 
protocollen, noodzakelijk is. Voorts ontbreken fundamentele gegevens over de 
doeltreffendheid van NVS bij idiopathische epilepsie. Onderzoek naar de efficaciteit van NVS 
in GAERS, een model voor idiopathische absence epilepsie, kan helpen om de algemene 
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principes te verduidelijken die aan de grondslag liggen van NVS. In dit model namen wij een 
tijdelijke verlenging van de aanvalsduur na acute NVS waar. Wanneer echter met een hogere, 
voor de dieren voelbare intensiteit gestimuleerd werd, konden de typische SWDs onmiddellijk 
worden onderbroken. Na één week van chronische NVS waren de aanvallen niet beduidend 
lager dan in de controlegroep. Men kan de hypothese vooropstellen dat een langere periode 
van NVS of vroegere interventie tijdens het leven vereist is om een gevestigd en genetisch 
gedreven epilepsiesyndroom te beïnvloeden. In Fast ratten, met een genetische vatbaarheid 
voor amygdala kindling, werd epileptogenesis niet verhinderd door dagelijks twee uren NVS 
toe te dienen voor de kindling stimulus. Opnieuw werden zowel excitatorische als 
inhibitorische effecten van NVS waargenomen in dit model. Aanvalsprofielen bij deze 
volledig gekindelde ratten werden erger wanneer NVS voor de kindling puls werd gegeven, 
terwijl NVS onmiddellijk na de kindling puls gegeneraliseerde convulsies in een subpopulatie 
van de NVS-groep volledig kon verhinderen. Bovendien scheen NVS geen significante 
cognitieve bijwerkingen te hebben in de “Morris water maze” in deze Fast ratten. Tot slot 
verminderde NVS het lichaamsgewicht in GAERS na twee weken van behandeling. 
Daarenboven werd gewichtsaanwinst, geassocieerd met het kindling proces, verhinderd bij de 
Fast ratten, wat gekoppeld was aan een verlaagde voedselopname. Het is duidelijk dat de 
complexiteit van NVS verder moet worden onderzocht om de behandeling van patiënten met 
refractaire epilepsie te optimaliseren.  
Verscheidene functionele beeldvormingstudies zijn uitgevoerd om de activering of de 
inhibitie van hersenenstructuren te onderzoeken door NVS. Deze studies vonden 
veranderingen aan beide zijden van de hersenen door unilaterale linker NVS en wezen op een 
belangrijke rol voor de thalamus en de temporale kwabstructuren in het werkingsmechanisme 
van NVS. Er is echter geen consensus betreffende de aard van de veranderingen (activatie of 
inhibitie) noch over andere hersenstructuren die eventueel aangesproken worden door NVS. 
Deze discrepantie kan aan een aantal factoren worden toegeschreven zoals verschillen tussen 
de gebruikte beeldvormingtechnieken (PET, SPECT, fMRI), de contrastagenten, de 
scanningprotocollen, de stimulatieparameters, de medicatie, de duur van de ziekte en respons 
op de behandeling. Heterogeniteit van de patiëntensamples is moeilijk te vermijden. 
Bovendien zijn gegevens afkomstig van gezonde individuen onmogelijk te verzamelen 
omwille van ethische redenen aangezien NVS een vrij invasieve procedure is. Daarom 
onderzochten wij of het haalbaar is om het effect van acute en chronische NVS op het 
glucosemetabolisme van de hersenen van de rat na te gaan met micro-PET. Wij konden 
aantonen dat acute en chronische NVS veranderingen veroorzaakten in het 
glucosemetabolisme in gebieden belangrijk voor aanvalscontrole zoals hippocampus en 
striatum. Onze pilootstudie toonde aan dat “small animal PET” een nuttige en veelbelovende 
techniek is voor de weergave van hersenactivering in lange termijn studies bij de rat. 
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Résumé 
L’épilepsie est une maladie grave qui se manifeste chez 0,5 à 1 % de la population et 
qui se caractérise par l’apparition répétée et spontanée de crises épileptiques. Une crise est 
associée à un changement de l’état de conscience et/ou du comportement dû à une décharge 
neuronale excessive dans une ou plusieurs structures corticales. Malgré le développement 
pharmaceutique de nouveaux anti-épileptiques, un tiers des patients réagit insuffisamment aux 
médicaments (épilepsie réfractaire). Il en résulte une recherche continuelle de nouveaux 
traitements comme la chirurgie de l’épilepsie (résection de la zone épileptogène), la 
stimulation du nerf vague et la stimulation cérébrale profonde. En plus de la recherche 
existante sur l’efficacité des traitements suppressifs, nous voulons explorer les thérapies 
capables non seulement d’entraîner des modifications plastiques dans le réseau épileptique 
mais également de présenter simultanément un effet modulateur. L’impact des thérapies qui 
pourraient ralentir les processus épileptogènes ne doit pas être sous-estimé.  
  L’anti-épileptique levetiracetam (LEV) et la stimulation du nerf vague (SNV) 
constituent deux nouveaux traitements de l’épilepsie réfractaire. Le LEV supprime 
rapidement les crises aussi bien dans les études animales que chez les patients. En plus, les 
études précliniques suggèrent que le LEV possède des propriétés anti-épileptogènes et 
neuroprotectrices, ayant la possibilité de ralentir ou même d’arrêter la progression de la 
maladie. La SNV peut aussi avoir un effet immédiat sur les crises chez l’homme et l’animal 
avec en plus une efficacité élevée à long terme. Ces modalités de traitements peuvent être 
considérées comme neuromodulatrices puisqu’il est évident qu’elles provoquent des 
changements dans le fonctionnement et l’organisation du système nerveux central en 
influençant et en initiant des signaux neurophysiologiques. 
  Les études chez l’homme sont difficiles en raison de l’hétérogénéité des populations 
de patients (âge, durée de l’épilepsie, type d’épilepsie, médicaments et terrain génétique) et à 
cause de la difficulté d’explorer les effets reliés à la thérapie d’une manière systématique. 
C’est pour cette raison que nous avons décidé de nous concentrer sur deux modèles animaux 
qui se rapprochent fortement de la pathophysiologie humaine. Ce sont des modèles 
chroniques avec des crises résultant d’une épileptogenèse liée à des modifications génétiques. 
Les « genetic absence epilepsy rats from Strasbourg (GAERS) » présentent une forme 
d’épilepsie de type absence héréditaire et le « Fast rat strain » est caractérisé par une 
prédisposition génétique pour le développement de l’épilepsie par « kindling » de l’amygdale, 
un modèle validé de l’épilepsie du lobe temporal. 
 En plus des effets anti-épileptiques du LEV, des propriétés anti-épileptogènes furent 
observées dans le modèle de « kindling » de l’amygdale et chez le « rat épileptique spontané 
(RES) », un modèle d’épilepsie généralisée caractérisé par des convulsions toniques 
spontanées ainsi que des absences. L’administration du LEV réduit de manière importante 
l’apparition des crises de type absence chez les GAERS. Une étude pilote chez le GAERS a 
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confirmé un effet anti-épileptique robuste du LEV et révélé l’effet anti-épileptogène. Ceci 
nous a encouragé à explorer les propriétés neuromodulatrices du LEV chez le GAERS plus en 
détail. Notre travail a consisté à examiner l’effet du LEV sur les décharges pointe-
ondes (spike and wave discharges, SWDs ) chez le GAERS en fonction de l’âge. Le LEV a 
été administré de façon chronique avant l’âge d’apparition des SWDs dans l’EEG cortical. 
Notre travail montre que l’administration chronique du LEV supprime l’activité cérébrale 
épileptiforme chez les jeunes GAERS. De plus, l’effet anti-épileptique subsiste après la fin du 
traitement (PN61 – PN64), ce qui pourrait indiquer une inhibition des processus 
épileptogènes. Cet effet est cependant transitoire, car à l’âge de quatre mois (adulte) aussi 
bien les animaux non traités que les animaux traités présentent des SWDs sur l’EEG, qui ne 
diffèrent ni en durée ni en quantité. Des études plus poussées seront nécessaires pour définir 
une fenêtre temporelle optimale afin d’obtenir un effet plus permanent sur l’éptileptogenèse 
chez le GAERS. 
 La SNV est utilisée depuis 1988, et environ 30 000 patients épileptiques à travers le 
monde sont traités par cette méthode. L’expérience et la connaissance concernant la SNV 
augmentent rapidement, cependant plusieurs questions restent sans réponse. La SNV est 
utilisée pour les épilepsies généralisées et partielles, alors que les ‘répondeurs’ ne sont pas 
identifiés clairement. Un tiers des patients actuellement traités avec la SNV ne présente pas 
d’amélioration. Le mécanisme d’action de la SNV n’est pas encore parfaitement identifié. 
Une meilleure compréhension de ce mécanisme pourrait augmenter l’efficacité du traitement 
par l’identification des syndromes épileptiques spécifiques ou de formes d’épilepsie qui 
réagissent de manière positive à la SNV ou à l’optimalisation des paramètres de stimulation. 
Un grand nombre de structures intracérébrales sont potentiellement influencées par la 
stimulation des fibres vagales afférentes dans le cou. Les études animales initiales avec la 
SNV montraient des résultats prometteurs avec une diminution des anomalies critiques et 
intercritiques de l’EEG. Ces résultats ont constitué la base du développement futur de la SNV 
en tant que traitement de l’épilepsie chez l’homme. Néanmoins, l’efficacité de la SNV dans 
les études animales est évaluée en grande partie sur la base des modèles aigus (3-
mercaptopropionate, pentylenetetrazol, électrochocs et application de pénicilline ou de 
strychnine). Les protocoles correspondants utilisent une stimulation appliquée immédiatement 
avant ou après l’induction des crises. Quelques études seulement ont évalué l’effet de la SNV 
sur des modèles animaux chroniques. Il est évident que des recherches animales 
supplémentaires, utilisant les modèles chroniques et des protocoles aussi bien aigus que 
chroniques, sont nécessaires. En outre, il nous manque des données fondamentales à propos 
de l’efficacité de la SNV sur l’épilepsie idiopathique. Des recherches sur l’efficacité de la 
SNV chez le GAERS, un modèle d’épilepsie absence idiopathique, peut aider à clarifier les 
principes généraux qui se trouvent à la base de la SNV. Dans ce modèle nous avons remarqué 
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un allongement temporaire de la durée de la crise suite à la SNV aigue. Cependant, lorsqu’ 
une stimulation plus intense est utilisée, les SWDs typiques peuvent être interrompues 
immédiatement. Après une semaine de SNV chronique, les crises n’étaient pas différentes par 
rapport au groupe de contrôle. Nous émettons l’hypothèse qu’une longue période de SNV ou 
une stimulation avant les premiers symptômes est nécessaire pour influencer l’apparition d’un 
syndrome épileptique génétique. Deux heures d’administration quotidienne de SNV n’ont pas 
suffit à empêcher l’épileptogenèse chez les rats Fast, qui ont une sensibilité génétique à 
l’embrasement de l’amygdale. De même, des effets inhibiteurs aussi qu’excitateurs de la SNV 
sont observés dans ce modèle. Des profils de crises chez les rats ayant subi un « kindling » 
complet sont aggravés quand la SNV est donnée préalablement, tandis que la SNV 
immédiatement après le « kindling » arrive à empêcher les convulsions généralisées dans une 
sous-population du groupe SNV. De plus, la SNV ne paraît pas avoir d’effets secondaires 
cognitifs démontrable par le labyrinthe de Morris chez les rats Fast. La SNV entraîne une 
réduction du poids corporel des rats GAERS après deux semaines de traitement. Une hausse 
de poids typiquement associée au « kindling », est évitée chez les rats Fast (par absorption 
réduite de nourriture). Enfin, il est clair que la complexité de la SNV doit être étudiée en 
profondeur afin d’optimiser le traitement de patients épileptiques réfractaires.  
 Plusieurs études en imagerie fonctionnelle ont été conduites afin de rechercher les 
structures cérébrales activées ou inhibées par la SNV. Ces études montrent des changements 
cérébraux bilatéraux à la SNV unilatérale gauche, et soulignent le rôle important du thalamus 
et des structures temporales dans le mécanisme fonctionnel de la SNV. Il n’y a cependant 
aucun consensus quant à la nature des changements (excitation ou inhibition) ni quant à 
d’autres structures cérébrales qui pourraient être influencées par la SNV. Ces divergences 
peuvent être attribuée à plusieurs facteurs comme les différences entre plusieurs techniques 
d’imagerie (PET, SPECT, fMRI), les agents de contraste, les protocoles de scanning, les 
paramètres de stimulation, les médicaments, la durée de la maladie et la réaction au 
traitement. L’hétérogénéité des échantillons de patients est difficile à éviter. De plus, les 
données provenant d’individus en bonne santé sont impossibles à obtenir pour des raisons 
éthiques, la SNV étant une procédure assez invasive. C’est pour cela que nous avons examiné 
la possibilité d’explorer les effets de la SNV chronique et aigue sur le métabolisme glucosé du 
cerveau chez le rat en utilisant le micro-PET. Nous avons pu démontrer que la SNV chronique 
et aigue induisent des changements dans le métabolisme glucosé des régions cérébrales 
importantes pour le contrôle des crises comme l’hippocampe et le striatum. Notre étude pilote 
démontre que le « small animal PET » est une technique utile et prometteuse pour refléter 
l’activité du cerveau dans des études à long terme sur des rats. 
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Abbreviations 
AD  afterdischarge 
ADD  afterdischarge duration 
ADT  afterdischarge threshold 
AEDs  anti-epileptic drugs 
CAP  compound action potential 
DBS  deep brain stimulation 
EEG  electro-encephalogram 
EP  evoked potential 
fMRI  functional magnetic resonance imaging 
GABA  gamma-aminobutyric acid 
GAERS genetic absence epilepsy rats from Strasbourg 
LEV  levetiracetam 
MOA  mechanism of action 
n.d.  not determined 
NE  not effective 
NS  not significant 
NST  nucleus of the solitary tract 
PET  positron emission tomography 
PN   post natal day 
PPS  perforant path stimulation 
PTZ  pentylenetetrazole 
RKRHS rapid kindling with recurrent hippocampal seizures 
SAS  sustained amygdala stimulation 
SE  status epilepticus 
SEM  standard error of the mean 
SER  spontaneously epileptic rat 
SD  standard deviation 
SHS  sustained hippocampal stimulation 
SNR  substantia nigra pars reticulata 
SISWD  short irregular spike and wave discharge 
SWD  spike and wave discharge 
SPECT  single positron emission tomography 
VNS  vagus nerve stimulation 
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Dankwoord 
 
Het dankwoord komt tijdens het schrijven steeds het laatst aan bod, na het spreekwoordelijke 
bloed, zweet en tranen … Maar eigenlijk is het het belangrijkst, want zonder de hulp van al 
deze mensen was de thesis nooit tot stand gekomen. 
Prof. Dr. Paul Boon, mijn promotor, verdient een heel bijzondere plaats in dit dankwoord. Je 
hebt mij ingewijd in de wondere wereld van het brein. Je hebt vaak veel geduld moeten 
oefenen bij het verbeteren van de teksten en bent soms snel moeten bijspringen als ik in 
extremis nog met iets kwam aandraven. Ook heb je de bijzondere gave om van dingen die wat 
minder meevallen iets positief te maken. Soms vraag ik me af of je geen twee paar handen 
hebt en vier hersenhemisferen voor al de verschillende taken die je uitvoert. 
Prof. Dr. Walter Verraes, mijn co-promotor, dank om de link te leggen tussen de Faculteit 
Wetenschappen (vakgroep Biologie) en de Faculteit Geneeskunde. Meerderen zijn na mij ook 
dit pad ingeslagen. Dank voor je goede raad en interesse in mijn onderzoek. 
Prof. Dr. Romain Lefebvre, bedankt om ons een plaatsje te geven op de tweede verdieping 
van het Heymans Instituut. Het is een beetje mijn tweede thuis geworden… 
Prof. Dr. Wytse Wadman, alias de grote vriendelijk reus (GVR) en tevens een fantastisch 
wetenschapper. Super bedankt Wytse, voor het bijstaan met raad en daad, voor je kritische 
opmerkingen en de gastvrije ontvangst in Amsterdam. Een klein duimpje wordt nu stilaan 
groot… (of toch een beetje). 
Alle collega’s van het Laboratorium voor Klinische en Experimentele Neurofysiologie, een 
jonge, dynamische ploeg die elk jaar een beetje uitbreidt. Kristl, die me enorm geholpen heeft 
bij het maken van mijn licentiaatscriptie en waar ik ook later kon op rekenen. Corine, die 
altijd nog wel een gaatje in de agenda van Prof. Boon kon vinden. Pieter (alias de computer 
crack) en Robrecht, de eerste collega’s die erbij kwamen op het dierexperimentele lab. En 
Veerle voor de leuke babbels die zich niet enkel beperkten tot NVS. Ook de ingenieurs Peter 
(voor de zwarte-gaten-gesprekken: ik denk toch dat ze bestaan) en Hans (voor het 
relativerende tegenwicht). De collega’s Tim en Tine: bedankt voor het nakijken van m’n 
teksten, met jullie erbij is het er zeker niet saaier op geworden in het labo! Benjamin 
natuurlijk, de Franstalige collega, waar we voornamelijk in het Engels mee 
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